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PREFACE
This thesis describes research undertaken during my 
appointment as Registrar in the University Department of 
Materia Medica, Stobhill General Hospital, Glasgow. Some 
of the work which it contains has been published or 
presented to learned societies. Reprints, where available 
are submitted with the thesis. I have been fortunate in 
having the cooperation and collaboration of a number of 
colleagues and friends. They are formally acknowledged. 
Except where stated, the work of this thesis has been 
personally carried out by me. The writing of this thesis 
is entirely my own work.
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SUMMARY
SUMMARY
Hypokalaemia is potentially fatal (Chapter 2). The 
internal regulation of potassium, i.e. the movement of 
potassium between body compartments, has not been 
extensively investigated (Chapter 1). Rapid movements of 
potassium can occur across cell membranes, e.g. in 
diabetic ketoacidosis the hyperkalaemia can be rapidly 
reversed by insulin administration, and the existence of 
a specific membrane enzyme controlling movement of 
potassium and sodium between the intracellular and
extracellular compartments, Na+/K+ ATPase, has been known 
for 30 years (Chapter 1.5).
Some acutely ill patients have hypokalaemia on 
admission to hospital which resolves without treatment. 
This observation led to the hypothesis that increased 
sympathetic activity, raising circulating adrenaline
levels, stimulates a Na+/K+ ATPase linked to a beta2 ~ 
adrenoreceptor on cell membranes pumping potassium into 
cells. Animal work by Clausen supported this theory and 
several studies in humans, some carried out in the 
Department of Materia Medica, were also supportive,
demonstrating that infusing adrenaline resulted in 
hypokalaemia (Chapter 1).
In the studies presented in this thesis both the 
mechanism and the clinical relevance of adrenaline 
induced hypokalaemia, with particular emphasis on the 
effects of a number of widely used drugs, have been
18
studied. Many drugs have been designed to specifically 
act on receptors in the sympathetic nervous system, 
either as agonists or antagonists, e.g. beta-blockers and 
beta2 ~agonists, and they are frequently administered to 
patients with cardiovascular disease who are at increased 
risk of dysrhythmias should hypokalaemia occur. Such 
patients are at increased risk of suffering acute stress, 
such as myocardial infarction, which increases 
circulating adrenaline levels.
An infusion regimen of (-)-adrenaline which would 
safely raise circulating adrenaline to concentrations 
similar to those seen in acute severe illness was 
developed (Chapter 3). This regimen consistently raised 
adrenaline levels seen in normal subjects during supine 
rest by 10 fold or more. During the infusions adrenaline 
levels did fluctuate, but they remained in the 
pathophysiological range. The regimen involved stepwise 
increases in the rate of adrenaline infusion and proved 
safe despite the adrenaline infusion being combined with 
other drugs with sympathomimetic activity.
The mechanism of adrenaline induced hypokalaemia in 
man is unproven. However, the possibility that adrenaline 
induced hypokalaemia could be the result of (5-agonist 
induced changes in plamsa insulin was excluded (Chapter
4.2). Both plasma insulin and potassium concentrations 
fell during the adrenaline infusion. Attenuation of 
adrenaline induced hypokalaemia by beta-adrenoceptor
19
antagonists with varying degrees of cardioselectivity 
(^2.) was studied and demonstrated that adrenaline induced 
hypokalaemia was mediated via the (32 adrenoceptor 
(Chapter 4.3 & 4.4). Whether the fact that
cardioselective beta-antagonists will be less effective 
in protecting patients from adrenaline induced 
hypokalaemia during the acute stress of severe illness is 
of any clinical significance remains unknown.
Salbutamol, a selective beta2-agonist, was also 
shown to cause hypokalaemia when given intravenously 
(Chapter 4.2). It is administered in high doses in acute 
attacks of asthma, where it might be expected that 
circulating adrenaline levels are raised. An additive 
hypokalaemic effect of exogenous adrenaline and 
salbutamol was demonstrated (Chapter 4.2) .
Hypokalaemia is a relatively common adverse effect of 
many diuretics and such hypokalaemia could increase the 
severity of hypokalaemia during acute stress. No 
synergistic action on potassium levels was demonstrated 
(Chapter 5) between adrenaline and any diuretic. However, 
both frusemide and bendrofulazide lowered plasma 
potassium and, therefore, during the adrenaline infusion 
more profound hypokalaemia was observed because baseline 
potassium was lower.
Theophylline, widely used as a bronchodilator, has 
been reported to increase circulating catecholamine
20
levels and to interact with sympathomimetics (Chapter 6.1 
& 6.2). Chronic theophylline therapy increased adrenaline 
induced hypokalaemia (Chapter 6.4). The mechanism of this 
interaction was not demonstrated, though the possibility 
that it was the result of theophylline increasing 
circulating adrenaline levels was excluded (Chapter 6.3).
Theophylline and sympathomimetics, such as 
salbutamol, are frequently given in combination, both as 
chronic therapy and in acute bronchospasm. The safety of 
this combination therapy has been questioned. Chronic 
oral theophylline therapy significantly increased the 
hypokalaemic effect of intravenous salbutamol (Chapter 
6.5). The clinical relevance of this observation is 
uncertain as patients are frequently on chronic $2~ 
agonist therapy which may cause down regulation of 
receptors.
Hypomagnesaemia can occur in situations in which 
circulating adrenaline levels are known to be raised, 
such as acute myocardial infarction (Chapter 7.1). The 
control of internal regulation of magnesium is not 
understood (Chapter 1.7). The role of adrenaline in the 
control of magnesium levels was studied, using the same 
adrenaline infusion regimen, and a small but significant 
fall in plasma magnesium was observed (Chapter 7.2). This 
was unaltered by pretreatment with diuretics (Chapter
7.3). The mechanisms and clinical relevance of adrenaline
21
induced hypomagnesaemia require further study but these 
have not yet been attempted.
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CHAPTER 1
PHYSIOLOGICAL CONTROL OF PLASMA POTASSIUM AND MAGNESIUM-
1. BACKGROUND AND SCOPE OF THESIS.
1.1 Background.
This thesis describes a series of investigations into 
the .phenomenon of adrenaline induced hypokalaemia. Though 
originally described over 50 years ago (D'Silva, 1934), 
adrenaline induced hypokalemia had been forgotten and it 
is only very recently that it has again been recognised 
and its clinical significance questioned.
The increasing use of auto-analysers in departments of 
biochemistry has revealed frequent cases of unexplained 
hypokalaemia and the observation that a significant 
proportion of these patient's plasma potassium 
concentrations spontaneously recovered without the need 
for potassium supplementation therapy (Morgan & Young, 
1982) aroused renewed interest in the causes of 
hypokalaemia, the homeostatic mechanisms controlling 
plasma potassium concentrations and the clinical 
importance of hypokalaemia.
Following the development of sensitive and reliable 
catecholamine assays it is now possible to measure 
circulating levels of catecholamines in many 
physiological situations ranging from rest to the stress 
of physical activity and illness (Engelman, Portnoy & 
Lovenberc, 1968; Passon & Peuler 1973; Da Prada & Zurcher 
1975). The observation that many of the patients with
24
unexplained hypokalaemia had acute illnesses which were 
associated with rises in circulating adrenaline led to 
the hypothesis that the hypokalaemia was adrenaline 
induced. This hypothesis was supported by studies showing 
that raising circulating adrenaline levels by exogenous 
infusion of adrenaline resulted in hypokalaemia.
This thesis describes the results of studies of 
adrenaline induced hypokalaemia which had the aim of 
determining the mechanism of adrenaline induced 
hypokalaemia and of examining the interactions with 
adrenaline, of a number of drugs used in general and 
specialist practice which may alter adrenaline induced 
hypokalaemia.
1.2 The sympathetic nervous system and adrenal medulla.
In man the sympathetic nervous system and the adrenal 
medulla regulates both metabolic and haemodynamic 
actions. In plasma three circulating catecholamines can 
be detected, noradrenaline, adrenaline and dopamine 
(Figure 1.2.1). Dopamine is a precursor of adrenaline and 
noradrenaline though specific dopamine receptors have 
been described in the renal circulation. There is still 
controversy about the physiological or pathological role 
of circulating dopamine (Weiner, 1985). Noradrenaline is 
primarily a neurotransmitter and, in contrast, adrenaline 
is a hormone in the traditional sense. From the classical 
work of Ahlquhist (Ahlquist, 1948) and later Lands (Lands
25
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Fig.1.2 .1. : STRUCTURE OF THE CIRCULATING 
CATECHOLAMINES
et al.,1967a; Lands, Luduena & Buzzo, 1967b) it is known 
that the sympathetic nervous system exerts its effects on 
a variety of target tissues via receptors. These 
receptors can be divided into alpha (a) and beta (3) sub- 
types which themselves can be further subdivided into 
and a2 subtypes and and (32 subtypes respectively, 
receptors are predominantly post-synaptic and their 
effect on smooth muscle is predominantly excitatory. a2 
receptors are mostly pre-synaptic and act as a feedback 
system to modulate further noradrenaline release from 
sympathetic nerve ending's storage vesicles. (3-j_ receptors 
predominate in cardiac muscle and are excitatory whereas 
£2 receptors are present on smooth muscle and glandular 
tissue. Many tissues have mixtures of receptors, an 
excellent example is the lung which has both as well 
as (3-j_ receptors in addition to the well recognised |32 
receptors on airway smooth muscle (Barnes, Karliner & 
Dollery, 1980).
Current evidence suggests that in man at rest the 
majority, if not all, the circulating noradrenaline is 
the result of spill-over of noradrenaline from post 
ganglionic sympathetic nerve endings in which 
noradrenaline is the sympathetic neurotransmitter. 
Sympathetic stimulation results in prompt exocytotic 
release of stored noradrenaline into the synaptic cleft. 
It has been shown that the adrenal medulla does release
26
noradrenaline and, under certain conditions, is a major 
source of noradrenaline (Silverberg et al., 1978) and 
achieves concentrations that produce biological effects. 
Noradrenaline is a potent al-agonist and is equipotent 
with adrenaline at (^-receptors but has little effect on 
^2 -receptors. 10-20% of the catecholamine content of the
adrenal medulla is noradrenaline. Noradrenaline levels 
increase on exercise and the relative contributions to 
this rise from increased spill-over from post-ganglionic 
sympathetic nerves and from adrenal medullary release is 
uncertain (Cryer, 1980).
All circulating adrenaline appears to originate from 
the adrenal medulla and with acute severe physical stress 
there is a large increase in adrenaline concentrations as 
a result of direct sympathetic stimulation of the adrenal 
medulla. Massive elevation, several hundred times resting 
values, has been reported following cardiac arrest 
(Wortsman Frank & Cryer, 1984) and insulin induced 
hypoglycaemia has been shown to increase levels several 
fold (Cryer, 1980) as does myocardial infarction. 
Adrenaline is approximately 10 times more potent than 
noradrenaline in producing metabolic effects, though the 
profile of actions of adrenaline and noradrenaline are 
not identical (Clutter et al.,1980), due to their 
differing affinities for a a ^ ,  £■]_ and receptors.
At rest physiological concentrations of adrenaline are
27
small and, whilst the effects of supraphysiological doses 
of adrenaline have been well documented (Weiner, 1985), 
it is only with the relatively recent development of 
highly sensitive assay techniques that it has become 
possible to examine the physiological role of circulating 
adrenaline. It remains unclear if basal resting 
adrenaline levels have any physiological role (Cori & 
Buchwald,1930; Clutter et al.,1980; Fellows, Bennett & 
McDonald, 1985; Freyschuss et al.,1986) and many authors 
have assumed that detectable adrenaline is the result of 
leakage from the adrenal medullae. It is now clear that 
low concentrations of adrenaline in the physiological 
range, two to three times the basal concentration, such 
levels are seen with mild exercise and smoking, have
detectable metabolic and haemodynamic actions, with
increases in heart rate and lipolysis (Clutter et 
al.,1980; Freyschuss et al.,1986).
Do pathophysiological concentrations of adrenaline cause 
significant hypokalaemia? As noted previously the 
observation of hypokalaemia on admission to hospital in 
a significant proportion of patients with acute severe 
illnesses, such as myocardial infarction, in whom
circulating adrenaline levels are known to be raised, and
that in some patients the plasma potassium levels 
spontaneously recovered has led to investigation of the 
role of catecholamines in the acute control of 
extracellular potassium.
28
1:3 The physiological role of potassium.
Potassium is the chief intracellular cation and is 
present in cells in a concentration of approximately 160
_ i
mmol 1 and 98%, 3,500mEq, of total body potassium is
intracellular. Extracellular potassium concentration is
_ -|
low, 3.5-5.0 mmol 1 , only 60-70 mEq in total (DeFonzo &
Bia, 1985). There is thus a high concentration gradient 
across cell membranes which contributes critically to the 
membrane potential of excitable tissues such as skeletal 
muscle, smooth muscle and the nervous system. Conversely 
intracellular sodium concentrations are low and 
extracellular concentration high. Work is therefore 
required to overcome both a chemical and an electrical 
gradient to move these ions across cell membranes. 
Movement of these ions is carried out by a specific, 
enzyme dependent, cell membrane bound, active transport 
mechanism, the Na+/K+ ATPase.
High intracellular concentrations of potassium are 
required by many metabolic processes, such as 
reabsorption of solutes by the kidney and uptake of 
nutrients by the intestine whilst active extrusion of 
sodium is required to maintain osmotic equilibrium across 
the membrane.
Failure to maintain potassium homeostasis will alter 
the function of many organs but the most dramatic effect 
is on the two highly specialised tissues which have the
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property of excitability, thus allowing the transmission 
of signals along the surface of the cell and between 
cells. Normal function of these tissues is dependent on 
the maintenance of an electrical potential across the 
membrane of the cell at a specific voltage, nerve and 
muscle.
Voltages across cell membranes are measured relative to 
the outside of the cell. The contribution of an 
individual ion is determined by the permeability of the 
membrane for that ion and the concentration gradient 
across the membrane. The prime ions in mammalian cells 
are sodium and potassium with a membrane permeability of 
1:30 and this ratio results in the resting membrane 
potential of -70mV. The excitability of such cells is 
dependent on the resting potential, -70mV, which is in 
turn dependent on the relative concentrations of 
potassium and sodium ions across the membrane. 
Hypokalaemia and hyperkalaemia will therefore alter the 
relative concentrations of potassium across the cell 
membrane and thus alter the resting potential and hence 
excitability.
1.4 The control of plasma potassium.
Plasma potassium concentration depends on intake and 
excretion, external balance, which determines whole body 
potassium stores, and the distribution between
30
extracellular and intracellular compartments, the 
internal balance.
External Balance:
The daily estimated intake of potassium is between 50- 
150mEq (3.7-11.0g of potassium chloride) in a normal diet 
(Fregly, 1981). Potassium is absorbed from the intestine 
by diffusion but absorptive processes may be involved. 
Thus a single meal may contain as much potassium, 3 
grams, as is present in the total extracellular space.
External potassium balance is primarily regulated by 
the kidney with, in health, only a small contribution 
from the gastrointestinal tract (Fig. 1.4.1). Excretion 
of potassium by the kidney is largely determined by the 
quantity of potassium in the diet, renal excretion rising 
in response to high potassium diets (Adam and Dawborn, 
1972) .
Most filtered potassium is reabsorbed in the proximal 
tubule and by the ascending loop of Henle and the major 
site for control of potassium excretion is the distal 
nephron (Berliner, 1961). In recent years it has become 
clear that renal tubular handling of potassium is more 
complex than originally thought and the exact mechanisms 
remain uncertain. In the early distal tubule active 
transport systems move potassium into cells on both the 
peritubular and luminal surfaces. Movement of potassium 
into tubular urine is passive as it is dependent on
31
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Fig. 1.4.1. : RENAL HANDLING OF POTASSIUM (K) 
AND MAGNESIUM (Mg)
electrical and chemical gradients. The luminal 
concentration of sodium and its accompanying anion are 
crucial, though poorly understood, controlling factors. 
More recent studies have suggested that under some 
circumstances the flow rate in the distal tubule is a 
further controlling factor (Wright, 1987). In the 
cortical collecting ducts potassium transport into 
tubular fluid is active and is again indirectly linked to 
intraluminal sodium concentrations and rate of flow of 
tubular fluid. Finally under conditions of metabolic 
alkalosis, solute diuresis or potassium loading further 
secretion of potassium may occur in the medullary 
collecting ducts. Thus potassium load, sodium delivery to 
the distal nephron and distal flow rates may all have a 
direct effect on renal potassium handling though the 
exact mechanisms are unknown.
Aldosterone is the principal mineralocorticoid and 
aldosterone levels increase in response to an increase in 
plasma potassium levels resulting in enhanced sodium 
reabsorption and potassium secretion in the distal 
tubules, probably by increasing the permeability of the 
luminal cell membranes and by increasing active transport 
of potassium across the peritubular membranes into the 
distal tubular cells (Cox, Sterns & Singer, 1978).
pH changes affect internal potassium regulation but, by 
altering renal tubular cell potassium content, also
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indirectly alter distal tubular potassium loss.
In renal failure the colon can become a route for 
significant potassium excretion but is not thought to be 
of significance in either health or non-renal diseases.
Internal Balance:
As stated above a single meal may contain as much 
potassium as the extracellular compartment and thus 
control mechanisms must be able to rapidly handle acute 
potassium loads. Previously it was believed that the 
actions of insulin, pH and aldosterone were the principal 
mechanisms recruited to maintain homeostasis.
Insulin levels rise following meals and it is also 
known that an increase in plasma potassium stimulates 
insulin release resulting in an intracellular shift of 
potassium (Bia & Defronzo, 1981). Experimentally supra- 
physiological doses of insulin results in plasma 
potassium uptake by the liver and muscle (DeFronzo, 
1987). It has not yet been convincingly shown that 
physiological doses of insulin have a significant effect 
on plasma potassium. Though it may be that the relatively 
high portal vein levels of insulin are sufficient to 
promote hepatic potassium uptake. Tolerance of potassium 
loads in insulin deficient diabetics and in normal 
subjects infused with somatostatin, which causes 
insulinopenia, is reduced which suggests that insulin 
does have a role in potassium homeostasis in health
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though it may not be major (DeFronzo et al., 1978).
Aldosterone's principal mode of action on plasma 
potassium is renal, as discussed above, however it may 
influence the handling of acute potassium loads though 
the evidence is controversial. Adrenalectomized high 
potassium load adapted animals are unable to handle acute 
potassium loads (Bia, Tyler & Defronzo, 1981).
pH and plasma bicarbonate separately influence internal 
potassium balance with an increase in either pH or 
bicarbonate increasing intracellular potassium (Fraley 
& Adler, 1977). The hyperkalaemia of acidosis has long 
been attributed to an exchange of hydrogen ions for 
potassium in cells but hyperkalaemia is not a feature of 
post-ictal lactic acidosis, nor does an infusion of 
organic as opposed to a mineral acid in dogs induce 
hyperkalaemia (Ledingham, 1983). The explanation for 
these discrepancies is not known.
1.5 Adrenaline and plasma potassium.
Over fifty years ago the first evidence that the 
adrenergic nervous system may influence plasma potassium 
levels emerged and there were several further reports 
suggesting an interaction subsequently. Despite this 
evidence the possibility that physiological 
concentrations of catecholamines may have a regulatory 
action, and be of clinical significance, had been ignored
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until this decade.
In 1934 D'Silva reported that the intravenous injection 
of 0.05mg of adrenaline in cats resulted in a very rapid 
and large rise in serum potassium but that this rise was 
short lived and was followed by a fall to levels below 
normal for 15-30 minutes (D'Silva, 1934). This worker 
then went on to demonstrate that the rise in serum 
potassium was the result of potassium release from the 
liver (D'Silva, 1936) and later workers demonstrated that 
the rise was mediated principally by alpha adrenergic 
receptors (Todd & Vick, 1971). In 1940 it was shown that 
adrenaline infusions had an identical effect on serum 
potassium as bolus injection (Larson, 1940). In these 
early experiments plasma catecholamine levels were 
unavailable thus making it impossible to relate observed 
effects to physiological doses and the mechanism of the 
hypokalaemia remained unknown.
In 1941 Dean proposed the existence of a sodium 'pump' 
in mammalian muscle cells to explain the observation that 
as the skeletal muscle cell membrane was permeable to 
sodium then there must be an active sodium excreting 
system to maintain intracellular sodium levels (Dean, 
1941). The next development was the description of 
adenosine triphosphate dependent fluxes of sodium and 
potassium across red cell membranes (Schatzmann, 1953) 
and in 1956 these fluxes were shown to be dependent, in
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the nervous system, on a Na+/K+ ATPase which could be 
inhibited by cardiac glycosides (Skou, 1956). Initially 
it was not thought that this 'pump* directly affected the 
cell membrane potential (Hodgkin & Horowicz, 1959). 
However, it was soon demonstrated that the sodium ' pump' 
could be electrogenic in many tissues (Thomas, 1972). In 
the 1970's membrane physiologists realised that the 
Na+/K+ ATPase could be directly stimulated by adrenergic 
amines with beta-adrenergic activity (Hays et al., 1974). 
In an elegant series of experiments since 1977 Clausen 
has shown in frogs the existence of a beta2 ~adrenergic 
receptor on skeletal muscle membranes linked to Na+/K+ 
ATPase (Clausen & Flatman, 1977; Clausen & Flatman, 1980', 
Clausen, 1983) .
In man the importance of catecholamines in potassium 
homeostasis was first suggested by a report in 1974 that 
the tolerance to an intravenous potassium load was 
impaired by adrenalectomy (Lockwood & Lum, 1974) and in 
1980 it was shown that beta2 ~adrenergic blockade reduced 
the hypokalaemic effect of adrenaline as well as blocking 
the protective effect of adrenaline on potassium loading 
(Rosa et al., 1980).
Further reports followed rapidly implicating beta2- 
adrenergic linked membrane bound Na+/K+ ATPase; chemical 
sympathectomy reduced potassium tolerance and adrenaline 
partially restored tolerance only in the absence of beta-
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blockade (Silva & Spokes, 1981) yet there was no change 
in the number of skeletal muscle cell pumps (Clausen, 
Hansen & Larrson, 1981); pre-treatment with the beta2“ 
agonist reduced the effects of endogenous catecholamines 
on Na+-K+ distribution (Buur et al., 1982).
Thus, there was increasing evidence from animal work 
and, to a lesser extent, from human work to implicate 
adrenaline in potassium homeostasis in man. The major 
questions that remained were whether adrenaline at 
physiological doses, that is those seen at rest or in 
stress, could influence potassium homeostasis in man and 
whether such effects were mediated through beta- 
adrenergic receptors which would have serious 
implications for many modern drugs which influence such 
receptors directly or indirectly.
1.6 The physiological role of magnesium.
Magnesium is the second most abundant intracellular 
cation and is present in plasma in relatively small 
amounts (<1%). Magnesium’s primary role is as an 
essential co-factor for many intracellular enzyme systems 
including several which are involved in key steps in 
intermediatory metabolism and phosphorylation both within 
the cell and at the cell membrane (Levine & Coburn, 
1984). Thus magnesium is essential for the hydrolysis of 
adenosine triphosphate, a central component of the 
cellular pumps which maintain the homeostasis of sodium,
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potassium and calcium. Magnesium is also involved in 
protein and DNA synthesis and may have a crucial role in 
the regulation of mitochondria (Anast & Gardner, 1981).
Total body magnesium stores are approximately 1000 
mmoles in man and magnesium is distributed in three 
compartments, 65% in the mineral phase of the skeleton, 
34% in the intracellular space and only 1% in the 
extracellular fluid. In plasma 75-80% of magnesium is in 
the ionic and complexed form and 20-25% is protein bound. 
Extracellular magnesium concentration is approximately
0.8 mmol 1“ .^ The intracellular concentration is 10 mmol 
1” ,^ but most is bound to cellular constituents, such as 
nucleic acid and protein. It is likely that the free 
intracellular magnesium concentration is between 0.1 and
1.0 mmol 1“  ^ (Levine & Coburn, 1984). Intracellular 
concentrations are carefully maintained despite changes 
in extracellular concentrations which implies the 
existence of specialized magnesium transport systems 
since magnesium can penetrate membranes, though slowly, 
and magnesium concentration is kept well below 
electrochemical equlibrium. Magnesium ions are small and 
highly polarized and have a large hydrated size in 
solution. They will thus pass with difficulty through 
small water-filled channels. These physical 
characteristics would explain the low membrane 
permeability of magnesium (Flatman, 1984).
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1.7 The control of plasma magnesium.
Regulation of magnesium balance is poorly understood. 
Magnesium is absorbed from the gut. Though studies of 
absorption are few in man, they have suggested both that 
absorption is sub-optimal, 35-45% (Johansson et al., 
1980), may be influenced by the composition of the diet 
(Lindeman, 1980) and that the magnesium salt present
alters the extent of absorption (Hodgkinson & Heaton,
1965). Average recommended daily magnesium requirement is 
350 milligrams, approximately 30mEq. (Dupin, 1981).
However, there is evidence that magnesium requirements 
are altered by the composition of the diet, requirements 
being higher with high protein diets (Caddell & Goddard, 
1967). Absorption sites are predominantly located in the 
small bowel.
60-70% of ingested magnesium is detected in faeces but 
there is no evidence of intestinal secretion of magnesium 
into the bowel lumen. The regulation of external 
magnesium balance is primarily via the kidneys and the 
filtered magnesium quantity is dependent on plasma 
magnesium concentration, only 3-5% of filtered magnesium 
is excreted (Massry, 1977). Excess magnesium results in 
decreased proximal tubular reabsorption. Renal
conservation is very efficient during periods of 
depletion (Levine & Coburn, 1984). Many diverse factors, 
including a variety of hormones, alter urinary magnesium
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excretion. These include extracellular volume expansion, 
hypercalcaemia, diuretics, alcohol ingestion, phosphate 
depletion, decreased parathyroid hormone activity, 
calcitonin, adrenocortical steroids, thyroxine and 
vitamin D (Dirks & Quamme, 1983). The relative importance 
of these various factors in magnesium homeostasis in man 
remains unknown and many of the reported effects may be 
indirect and of little physiological significance.
Internal regulation, the movement of magnesium between 
the intracellular and extracellular compartments, has 
received little attention though it is known that 
intracellular concentrations are maintained within a 
narrow range and that this homeostatic control is capable 
of adapting to wide variations in extracellular 
concentrations (Levine & Coburn, 1984). The mechanisms of 
this regulation are unknown (Ferment & Touitou, 1985).
In humans it has been reported that salbutamol, a 
agonist produces a small fall in magnesium concentrations 
(Philips et al., 1980). Additional evidence of a role for 
the adrenergic system in internal magnesium balance is 
suggested by the observations that in situations of acute 
stress with increased circulating catecholamine levels, 
such as myocardial infarction (Dyckner, 1980), cardiac 
surgery (Holden, Ionescu & Wooler, 1972; Scheinmann, 
Sullivan & Hyatt, 1969) and insulin-induced hypoglycaemia 
(Lindsay, 1976) hypomagnesaemia may occur.
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1.8 The scope of this thesis.
Thus there is evidence that the adrenergic 
neuroendocrine system may be involved in the internal 
regulation of potassium and magnesium. With the recent 
development of a number of drugs whose principal 
mechanism of action is either via adrenergic receptors or 
which are known to alter body cation stores, it is 
important to examine the potential of such drugs to 
interfere with potassium and magnesium homeostasis. The 
work presented in this thesis had the following aims in 
examining the effect of adrenergic stimulation on plasma 
potassium and magnesium.
(1) To determine a safe adrenaline infusion regimen 
capable of producing circulating adrenaline 
concentrations similar to concentrations reported in 
acute stress;
(2) Using such an adrenaline infusion regimen to 
determine if physiological adrenaline concentrations 
alter plasma concentrations of potassium and magnesium.
(3) To determine the subtype of beta-adrenoceptor 
responsible for the effect of adrenaline on plasma 
potassium by administering appropriate agonists and 
antagonists.
(4) Having established that physiological circulating
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concentrations of adrenaline induce significant 
hypokalaemia to demonstrate if there is any interaction 
with diuretic therapy.
(5) To investigate if there is any interaction between 
methyl-xanthines and circulating adrenaline on plasma 
potassium concentrations.
(6) To investigate if physiological circulating 
concentrations of adrenaline alter plasma magnesium 
concentrations and to examine there is any interaction 
with diuretic therapy.
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CHAPTER 2
PATHOLOGICAL CONSEQUENCES AND IMPLICATIONS OF 
HYPOKALAEMIA AND HYPOMAGNESAEMIA
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2. PATHOLOGICAL CONSEQUENCES AND IMPLICATIONS OF
HYPOKALAEMIA AND HYPOMAGNESAEMIA
2,1 The maintenance of cell membrane potential in 
excitable tissues.
Though all mammalian cells have a voltage potential 
across their resting cell membranes it is the two highly 
specialised cells, neurones and muscle cells, that have 
the property of excitability, that is when their cell 
membrane potential falls to a specific threshold then the 
cell depolarizes. Depolarization may be the .result of 
transmission of an impulse down the cell, from 
stimulation of receptors on the cell membrane or by the 
transmission from adjacent cells, as in neuronal axons, 
skeletal muscle and cardiac muscle respectively. Finally 
in the case of the cardiac conducting system the cells 
may spontaneously depolarise at a predetermined rate; 
that is show automaticity.
Alterations in intracellular and extracellular cation 
concentrations in these tissues will affect neuronal 
transmission in the case of the nervous system, 
contractility in skeletal muscle, and pacemaker functions 
and Impulse conduction in cardiac conducting tissue, and 
rates of spontaneous depolarization in cardiac muscle.
Membrane potentials are a direct result of the ratio of 
potassium concentration across the cell membrane. 
Surprisingly the exact Intracellular concentration of
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potassium remains uncertain and quoted figures have
_ i
varied from 140-160 mmol 1 . Though physical chemical
measurements suggest that the bulk of intracellular 
potassium has chemical activity and the potassium is 
completely exchangeable under physiological conditions it 
is also uncertain if there is non-uniform distribution or 
binding of a certain fraction of potassium within the 
cell (Kushmerick & Podolsky, 1969; Sperelakis & Ler, 
1979).
Since Bernstein it has been appreciated that the non- 
uniform distribution of inorganic ions across cell 
membranes must result in electrical potential differences 
across the membrane (Bernstein, 1902) and his original 
theory that the membrane was impermeable to all ions 
except potassium was modified when Boyle and Conway 
demonstrated that the frog sartorious cell membrane was 
also permeable to chloride and bicarbonate (Boyle & 
Conway, 1941) and the Nernst equation was thought to 
explain the relationship:-
E = R T In [Cl]i - R T In [K]i....etc.
F [Cl]o F [K]o
where E is the membrane potential, R is the gas constant, 
T is absolute temperature, F is the Faraday constant, and 
[K]j_ is the intracellular potassium concentration and 
[K]Q is the extracellular potassium concentration.
This equation therefore predicts a direct linear
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relationship between resting membrane potential and 
potassium concentrations across the membrane. There is, 
however, evidence to suggest that the situation is more 
complex.
In general resting cell membranes do have some degree 
of permeability to sodium ions which, combined with the 
fact the action potential involves influx of sodium, 
requires a mechanism of active sodium transport to remove 
sodium from cells thus achieving a steady state in which 
active transport out of the cell balances diffusion into 
the cell. The pump is considered to be nonelectrogenic,
i.e. no net charge transfer across the membrane occurs 
with active transport. The passive diffusion of sodium 
will alter the relationship between potassium 
concentrations and membrane potential according to the 
following equation
E = R T In [K]o + b[Na]o 
F [K]i + b[Na]i
where b is the ratio of the membrane permeability for Na 
and K, ?Na^pK anc^  ^ thought to be about 0.01 for
muscle and nerve. Therefore b[Na]j_ is small compared to 
[K]j_, and at high [K]Q and low b[Na]Q , b[Na]Q can be 
neglected and the equation reduces to the form of- the 
Nernst Equation so that E is a linear function of [K]Q . 
However at low [K]Q in the physiological range, b[Na]Q
46
becomes a significant fraction of the sum [K]Q + b[Na]Q 
and the linear relationship between E and [K ]Q no longer 
exists (Sperelakis & Lee 1979), Figure 2.1.1.
The inward current, represented by the spike of the 
action potential, is thought to be carried by sodium ions 
which enter the cell because of a sudden increase in 
membrane sodium permeability associated with excitation. 
Repolarization involves the movement of ionic charge in 
the opposite direction. The cell has thus lost potassium 
and gained sodium and active transport is required to 
restore the situation.
The effects of alterations in the concentrations of 
extracellular potassium on excitability are the result of 
changes in resting membrane potential. The relationship 
between cardiac resting membrane potential and 
extracellular potassium concentration is linear across 
the physiological range but deviates from linearity at 
the extremes of levels reported in man (Figure 2.1.1) In 
order to achieve propogated depolarization it is 
necessary to decrease the resting membrane potential to a 
given value, the threshold value. Not all tissues respond 
identically to changes in potassium concentrations, for 
example, the cells of the sinus node are particularly 
insensitive to changes in potassium concentration. The 
automaticity of the sinus node increases with increasing 
extracellular potassium concentration up to approximately
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6.0 mmol 1“ -^ and decreases when potassium concentrations 
exceed 6.0-8.0 mmol 1” .^ The automaticity of latent 
pacemaker cells is inhibited much earlier than the sinus 
node ((Antoni, Herkel & Fleckenstein, 1963; Vasalle et 
al., 1964). Thus hyperkalaemia decreases the incidence of 
both supraventricular and ventricular dysrhythmias 
(Fisch, 1973). Depolarizations to less than the threshold 
value results in small local changes but not to 
propogation. If the threshold potential is reached then 
an action potential occurs and the rate of rise of the 
action potential, which is thought to be due to the rate 
of inward movement of sodium current, can be shown to be 
dependent on the resting membrane potential. As resting 
membrane potential falls below -60mV the inward sodium 
current decreases to zero and therefore no action 
potential can occur.
Thus, any increase in extracellular potassium 
concentration leads to a decrease in resting membrane 
potential. The initial effect is to narrow the fall in 
membrane potential required to reach the threshold 
potential and, therefore, there is an increase in 
excitability with moderate hyperkalaemia. Spontaneous 
rhythmicity initially increases as a result of rises in 
extracellular potassium. However, as resting membrane 
potential falls further with severe hyperkalaemia, >8.0 
mmol I-1, then conduction velocity decreases due to the
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slower rise of the action potential and finally 
excitability falls as the inward sodium current which 
triggers the change in potential disappears. This has 
been demonstrated in atrium, AV node, Purkinje fibres and 
ventricular muscle (Swain & Weidner, 1957; Dominguez & 
Fozzard, 1970; Paes de Carvalho & Langer, 1963; Mendez, 
Mueller & Urguiaga, 1970).
Hypokalaemia increases resting membrane potential and 
thus prolongs depolarisation (Surawics, 1967) and may 
decrease autorhythmicity of myocardial cells but there 
is evidence it increases automaticity of Purkinje fibres 
(Vasalle et al., 1964; Vasalle & Hoffman, 1965; Dominguez 
& Fozzard, 1970). These changes lead to an increased 
incidence of escape rhythms, both supraventricular and 
ventricular (Fisch, 1973). Hypokalaemia can result in A-V 
conduction delay or even block and may depress 
intraventricular conduction by an unknown mechanism 
(Fisch, 1973).
In cardiac muscle changes in extracellular potassium 
concentrations are not thought to alter cardiac muscle 
contractility and the same probably holds true for 
skeletal muscle, though some doubt persists.
It has been demonstrated that Na+/K+ ATPase is a 
vectorial enzyme and extends across the cell membrane 
bridging both the inner and outer layers. It is activated 
by both Na+ and K+, different sites are involved, the K+-
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sensitive sites being located on the outer surface whilst 
the Na+sensitive sites are on the cytosolic face of the 
membrane. The preferred substrate is ATP complexed with 
Mg2+, and the complex is required at the cytosolic 
surface. Heart muscle contains 6 x 10^ molecules of 
ATPase per gram, and each ATPase transports 3 Na+ out and 
2 K+ in per cycle (Bentfield et al., 1977). Provided that 
sufficient Mg-ATP substrate is available the normal 
myocardium has a large reserve of Na+/K+ ATPase activity 
(Nayler, 1981) .
2.2 Hypokalaemia: Risks in ischaemic heart disease and 
hypertension.
Hypokalaemia is a relatively common finding in 
hospitalized patients, Lawson reporting significant 
hypokalaemia in 1% of 58,000 hospitalised patients and 
the hypokalaemic group had a fourfold greater mortality 
compared to their age and sex matched normokalaemic 
controls (Lawson et al., 1979). An interesting point to 
emerge from this study was that diuretic therapy rarely 
caused profound hypokalaemia (<2.0mmol 1”^).
A wide variety of conditions have been reported to 
cause potassium deficiency and hypokalaemia. These range 
from inadequate dietary intake, increased
gastrointestinal losses and a variety of renal 
abnormalities, leading to increased renal excretion 
ranging from hormonal influences to drug therapy. A full 
list of causes is given in Table 2.1.1. Drugs may
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alter plasma potassium, either by altering total body 
potassium stores or by altering the distribution of 
potassium between the intracellular and extracellular 
compartments and these are listed in Table 2.1.2.
Clinically hypokalaemia is often asymptomatic but, if 
symptomatic, the pattern of symptoms may be as dependent 
on the rate of fall of plasma potassium as well as to the 
absolute level of plasma potassium and may be unrelated 
to the extent of total body potassium loss. Hypokalaemia 
secondary to potassium loss, for example due to diuretic 
therapy, reflects a depletion of whole body potassium, 
both intracellular and extracellular. There has to be 
large potassium loss, usually 200mEq or more before 
significant hypokalaemia develops. The fall in plasma 
potassium is slow as adaptive mechanisms attempt to 
decrease potassium losses.
Eventually homeostatic mechanisms are exhausted and 
then plasma potassium falls rapidly. Initially 
intracellular potassium levels are maintained to avoid 
osmotic pressure damage and intracellular enzyme systems 
failing. In skeletal muscles the concentration difference 
increases as plasma potassium levels fall resulting in 
hyperpolarization as predicted by the Nernst equation 
(Bilbrey et al., 1973). As potassium deficiency increases 
further skeletal muscle plasma membrane integrity 
apparently decomposes so that membrane potential falls to
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Table 2.1.1 Causes of hypokalaemia.
1: Intracellular shifts- 
High dose insulin 
Periodic paralysis
2: Gastrointestinal Loss- 
Pyloric stenosis 
Bulimia nervosa 
Anorexia nervosa 
Ileostomy
Ureterosigmoidostomy.
3: Increased renal losses-
a) Primary renal disorders:
Renal tubular acidosis 
Acute tubular necrosis
b) Solute diuresis:
Glucose
Mannitol
Carbenicillin
c) Endocrine disease:
Aldosteronism 
(Primary or Secondary)
Cushing's disease 
4: Secondary to pharmacological agents: see
Alkalosis
Diarrhoea 
Villous adenoma 
Purgative abuse 
Fistulas
Chronic renal 
failure
Urea
Saline infusion 
Penicillin
Renin secreting 
tumours
Table 2.1.2.
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Table 2.1.2 Pharmacological agents which modify
potassium balance.
1: Drugs causing potassium depletion.
Potassium losing diuretics - Thiazides
- Loop diuretics
- Mercurial diuretics
- Carbonic anhydrase 
inhibitors
Corticosteroids with mineralocorticoid activity 
Excess Liquorice
Nephrotoxic antibiotics - Aminoglycosides
- Outdated tetracycline
- Amphotericin B 
Penicillin and semisynthetic penicillins (high dose) 
Laxative abuse'
2: Drugs causing potassium retention.
Potassium sparing diuretics - Spironolactone
- Triamterene
- Amiloride
Converting enzyme inhibitors- Captopril 
Non-steroidal anti-inflammatory drugs.
3: Drugs increasing cellular uptake of potassium.
Insulin
Salbutamol
4: Drugs decreasing cellular uptake of potassium. 
Phenylephrine Succinylcholine
Digitalis intoxication Arginine infusion
Chemotherapy lysis
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abnormally low levels and, at this point, muscle enzymes
appear in the plasma (Knochel & Carter, 1976). It is
known that skeletal muscle is the primary site of
potassium deficiency and it seems that skeletal muscle 
gives up its potassium content so that other vital
tissues are less affected (Knochel & Schlein, 1972).
It is probably inappropriate to assume that myocardial 
muscle cells respond identically. There are no studies of 
myocardial potassium concentrations in living, potassium- 
deficient humans. If, however as seems likely, there is 
an increase in the relative concentrations of potassium 
across the myocardial cell membrane then 
hyperpolarization will occur. This will result in the 
cell requiring a larger impulse to trigger 
depolarization. If the impulse is not sufficient to 
invoke depolarization then the excitation-contraction 
sequence does not occur and ventricular escape activity 
is more likely (Knochel, 1984). Acute hypokalaemia 
secondary to stimulation of the active transport system, 
as seen with metabolic alkalosis, results in a very rapid 
change in the relative concentrations of potassium across 
the membrane as potassium is pumped into the cells and 
extracellular concentrations fall. Maintenance of the 
resting potential is impossible, hyperpolarization 
results and the electrical stability of the cell is 
compromised.
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The life-threatening effects of hypokalaemia result 
from changes in resting membrane potential in cardiac 
conducting tissue and myocardial cells which increase the 
risk of cardiac dysrhythmias. Though severe hypokalaemia 
may by asymptomatic, reported symptoms include muscle 
weakness, varying from mild to profound, postural 
hypotension, decreased gatrointestinal motility, both due 
to decreased smooth muscle tone (Biglieri and Mcllroy,
1966), rhabdomyolysis (Knochel & Schlein, 1972), 
confusional states and, as a result of renal tubular 
effects, polyuria, metabolic alkalosis and sodium 
retention occur.
Severe hypokalaemia presents a risk even to otherwise 
healthy humans, however mild to moderate hypokalaemia is 
much commoner. Which particular groups of patients could 
be at increased risk from mild to moderate degrees of 
potassium deficiency?
Patients with myocardial ischaemia secondary to coronary 
heart disease have an increased risk of clinically 
significant or fatal dysrhythmias (Braunwald, 1984). Co­
existent hypokalaemia increases this risk further 
(Dyckner, Helmers & Wester, 1984). Ischaemic heart 
disease is frequently complicated by ventricular failure 
requiring diuretic therapy, commonly loop diuretics, such 
as frusemide, or in milder cases thiazide diuretics. 'Both 
groups of diuretics cause a degree of potassium loss and
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may thus result in hypokalaemia. On commencing thiazide 
diuretics the average fall in serum potassium is 0.5 mmol 
l”1 (Morgan & Davidson, 1980). In the Veteran's 
Administration Study of treatment of hypertension 23% of 
patients receiving thiazide diuretics developed serum 
potassium levels between 2.5 and 3.4 mmol l"1 and these 
remained low throughout the two year study period (VA 
Cooperative Study, 1970) and 3% of these patients had 
persistent potassium levels below 3.0 mmol 1“ .^ Other 
reports have suggested that up to 50% of hypertensives 
receiving thiazide diuretics have a resting serum 
potassium <3.5 mmol 1“  ^ (Morgan & Davidson, 1980; MRC 
Working Party, 19.81) and the incidence of ventricular 
ectopic beats has been shown to be inversely related to 
serum potassium level (MRC Working Party, 1983).
Recently there have been more and more reports of 
hypokalaemia occuring in a proportion of patients 
admitted to hospital with an acute myocardial infarction 
(Dyckner et al., 1975, Solomon & Cole, 1980; Donnelly et 
al., 1980; Dyckner et al., 1984; Thomas & Hicks, 1981). 
These hypokalaemic infarct patients have an increased 
incidence of dysrhythmias and a higher morbidity and 
mortality (Dyckner et al., 1975). The only identifiable 
predisposing cause in many cases is diuretic therapy. 
However, much of this evidence is controversial, these 
studies are observational, often retrospective and
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uncontrolled and some authorities doubt that chronic mild 
to moderate hypokalaemia secondary to diuretics is 
clinically important.
In addition, there are a significant number of patients 
who have no known predisposing cause for hypokalaemia. 
Circulating adrenaline and noradrenaline levels rise in 
acute myocardial infarction though the extent of this 
rise is very variable, varying from normal levels to a 
twenty-five fold increase. This rise is not simply 
explained by the extent of the infarct or the presence of 
complications. Patients with cardiogenic shock have high 
levels but equally patients with clinically uncomplicated 
infarction may also have raised levels (Christenson & 
Videbaek, 1974; Cryer, 1980; Karlsberg, Cryer & Roberts, 
1981; Vetter et al., 1974). The chronotropic action of 
high catecholamine levels will increase the risk of 
cardiac dysrhythmias and, in addition, the increased 
catecholamine levels may be a cause of hypokalaemia.
Thus patients with ischaemic heart disease are at 
increased risk if they develop hypokalaemia, whether the 
hypokalaemia is the result of diuretic therapy or of 
acute stress, such as myocardial infarction.
A similar situation exists in the treatment of 
hypertensive patients, who will often have co-existent 
ischaemic heart disease and are at risk from myocardial 
infarction and cardiac dysrhythmias. The cornerstone of
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many anti-hypertensive treatment regimens is thiazide 
therapy, either alone or in combination with other anti­
hypertensive drugs. The Veterans Administration 
Cooperative study and the MRFIT hypertension study 
suggested that thiazide diuretic therapy may carry a risk 
of significant complications including hypokalaemia and 
dysrhythmias (MRFIT Research Group, 1982; Veterans 
Administration Cooperative Study Group, 1982), though 
these interpretations remain controversial (Moser, Black 
& Stair, 1986). Therefore, if a hypertensive patient with 
diuretic induced hypokalaemia, suffers an acute ischaemic 
event, then the risk of fatal dysrhythmias will increase 
if adrenaline does indeed lower plasma potassium further.
2.3 Hypokalaemia; Consequences in acute asthma and 
chronic airflow limitation.
Hypokalaemia is not a recognised problem of standard 
bronchodilator drug regimens routinely used in asthma and 
chronic airflow limitation (chronic bronchitis and 
emphysema). Hypokalaemia has been observed during the 
treatment of acute exacerbations of both asthma and 
chronic airflow limitation but has received little 
attention.
The treatment of acute asthmatic attacks has been 
closely scrutinised recently because the death rate 'from 
asthma is increasing in many countries despite the
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introduction of effective and specific anti-asthmatic 
therapy (Burney, 1986; British Thoracic Association, 
1982; Stableforth, 1983; Johnson et al., 1984; Wilson,
1984) and in New Zealand this increase has reached 
'epidemic' proportions since the start of this decade 
(Jackson et al., 1982). There is now increasing evidence 
of a rise in asthmatic deaths in the U.S.A. (Coleman, 
Paulozzi & Buist, 1985; Robin, 1988).
This reawakening of interest in asthma deaths mirrors 
an identical response in the 1960's when certain 
countries, U.K., New Zealand and Australia reported a 
dramatic increase in asthmatic death rates following the 
introduction of the first metered dose aerosol inhaler 
containing a high dose of a non-selective (3-adrenergic 
agonist, isoprenaline (Spiezer, Doll & Heaf, 1968; 
Speizer et al 1968; Inman & Adelstein, 1969; Anonymous 
(Editorial), 1969). No epidemic was seen in countries 
which did not introduce this device (Fraser & Doll,1971; 
Stolley, 1972). One country, Australia, did, however, 
fail to demonstrate a simple relationship between the 
sales of isoprenaline and asthma deaths (Gandevia, 1973). 
Though many theories Were proposed to explain this 
epidemic none was ever proven (Speizer et al., 1968b).
The major theories were: i) that because isoprenaline is 
non-selective patients were, during attacks of acute 
asthma, taking excessive doses which triggered fatal
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cardiac dysrhythmias either by direct myocardial 
stimulation or by increasing hypoxia secondary to 
alterations in ventilation-perfusion induced by 
isoprenaline effects on pulmonary vessels (Palmer & 
Diament, 1969; Collins et al., 1969; Knudsen & 
Constatine, 1967); ii) that excess use of the inhaler 
meant increased inhalation of the propellant, freon, 
which is known to be cardiotoxic and arrhythmogenic in 
high doses; iii) patients delayed seeking medical advice 
because they believed that with the advent of a new 
powerful bronchodilator, which they could administer 
themselves, they could control attacks. None of these 
theories has been totally disproven though the role of 
freon was widely investigated and it was demonstrated 
that it was virtually impossible to achieve cardiotoxic 
levels of freon from an aerosol inhaler (Clarke & 
Tinston, 1972; Dollery et al., 1974; Anonymous 
(Editorial), 1975). Following warnings in the medical 
press the sale of isoprenaline inhalers fell, the high 
dose isoprenaline inhaler, Isoforte, was withdrawn, the 
use of corticosteroids increased, as did the admission 
rate for asthma and the asthma death rate fell back 
towards previous figures (Committee on Safety of Drugs, 
1967). Inhaled sympathomimetic agents were, however left 
under a cloud for many years thereafter, though today 
sales of sympathomimetic inhalers now exceed the mid­
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sixties figures several fold (Stableforth, 1983) and all 
subsequent studies examining the circumstances of death 
in asthma have emphasised undertreatment as a major cause 
rather than overtreatment (McDonald, Seaton & Williams, 
1976, Fraser et al., 1971; B.T.A., 1982).
The current increase in asthmatic death rates is 
equally difficult to explain. The epidemic in New Zealand 
does seem to be waning, though death rates for asthma 
remain higher than in other comparable countries, and it 
has been suggested that the cause may have been the 
excessive self-administration of 0 2 -a9 onists v^a home 
nebulisers, widely used in New Zealand since just prior 
to the start of this recent increase in the death rate. 
The widespread use of nebulisers leading to patients 
delaying seeking medical advice until it was to late 
(Grant, 1983). The risks of nebulised beta-agonists in 
asthma or chronic airflow limitation are unclear from the 
current literature. Sudden death has been associated with 
nebuliser use (Anonymous, 1984; Cochrane, Prior & Rees 
1985; Sears et al, 1987). One group has reported no 
increase in cardiac dysrhythmias following nebulisation 
on oxygen (Ebden et al, 1987) this contrasts with the 
observations of an increase in cardiac dysrhythmias by 
others in an elderly group of patients using air driven 
nebulisers (Higgins et al, 1987).
The alternative explanation for the New Zealand
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"epidemic” offered has been that combination therapy with 
p2 _ag°nists and methyl-xanthines is cardiotoxic or 
increases the incidence of dysrhythmias during attacks of 
asthma (Sutherland & Wilson, 1981; F.D.A., 1981; Wilson, 
Sutherland & Thomas, 1981). It has been demonstrated in 
animals that cardiac dysrhythmias are commoner in animals 
treated with this combination (Joseph et al., 1981; 
Nicklas, Whitehurst & Donohue,1982) and there are reports 
in the literature that patients receiving this 
combination have an increased incidence of extrasystoles 
when continous cardiac monitoring is carried out (Banner 
et al., 1979; Pierson et al. , 1980; Josephson, 1982;
Billing et al., 1982; Al-Hillawi, Hayward & Johnson,
1984). The clinical significance of these findings from 
uncontrolled studies is uncertain. There has been one 
report suggesting that cardiac dysrhythmias were 
increasingly complicating severe and fatal attacks of 
asthma predominately in older subjects (Coleman et al. ,
1985) .
Prior to the introduction of specific 3-agonists, when 
oral ephedrine was widely used in combination with oral 
theophylline, it was recognised that there was an 
interaction between these drugs leading to an increase in 
the frequency of side-effects (Weinberger & Bronsky, 
1975).
How might either 32"a9°nists or theophylline alone or
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in combination put asthmatic and bronchitic patients at 
risk? Hypoxia is present even in relatively mild attacks 
of asthma and respiratory acidosis will develop in severe 
attacks (Crofton & Douglas, 1981). Both these metabolic 
derangements are known to increase the risks of cardiac 
dysrhythmias and it has been demonstrated that hypoxia 
increases the cardio-toxicity of isoprenaline (Collins et 
al., 1969). As previously discussed it is possible that 
(^-adrenergic stimulation may cause hypokalaemia. Thus 
specific ^-agonist bronchodilators, such as salbutamol, 
though they will possess less chronotropic activity on 
the heart via the (3 adrenoceptor, may precipitate 
significant hypokalaemia which, accompanied by hypoxia 
and acidosis, may trigger life-threatening dysrhythmias. 
Combination with theophylline, which by itself has been 
reported to cause hypokalaemia in overdosage (Helliwell & 
Berry, 1979; Buckley, Brathwaite & Vale, 1983; Kearney et 
al., 1985) and which previous evidence has suggested 
increases the sympathomimetic action of adrenergic 
agonists may further compound the situation. Thus 
hypokalaemia could be a common pathway by which both 
these bronchodilators would place patients at increased 
risk when combined with the other acute metabolic 
derangements present during the stress of acute attacks 
of bronchospasm.
One final area of dispute is the possible role of
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circulating catecholamines in acute attacks of asthma and 
bronchitis. Severe asthma is both frightening and
stressful and would be expected to cause a 
sympathoadrenal response and a rise in circulating 
adrenaline. A possible additional factor may be hypoxia 
which has been shown to increase circulating
catecholamines, at least during the stress of exercise 
(Escourrou, Johnson & Rowell, 1984). The original 
evidence, using less sensitive assay methods suggested 
that even simple exercise induced asthma resulted in 
increases in circulating adrenaline (Zielinski et al., 
1980; Griffiths et al., 1972; Chryssanthouplous et al., 
1978). However a- more recent similar study found no 
change (Barnes et al. , 1981) and a study of patients
during acute severe attacks of asthma could only 
demonstrate a rise in noradrenaline levels but not 
adrenaline (Ind et al., 1985). In a personal 
communication these authors did report that the subjects
who were so severely ill as to require intensive therapy
did have raised adrenaline levels. It would seem logical 
from our knowledge of the sympathoadrenal system that the 
chronic stress of a prolonged asthmatic attack leads to 
increased neuromuscular activity, and hence increased 
spillover of noradrenaline into the blood stream, but no 
rise in adrenaline. However when the attack becomes so 
severe that significant hypoxia and respiratory acidosis
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supervene then possibly the adrenal medulla responds by 
releasing adrenaline which could further stimulate $2~ 
adrenoceptors linked to the Na+/K+ ATPase and could 
further increase any fall in plasma potassium already 
caused by bronchodilator therapy.
Therefore, in conclusion, hypokalaemia secondary to 
bronchodilator therapy and, possibly to increased 
circulating adrenaline, may occur in acute severe attacks 
of either asthma or bronchitis.
2.4 Hypomagnesaemia: Clinical consequences.
The incidence and importance of magnesium deficiency in 
clinical practice has only recently been investigated. An 
increasing number of causes of magnesium deficiency are 
being recognised and are listed in Table 2.4.1. World 
wide the most important causes are malnutrition and 
alcoholism. In western medical practice the two 
aetiologies which have received most attention have been 
magnesium deficiency secondary to total parenteral 
nutrition and magnesium deficiency complicating diuretic 
therapy with loop diuretics and thiazide diuretics 
(Wester & Dyckner, 1981).
Assessing the relevance of magnesium deficiency is 
difficult as serum magnesium levels, unlike potassium 
levels, show no clear relationship with muscle magnesium 
levels (Heaton & Martindale, 1965), though some studies 
have demonstrated decreased muscle magnesium in magnesium
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deficiency states (Ryan, 1986).
Not all patients receiving these diuretics will develop 
magnesium deficiency and even of those that do the vast 
majority will be asymptomatic (Sheenan & White, 1982; 
Swales, 1982). 6.9 to 11% of hospitalized patients have
been reported to be hypomagnesaemic (Whang et al., 1980; 
Wong et al., 1983), 42% of patients with hypokalaemia
have coexistent hypomagnesaemia ((Whang et al., 1984) and 
37% of patients with congestive cardiac failure who are 
receiving diuretic therapy will have low serum magnesium 
levels (Wester & Dyckner, 1985). Thus, though 
relatively common, the severity and clinical importance 
of diuretic induced hypomagnesaemia remains uncertain. 
Dyckner and Wester have reported that coexistent 
magnesium deficiency increased potassium depletion 
(Wester & Dyckner, 1981), these findings would support 
the view that A.T.P. does require intracellular magnesium 
as an essential cofactor. A further interaction between 
these two cations is that membrane permeability to 
potassium is altered by magnesium depletion (Skou, 1965). 
Magnesium deficiency can be fatal even to otherwise 
healthy subjects, as shown by a number of sudden deaths 
which occurred in the 1970's in patients on liquid 
protein preparations for the treatment of gross obesity. 
A large magnesium loss occured which, combined with
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Table 2.4.1 Causes of magnesium deficiency.
- Nutritional Causes:
Prolonged parenteral feeding. 
Starvation with acidosis. 
Protein calorie malnutrition,
Diabetic
ketoacidosis
Alcoholism
II - Intestinal Causes:
Chronic diarrhoea - any aetiology.
Ill- Renal Disease:
Renal tubular acidosis.
Intestinal 
Malabsorption.
Acute tubular 
necrosis-diuretic 
phase.
Chronic glomerulonephritis.
Familial and sporadic renal magnesium loss.
IV - Drug Therapy:
Diuretics:-
- Thiazide diuretics.
- "Loop” diuretics.
Antibiotic induced 
tubular dysfunction:
- Gentamicin.
- Amphotericin.
- Carbenicillin.
- Tircacillin.
Antineoplastic therapy - Cisplatin,
V - Endocrine Causes:
Primary and secondary hyper­
aldosteronism .
Malignant hypercalcaemia.
Primary hyperparathyroidism.
Hyperthyroidism, 
Excessive lactation, 
Pregnancy.
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lipolysis, which releases long chain free fatty acids 
which bind magnesium, resulted in acute and severe 
hypomagnesaemia (Lantigua et al., 1980) leading to 
cardiac dysrhythmias.
Though patients with severe magnesium deficiency may 
have no symptoms or clinical signs, the signs, symptoms 
and clinical complications of magnesium deficiency are 
well recognised and are listed in Table 2.4.2. It is of 
interest to note the similarity of many symptoms to those 
of hypocalcaemia.
The variability of the clinical manifestations of 
hypomagnesaemia may be the result of the effects of 
magnesium on cell calcium handling. Magnesium may bind 
competitively to the same sites as calcium, producing the 
same physiologic response; it may compete with calcium 
for a binding site but not exert an effect; or it may 
alter the distribution of calcium by changing the flux of 
calcium across the cell membrane or by displacing it from 
intracellular binding sites with a rise in intracellular 
calcium concentrations. Profound magnesium deficiency 
primarily affects excitable tissues producing 
neuromuscular irritability and tetany in the nervous 
system and in the cardiovascular system, cardiac 
dysrhythmias and increased vascular tone and reactivity. 
This increase in vascular tone and reactivity is the 
result of increased intracellular calcium concentrations
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Table 2.4.2 Clinical manifestations of magnesium
deficiency.
I - Neuromuscular Hyperactivity:
Limb and facial muscle tremor. 
Convulsions.
Chvostek sign.
Spontaneous carpopedal spasm. 
Dysophagia and gut hypomotility.
II - Psychiatric Disturbances:
Apathy.
Coma.
III - Cardiovascular Effects:
Ventricular dysrhythmias -
- premature ventricular beats.
- ventricular tachycardia.
- ventricular fibrillation.
Myoclonic jerks. 
Ataxia.
Trousseau sign. 
Nystagmus.
Delirium.
Sudden death.
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secondary to magnesium deficiency (Altura & Altura, 1978) 
and magnesium deficiency may cause coronary artery spasm 
(Turlapaty & Altura, 1980). In the presence of magnesium 
deficiency Na+/K+ ATPase is impaired and this results in 
a fall in resting membrane potential, partial 
depolarisation of the cell membrane and hyperirritability 
of excitable tissues. A recent report showed that 
magnesium deficiency increased the cardiotoxic effects of 
supraphysiological doses of adrenaline in rats (Vormann 
et al., 1983), though the mechanism of this interaction 
is unclear.
Undoubtedly the most serious and increasingly recognised 
complication is cardiac dysrhythmias and these may appear 
suddenly and be unresponsive to conventional anti- 
dysrhythmic drug therapy.
Assessing the significance of magnesium deficiency in 
the genesis of dysrhythmias in these patients is
complicated by the frequent co-existent potassium
deficiency. Often the dysrhythmia is attributed to the 
potassium deficiency. Further complicating accurate 
assessment of aetiological factors is the observation 
that in some magnesium deficient patients potassium 
replacement is ineffective until magnesium is also
replaced (Chadda, Lichenstein & Gupta, 1973). In animals 
severe magnesium deficiency has been shown to result in 
myocardial fibrosis, necrosis and calcification
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(Heggtveitt, Herman & Mishra, 1964). Digitalis toxicity 
is enhanced by hypomagnesaemia (Kim, Freed & Bures, 
1961). There are well documented cases of magnesium 
deficient patients with life-threatening dysrhythmias 
being successfully treated with magnesium supplements 
(Loeb et al., 1968, Chadda et al., 1973; Iseri, Freed & 
Bures, 1975). However, there are no controlled series and 
the incidence of severe magnesium related 
tachydysrhythmias is not known. An increasing number of 
reports have shown that patients admitted with acute 
myocardial infarction have lower serum magnesium levels 
than matched controls (Abraham et al., 1977; Dyckner,
1980), even when preceding diuretic therapy is taken into 
account (Petersen, Christiansen & Transbol, 1978). In two 
studies of patients with myocardial infarction a higher 
incidence of atrial fibrillation and supraventricular 
tachycardia was found in the hypomagnesaemic patients 
(Dyckner, 1980; Bigg & Chia, 1981). A recent observation 
in a placebo controlled randomised study of patients with 
acute myocardial infarction who received intravenous 
magnesium on admission to hospital has been a lower 
incidence of complicating cardiac dysrhythmias and a 
lower mortality at four weeks in those given magnesium 
(Rasmussen et al., 1986). This interesting study requires 
confirmation but emphasises the possibility that 
magnesium deficiency may be important in these patients.
71
In asthma diuretics are not a standard form of therapy, 
however, they are widely used in patients with advanced 
chronic airflow limitation when complicated by cor 
pulmonale. Patients with severe chronic airflow 
limitation are frequently malnourished (Wilson, Rogers & 
Hoffman, 1985) and this is an additional risk factor for 
hypomagnesaemia. There have been no published studies of 
magnesium balance and status in these patients.
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CHAPTER 3 
METHODS
METHODS
3.1 Physiological and pathophysiological catecholamine 
levels.
The sympathoadrenal system exists to provide a rapid 
response to situations of 'fight or flight'. There is 
evidence that not only physical stress but also 
psychological stress can result in release of adrenaline 
from the adrenal medulla (Anfilogoff et al, 1987).
Catecholamines are cleared from extracellular fluid 
rapidly by uptake into sympathetic postganglionic neurons 
(uptake-^), where they are stored, and into extraneuronal 
cells (uptake2 ) where they are metabolized 
(Iverson,1975). Uptake^, a relatively high affinity, low 
capacity system has a higher affinity for noradrenaline, 
whereas, in contrast, uptake2 is a low affinity, high 
capacity system with a higher affinity for adrenaline. 
There is now evidence that both noradrenaline and 
adrenaline clearance systems are in turn modulated by 
beta-adrenergic receptors (Cryer et al, 1980). Adrenaline 
is rapidly cleared from the blood to metanephrine 
following methylation by catecholamine-o-methyl 
transferase (C.O.M.T.) and to a lesser extent by 
deamination by monoamineoxidase (M.A.O.). The majority of 
an injected dose of adrenaline appearing in the urine as 
metabolites, principally 4-OH, 3 methoxymandelic acid
(V.M.A.), though in health trace amounts of adrenaline
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are detectable in urine.
Plasma concentrations of adrenaline vary widely during 
day to day activities, varying from 0.19 to 0.22 nmol l”1
( 35-40 pg ml- -^) whilst resting supine to 0.30-0.41 nmol
—  1 —  11 x (55-75 pg ml ±) on standing (Cryer, Santiago & Shah,
1974) and to 1.9 to 2.9 nmol 1“  ^ ( 350-540 pg ml“ )^ on 
severe physical exercise (Galbo, Holst & Christensen,
1975).
Acute stress results in release of adrenaline, 
cortisol, growth hormone and prolactin (Rose & Sachar, 
1981). Adrenaline is claimed to be the most sensitive and 
consistent index of the response to stress (Wortsmann, et 
al, 1984). Adrenaline rises with psychological stress 
when the rise of the other hormones is only modest 
(Anfilogoff et al, 1987). Stress in illness obviously 
differs depending on the individual situation and 
involves a mixture of acute and chronic physical stress 
and psychological stress. In animals the rise in plasma 
adrenaline is related, following coronary artery 
ligation, to the fall in arterial pressure temporally, 
but the magnitude of the rise is related to the size of 
the infarct (Karlsberg et al, 1979). In man the most 
widely used experimental tool to study adrenomedullary 
stress has been insulin induced hypoglycaemia, an acute, 
life-threatening form of stress, leading to large rises 
in adrenaline levels. Adrenaline levels have also been
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found to rise in a variety of illnesses, the highest 
levels of circulating adrenaline, increases of 30 to 300 
fold, have been reported following cardiac arrest.
The sympathetic response may be further modified by the 
individual patient's psychological response to their 
illness. In a group of patients in an intensive care unit 
plasma adrenaline levels were approximately twice normal, 
whereas in patients admitted during an acute myocardial 
infarction levels may be elevated up to twenty-five fold 
(Christensen & Videbaek,1974; Karlsberg et al,1981). 
Elevation of catecholamine levels has been correlated 
with the presence of left ventricular failure, shock and 
life threatening ventricular dysrhythmias ( McAlpine & 
Cobbe,1988), nevertheless in these studies there were 
wide differences between individual patient's adrenaline 
levels despite similar severity of illness.
As stated previously (see Chapter 1.1), it is unclear 
if the plasma adrenaline levels found on supine rest have 
any biological effects. For example, debate continues 
regarding the relationship between diurnal variation of 
plasma adrenaline and nocturnal bronchoconstriction in 
asthma (Barnes et al, 1980). There is now convincing 
evidence that in the lower part of the physiological 
range adrenaline has detectable physiological effects. 
Increases in heart rate, peripheral blood flow and 
metabolic rate, along with falls in diastolic blood 
pressure, were seen with low dose infusions of adrenaline
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(10 ng min-1 kg-1) which raised circulating levels from 
0.15 nmol l--*- (21 pg ml”-*-) to 0.73 nmol 1“  ^ (135 pg ml”-*-) 
(Fellows et al, 1985). Venous plasma catecholamine 
measurements have the limitation that peripheral tissues, 
principally skeletal muscle, remove adrenaline resulting 
in a fall across the peripheral circulation of 50% from 
arterial levels (Best & Halter, 1982). Freyschuss and co- 
workers infused low doses of adrenaline into normal 
subjects whilst measuring arterial adrenaline levels and 
demonstrated significant metabolic and haemodynamic 
effects at arterial concentrations of 1.3 nmol 1”-*- (235 
pg ml”-*-) (Freyschuss et al, 1986).
As all previous studies in patients examining the 
pathophysiological role of circulating catecholamine 
levels have related their observations to venous 
adrenaline concentrations it is therefore logical to 
examine the effects of similar venous concentrations of 
adrenaline when investigating adrenaline induced 
hypokalaemia and, therefore, venous blood has been used 
to measure circulating adrenaline concentrations 
throughout in these studies.
3.2 Catecholamine assays.
Fluorimetry
Until the early nineteen seventies the only method 
available for measuring adrenaline and noradrenaline 
levels in biological materials and plasma was by
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fluorimetry (Lund, 1949). The lower limit of detection 
using the fluorometric method was 38 nmol 1“  ^ (700 pg 
ml“ )^ for adrenaline and 10 nmol 1“ -^ ( 200 pg ml” )^ for
noradrenaline (Griffiths & Leung, 1970). The detection 
limit for adrenaline was, therefore, well above the 
concentrations found at rest in normal human subjects 
(Anton & Sayre, 1962). The introduction of semi-automated 
methods made this technique less time-consuming and less 
expensive but it remained a research tool (Merrils, 
1963). Principally because of its high lower limit of 
detection, the only clinical application was in the 
investigation of suspected phaeochromocytoma, a condition 
in which circulating catecholamines are greatly 
increased.
Gas Liquid Chromatography
In the early nineteen seventies more sensitive gas 
liquid chromatography methods were developed. Again the 
cost of the equipment, the complexity of sample cleanup 
and derivatization made it expensive and limited its use 
for both clinical and research applications (Jacob & 
Vogt, 1977).
Radioimmunoassay
At approximately the same time a cheaper method of 
measuring low plasma and tissue concentrations of 
catecholamines was developed using a specific • and 
sensitive radioimmunoassay technique [R.I.A.] (Passon St 
Peuler, 1973; DaPrada & Zurcher, 1975). This method has
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proven accurate and sensitive but does involve multiple 
sample handling, enzyme preparations and labelled 
compounds. The required materials are available as kits 
allowing widespread use of this technique though the cost 
per sample assayed does remain relatively high, 
approximately £30.00/sample at commercial assay rates. 
Nonetheless this method allows accurate measurement of 
adrenaline concentrations into the femtomole range from 
plasma samples (DaPrada & Zurcher, 1975). Thus, for the 
first time it was possible to investigate the 
physiological role of the low concentrations of 
adrenaline present at rest and during light exercise. For 
much of the work in this thesis this was the assay method 
used to measure circulating adrenaline and noradrenaline 
concentrations.
Briefly, the two catecholamines are converted to their 
O-methyltransferase analogues by catechol-O-
methyltansferase in the presence of S-adenosyl- 
methionine-3H thus labelling O-methylated products. These 
are transformed to less polar complexes by adding sodium 
tetraphenylborate and extracted into diethyl ether and 
the products of the reaction separated by thin layer 
chromatography. Metanephrine, the product of methylation 
of adrenaline, and normetanephrine, the product of 
methylation of noradrenaline, are further oxidised to 
vanililin and the radioactivity counted after extraction. 
Internal and external standards are also run and the 
samples ' are counted in a liquid scintillation
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spectrometer and radioactivity in both the samples and 
the standards is corrected for the counts per minutes in 
the blanks. The concentration of the amines for each 
sample is then calculated based upon the internal 
standard. Though it has been claimed that this method can 
be used to measure catecholamine levels in the femtomole 
range, it is certainly accurate with good linearity over 
the picogram and nanogram ranges. The intra-assay 
variability is acceptable with a coefficient of variation 
of approximately 12% in human plasma and a inter-assay 
coefficient of variation of 18% (Da Prada & Zurcher,
1975) Thus the method is accurate but, though little 
sophisticated equipment is needed, it is complex and 
relies on the purity of the catechol-O-methyltransferase 
enzyme and careful extraction procedures by laboratory 
staff. A single technician can only analyse, 
approximately, 40-50 samples in two days. This relative 
expense limited the number of plasma catecholamine 
samples which could be assayed in these studies.
High Performance Liquid Chromatography
Since the beginning of this decade increasingly 
sophisticated assays based on high performance liquid 
chromatography (H.P.L.C.) have been used to measure 
plasma catecholamines and the recent application of 
electrochemical detection methods to H.P.L.C. has, for 
the first time, allowed accurate detection of relatively
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low plasma concentrations of catecholamines (Mefford et 
ai.,1981; Watson, 1981; Kissinger, Bruntlett & Shoup,
1981) .
The technique is based on a direct conversion of 
chemical information to an electrical signal without the 
need for intermediate optical or magnetic carriers. All 
catechol derivatives can be readily oxidised at a 
graphite electrode to generate the corresponding 
othroquinone, two protons and two electrons. Thus if the 
the anodic current, i.e. the rate at which electrons are 
transferred across the electrode-solution interface, is 
measured then the instantaneous current is directly 
proportional to the number of molecules coming into 
contact with the interface per unit time and this can be 
used to determine the concentration of the reactant in 
the neighbouring solution. The problem faced in assaying 
catecholamines in both tissues and plasma was that all 
catechol derivatives react similarly and cannot be 
distinguished. The development of modern reversed phase 
or ion-exchange liquid chromatography, using 
microparticle columns capable of rapidly separating 
closely related compounds, has now made this technique 
applicable to the measurement of catecholamines in 
plasma. The instrumentation and reagents are relatively 
inexpensive and the number of sample manipulations are 
fewer than with earlier methods.
The method used was developed by Howes and co-workers
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and has a coefficient of variation of 5-10% and a limit 
of detection of 0.1 nmol l"1 (20 pg ml-1) for both
adrenaline and noradrenaline. The system was a paired ion 
reverse phase HPLC system with an electrochemical 
detector with a mobile phase containing phosphate buffer 
and octyl sulphonic acid as the paired ion reagent. A 5 
micron ODS column was employed with 3,4 dihydroxy
benzolamine hydrobromide as the internal standard (Howes, 
Miller & Reid, 1985).
The major disadvantage of this method is that the
reliability of the instrumentation and columns is not 
perfect and, thus, the degree of sensitivity is less than 
with the radio-enzymatic assay method.
Goldstein and coworkers directly compared the accuracy 
of the liquid chromatography method, using
electrochemical detection, with the radio-enzymatic assay 
in measuring noradrenaline and adrenaline levels in 
normal resting healthy subjects. In a series of 25
samples the correlation between the two methods was 0.99.
However at concentrations below 0.55 nmol 1” -^ (100 pg ml” 
the coefficient of variation of the H.P.L.C. methods
with E.C.D. was higher (26-46% for adrenaline
—  1 —  1concentrations less than 0.55 nmol 1 -1- (100 pg ml A)
compared to a C.V. of 7-11% above this level) and these 
authors conclude that at very low plasma adrenaline and 
noradrenaline concentrations then the H.P.L.C. method is 
less reliable (Goldstein et al., 1981). As resting plasma
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adrenaline concentrations are usually in the range 0.19-
—  1 —  10.41 nmol 1 ( 35-75 pg ml ) then this method is not
applicable to situations where adrenaline levels are
known to be this low. It is, however, accurate at the
levels of adrenaline which result from the adrenaline
infusion protocols used in these studies.
3.3 Adrenaline infusion regimen.
Infusion of high doses of adrenaline into subjects, 
normal or ill, can be hazardous with a variety of 
possible adverse effects occurring, ranging from acute 
chronotropic effects on the heart, triggering cardiac 
arrhythmias, to myocardial necrotic lesions and renal 
glomerular damage with chronic infusions (Horak et al, 
1983; Mandal et al, 1977). Early studies of the effects 
of adrenaline in man used intravenous bolus injections 
and more recent studies used short infusions of 
relatively large doses of adrenaline. These studies 
failed to achieve steady-state adrenaline concentrations 
and, thus, make observation of concentration-effect 
relationships impossible (Duff & Swan, 1951; Swan 1951; 
Massara, Tripodina & Rotunno, 1971).
An infusion regimen which was safe, which could be 
continued for 120 minutes and which would achieve 
circulating adrenaline level in the physiological -range 
with levels similar to those seen in acute severe 
illness, between 1.0-5.0 nmol 1~^, had to be developed.
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An additional complicating factor was the wide inter­
individual variation in catecholamine clearance 
(Fitzgerald et al, 1979) and, therefore, any infusion 
regimen chosen would result in a wide range of adrenaline 
concentrations in different individuals (Clutter et al., 
1980). For safety a step infusion regimen was designed, 
starting with a very low dose of adrenaline, and 
increasing the dose once steady state had been achieved 
with each dose, if there were no untoward effects. 
Previously published data suggested that steady state 
would be achieved for a given dose after 5-8 minutes and 
the infused dose was therefore increased at 10 minute
intervals, providing the heart rate had not increased by 
_ 1
20 beats m m  ■L or the systolic blood pressure had not 
increased by 30mm Hg.
-1 -1The starting dose of adrenaline was O.Olug kg min . 
This dose was increased stepwise at 10 minute intervals 
to 0.02ugkg-  ^min” ,^ then to 0.04]igkg“  ^min”  ^ and finally 
to 0.06jig kg-  ^ min” .^ This dose was then continued for 
the period of the adrenaline infusion, a further 90 
minutes. In 4 subjects plasma adrenaline concentrations 
were sampled both during and following the adrenaline 
infusion to confirm the plasma adrenaline levels achieved 
by this regimen were in the desired range and to document 
the time course for adrenaline levels to return to 
baseline after the infusion. Such a sampling protocol was 
not possible in every subject in these studies due to
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considerations of cost, as the more expensive radio- 
enzymatic assay was required to measure the low 
adrenaline levels seen after the infusions.
The data in the 4 subjects in whom the time adrenaline 
concentration profile was examined is given in Table
3.3.1 and indivdual concentration time curves are given 
in Appendix 3.
During the stepwise increase in the infused dose the 
effect of an infusion rate of 0.02ug kg”-*- min”-*- was
unpredictable, the adrenaline levels rising in one 
subject, falling in one and being unaltered in a third. A 
dose of 0.04ug kg”-*- min”-*- increased adrenaline levels in 
all subjects to a very variable degree, one to six fold 
times basal levels. The maximum dose, 0.06p.g kg”-*- min”-*-, 
increased adrenaline levels in all subjects five to ten 
fold within 5 minutes of commencing this dose (95').
During the period of the infusion of this dose, 0.06y.g
-1 . — 1kg A m m  adrenaline levels did fluctuate. The infusion 
pump used, the Braun IV is a highly accurate volume
infusion device and it is unlikely that it is the cause 
of this variablity. The most likely explanation being 
variation in the subject's arm position. The arm was not 
splinted, so as to allow subjects to read, eat and drink. 
Possibly, flexion of the arm led to partial venous
obstruction and a fall in the delivery of adrenaline to 
the central circulation due to the resultant venous
pooling. Equally when the arm is straightened then a
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Table 3.3.1 Time-Plasma adrenaline concentration curves
during and after the adrenaline infusion regimen in _4 
normal subjects.
Subject Number
Time Adr. Dose
—  1 —  1(mins) (ug kg x min A)
30 0 0.11 0.24 0.27 0.55
80 0.02 0.13 0.58 0.09
90 0.04 0.88 2.00 2.90 0.39
95 0.06 2.60 2.60 2.70 1.90
100 0.06 1.40 2.10 2.90 3.80
110 0.06 1.00 3.50 3.60 3.80
120 0.06 1.70 2.40 4.50 3.20
150 0.06 2.70 - 2.60 2.60
180 0.06 2.20 3.80 3.50 1.50
182 0 0.49 4.20 1.10 1.70
185 0 0.83 1.60 0.54 0.78
210 0 0.33 0.94 0.21 0.20
86
bolus of adrenaline would be delivered to the central 
circulation.
The range of plasma adrenaline concentrations observed 
during the infusion was wide, ranging from 1.0 to 5.0 
nmol 1“-*-. In all subjects the average plasma adrenaline 
concentration lay between 2.0 and 4.0 nmol l--*- and this 
was at least 20 times basal plasma adrenaline 
concentrations in all subjects. At no time during the 
infusions were plasma adrenaline concentrations less than 
10 times the basal concentrations. During the 90 minute 
period of a constant rate of infusion of adrenaline 
(0.06ug kg” -^ min”-*-) the adrenaline levels fluctuated
randomly in three of the subjects, but in the fourth the 
adrenaline levels fell progressively during the period of 
the infusion. The reason for this progressive fall is 
unclear, though one possible explanation is that the 
patient was inadvertently given a large bolus of 
adrenaline whilst the adrenaline infusion was being 
altered and the levels fell thereafter.
The infusion of adrenaline was stopped at 180 minutes 
and an infusion of 5% (+)-glucose continued, thereafter, 
through the same intravenous cannula at the same rate, 12 
mis hr-1. Sampling at 180' and 182' revealed that in two 
subjects the plasma adrenaline concentration had risen 
above the 180' level at 182', two minutes after the 
adrenaline infusion had ceased. The most likely 
explanation for this finding is that small volumes of the
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adrenaline containing solution were in the cannula and 
were infused when the (+)-glucose infusion was commenced. 
However, in both these subjects the adrenaline 
concentration had fallen when measured after a further 3 
minutes at 185'. Paradoxically in one subject (No. 1) the 
adrenaline concentration which had fallen steeply between 
180' and 182’ rose slightly between 182' and 185' 
minutes, possibly because of delay in restarting the 
infusion pump with the 5% (+)-glucose solution. As a
result of this transient rise in adrenaline concentration 
after the end of the adrenaline infusion it is difficult 
to accurately calculate the half-life of the infused 
adrenaline. In these four subjects the half life varied 
between 3 and 13 minutes but it is important to emphasise 
these are only estimates and there may be a relatively 
large error in some subjects for the reasons discussed 
above. At 210 minutes, 30 minutes after the cessation of 
the adrenaline infusion, adrenaline levels had returned 
to basal levels in all but one of the subjects in whom it 
remained elevated at approximately four times the 
previous basal level (subject 2).
In summary, the results suggest that, with this 
infusion regimen, circulating plasma adrenaline levels 
were increased by at least 10 fold. During the period of 
continous adrenaline infusion marked fluctuations in 
adrenaline levels did occur. Thirty minutes after the end 
of the adrenaline infusion plasma adrenaline levels will
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usually have returned to basal levels.
3.4 Standard Measurements and Assays.
Sample handling and analysis.
Plasma catecholamine and plasma potassium samples were 
collected and handled in a similar fashion for all 
studies reported in this thesis. In separate studies 
other assays were used, e.g. plasma insulin (4.2) and 
details of these assays are given in the appropriate 
chapter.
Briefly, catecholamine samples were collected into 
heparinised tubes, kept on ice, centrifuged at 4°C and 
stored at -70°C until assayed by one of two methods as 
outlined above (3.2), either by the radioenzymatic method 
(Da Prada & Zurcher, 1975) or by H.P.L.C. (Howes et al, 
1985) .
Plasma potassium samples were collected into glass 
tubes at room temperature and centrifuged within 20 
minutes and separated. They were subsequently analysed on 
an automated autoanlayser using standard flame photometry 
methods (SMA-C, Technicon Instruments Corporation, New 
York, U.S.A.).
Haemodynamic Measurements.
In all studies heart rate and blood pressure were 
closely monitored during the adrenaline infusions. Heart 
rate and blood pressure were measured, in duplicate, at 
all appropriate time points by the use of a semi­
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automated sphygmomanometer, Sentron (Bard Biomedical 
Division, Lombard, Illinois, U.S.A.). Electrocardiograms 
were recorded with praecordial electrodes and displayed 
continously on an oscilloscope linked to a polygraph 
(Grass Model 7D).
3.5 Statistical Analysis.
As the number of subjects studied in each of these 
experiments was relatively small, and as all studies 
involved multiple comparision of treatments with placebo, 
the most appropriate form of analysis was analysis of 
variance as applied to repeated measures (Winer, 1971). 
If there were significant differences between baseline 
then allowance for such baseline differences was made in 
the analysis of variance program used (Bryce, 1981). 
Where appropriate paired student’s t-test was used to 
examine differences before and after an intervention, if 
repeated measurements were not involved, e.g. adrenaline 
clearance on placebo and theophylline (Chapter 6.3).
3.6 Ethical Permission.
The protocols of all the studies which are described in 
this thesis were submitted to, and approved by, the 
Research and Ethical Committee of the Northern District 
of Greater Glasgow Health Board. All subjects gave fully 
informed, written consent before participating in these 
studies.
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4. BETA ADRENOCEPTORS IN THE CONTROL OF PLASMA 
POTASSIUM.
4.1 Introduction.
As discussed above (Chapter 1.5), a number of separate 
pieces of evidence have accumulated, since D'Silva's 
original experiment in 1934 (D'Silva, 1934), particulary 
the work of Clausen, to suggest that a beta2 -adrenoceptor 
was central to the phenomenon of adrenaline induced 
hypokalaemia.
The aims of the three studies described in this chapter 
were to examine the mechanism of adrenaline induced 
hypokalaemia further by studying:-
(1) the effect of adrenaline infusions on insulin 
secretion, as increased insulin levels would result in 
hypokalaemia by increasing transport of potassium into 
cells.
(2) the effect of stimulation of the beta2 -adrenoceptor, 
using the highly selective beta2 _adrenoceptor agonist, 
salbutamol, to exclude any possible contribution to 
adrenaline induced hypokalaemia by the activity of 
adrenaline at the beta-]_-adrenoceptor or alpha-receptor.
(3) the effect of selective and non-selective antagonists 
of the beta-adrenoceptor on adrenaline induced 
hypokalaemia. In two similar studies the effect on 
adrenaline induced hypokalaemia of five beta-adrenoceptor 
agonists, each with different pharmacological profiles
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was examined. In addition, the action of the beta- 
antagonists on the haemodynamic effects of adrenaline, 
i.e. its chronotropic action, a predominately beta^- 
adrenoceptor action, and the fall in diastolic blood 
pressure, a beta2 -adrenoceptor action, were also 
examined.
4.2 Non-selective and selective beta-adrenergic 
stimulation ^ the effect on plasma potassium.
4.2.1 Introduction.
Insulin promotes intracellular shift of potassium, a 
fact long applied in clinical practice in the treatment 
of life-threatening hyperkalaemia. Control of insulin 
release is complex and involves many factors, including 
the sympathetic nervous system (Porte et al, 1966). 
Insulin release, stimulated by adrenaline, is a possible 
mechanism for adrenaline induced hypokalaemia. The effect 
of the adrenaline infusion regimen on plasma insulin was 
therefore studied.
In animal skeletal muscle previous work has suggested 
that the effect of adrenaline on plasma potassium is 
mediated via a membrane bound Na+/K+ ATPase linked to a 
beta2 -adrenoceptor (Clausen & Flatman, 1977). By adding 
another limb to this study the effect of a highly 
selective beta2 -adrenoceptor, salbutamol, on plasma 
potassium, insulin and glucose could be compared to the 
effects of adrenaline.
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The two principal aims were therefore to exclude 
insulin release as the mechanism of either adrenaline 
induced hypokalaemia or salbutamol induced hypokalaemia. 
Secondly to examine if adrenaline induced hypokalaemia is 
the result of beta2-adrenoceptor stimulation by comparing 
adrenaline's effects with salbutamol's.
Modifying the design of the study allowed study of a 
further question, do salbutamol and adrenaline have an 
additive effect in lowering plasma potassium? Salbutamol 
is a widely used bronchodilator, frequently given to 
patients both as a maintenance treatment and during the 
treatment of life-threatening attacks of dyspnoea when 
adrenaline levels may be raised (2.3).
In summary in this single blind, crossover study 
salbutamol or placebo was administered to subjects in 
whom adrenaline or placebo had been infused sufficient to 
achieve pathophysiological circulating adrenaline 
concentrations (Struthers & Reid, 1984). The effects of 
these combinations of infusions on cardiac rhythm, blood 
pressure, plasma potassium, glucose and insulin were 
studied.
4.2.2 Methods.
Eight healthy subjects, 4 males, 4 females, age range 
22-37 years, weight range 52-85kg., were studied on four 
separate occasions at least one week apart, receiving one 
of four treatments in random order in a single blind,
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crossover design. They had normal electrocardiograms, 
serum biochemistry and haematology before study. They 
were receiving no drug therapy.
The four treatments consisted of:
- 1) An (-)-adrenaline infusion intravenously and a 
control vehicle salbutamol infusion;
- 2) A control vehicle adrenaline infusion and an 
active salbutamol infusion;
- 3) Both an active (-)-adrenaline and an active 
salbutamol infusion;
- 4) Two control vehicle infusions.
Randomisation was by means of a balanced Latin square
design. Study days were identical in all respects other 
than the treatments administered.
Subjects were studied supine after a standard light 
breakfast and no alcohol, caffeine or cigarettes for at 
least 12 hours. Cannulae were inserted, one into each 
forearm. The adrenaline infusion regimen used was a 
modified protocol from that outlined in Chapter 3. After 
30 minutes supine rest, a 5% (+)-glucose infusion
containing ascorbic acid, 1 mg ml“ ,^ was given, at a rate 
of 12 ml hour-  ^ for 60 minutes. This was followed by an 
(-)-adrenaline infusion in 5% (+)-glucose containing
ascorbic acid, lmg ml"’^ , at a rate of 0.03]ig kg-  ^ min-  ^
for 10 minutes or 5% (+)-glucose also containing ascorbic 
acid was continued as a control. If there were no 
symptoms or adverse effects then the infusion rate was
95
increased to 0.06ug kg-1 min-1 and continued for a total
of 110 minutes.
During the second hour an intravenous infusion of
salbutamol (Ventolin, Allen & Hanburys Ltd., Greenford ,
Middlesex, U.K.) or an identical (+)-glucose vehicle
salbutamol infusion was administered according to the
randomised design. The salbutamol infusion was commenced
—  1 - 1at a dose of 40 ng kg x m m  increasing stepwise at 15
minutes intervals to a dose of 80 ng kg”-*- min”-*- and then
to 120 ng kg”-*- min”-*- if no adverse effects occurred. This
final dose of salbutamol was continued for 30.minutes, a
total duration of salbutamol of 60 minutes, average rate
—  i — 1of delivery over, the hour being 90 ng kg x m m  x. 
Following the salbutamol and adrenaline infusions or 
identical vehicle controls a 5% (+)-glucose infusion was 
continued for a further one hour. Exact times of the 
various measurements and treatments are shown in Fig
4.2.1.
Blood pressure and heart rate were measured by a semi­
automated sphygmomanometer (Chapter 3.4).
Samples for plasma potassium and plasma catecholamines 
were handled as described previously (Chapter 3.4). 
Plasma catecholamine levels were assayed by the 
radioimmunoassay method (Chapter 3.2).
Plasma insulin samples were collected into heparinised 
tubes, kept on ice, and centrifuged at 4°C and stored at 
-70°C for subsequent analysis using a conventional
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Fig. 4.2.1: OUTLINE OF STUDY DAY
double antibody radioimmunoassay based on guinea-pig 
anti-insulin serum (Wellcome). I125-insulin (Amersham 
International) and a rabbit anti-guinea pig second 
antibody covalently linked to Sepharose Cl 4B. Glucose 
samples were measured by a Beckman glucose analyser using 
the glucose oxidase method. Salbutamol levels were 
measured at the start of the 120 ng kg--*- min "-*- dose and 
at the end of the infusion by high pressure liquid 
chromatography.
Results are expressed as mean + standard deviation. The 
four treatment days were compared by repeated measures 
analysis of variance and significance values are quoted, 
corrected for variations in baseline (Chapter 3.5).
4.2.3 Results.
All subjects tolerated the infusions of both adrenaline 
and salbutamol alone and together with no serious adverse 
effects though all were aware, on direct questioning, of 
tremor of the upper limbs with salbutamol but not with 
adrenaline.
Basal resting plasma adrenaline levels, prior to the 
infusions, were not significantly different on any of the 
four study periods (Table 4.2.1).
Salbutamol was only identified in plasma following 
active salbutamol infusions. Salbutamol concentrations 
are shown in Table 4.2.1 at the start and at the end of 
the highest dose of salbutamol infused (120 ng kg”-*- min--*-). 
As would be predicted from salbutamol's long half-life,
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Table 4.2.1:- Salbutamol and adrenaline concentrations.
Plasma adrenaline (lower limit of detection 0.1 
_ 1
nmol 1 -1-) before and at the end of the adrenaline 
infusion period and salbutamol concentrations 
after 30 and 60 minutes of the active or control vehicle 
infusions (mean+S.D.; n=8).
(A=adrenaline; S=salbutamol; U .D .=undetectable.).
Treatment
Vehicle A 
+
Vehicle S
Salbutamol Cone 
(ng ml"1)
1801 210 *
U.D. U.D.
Adrenaline Cone, 
(nmol l"1)
30' 210'
< 0.1 < 0.1
Adrenaline
+
Vehicle S
U.D. U.D, 0.16±0.16 2.33 + 1.62
Vehicle A
+ 2.610.8 
Salbutamol
4.610.8 0.1210.03 < 0.1
Adrenaline 
+ 1.910.5
Salbutamol
4.410.3 < 0.1 3.1711.89
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salbutamol levels were still rising at the end of the 
infusion.
Heart rate before the infusion was not significantly 
different on any of the treatments (Table 4.2.2). Heart 
rate did not alter significantly during the study in 
which both vehicle infusions were given. It did alter 
significantly on all three of the other treatments (Table
4.2.2). the greatest increase in heart rate was seen on 
the combined adrenaline and salbutamol treatment (99+19 
beats min--*- compared to 65±ll,p<0.001, ANOVA) . There were 
smaller significant rises in heart rate on salbutamol 
alone and on adrenaline alone (Table 4.2.2).
Systolic blood pressure rose significantly with
salbutamol alone but did not rise significantly on the 
other study days compared to the control study day (Table
4.2.3). Diastolic blood pressure showed a small but 
significant fall on adrenaline alone (Table 4.2.4).
On the control study day potassium levels rose
slightly, but not significantly, from the baseline of 
3.8±0.3 mmol 1“  ^ to 4.0±0.3 mmol 1”  ^ at the end of the 
5% (+)-glucose infusions (Fig 4.2.2). Potassium levels
fell and were significantly different from placebo on all 
three active treatments, by 0.45mmol 1”  ^ on adrenaline 
alone (p<0.01), by 0.48 mmol l”1 on salbutamol alone 
(p<0.01) and by 0.94 mmol I-1 with the combination of 
adrenaline and salbutamol (p< 0.001, Figure 4.2.2, Table
4.2.5). The fall in plasma potassium with the combination
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Tim
30
60
90
100
110
120
150
165
180
195
210
240
270
4.2.2:- Mean heart rate at each time point on each 
treatment.
(beats min-1; n=8, meaniS.D.).
Placebo Adrenaline Salbutamol Adren. + Salb.
67 + 9 71 + 9 67 + 9 68 + 7
64 + 9 70 + 7 67 + 8 65 + 8
64 + 9 68 + 8 65 + 10 64 + 6
61 + 10 70 + 9 65 + 7 71 + 11
62 + 11 . 74 + 11 64 + 9 71 + 10
62 + 11 73 + 11 66 + 7 71 + 9
63 + 10 77 + 9 64 + 10 77 + 13
62 10 76 + 12 68 + 14 82 + 14
64 + 10 75 + 12 74 + 12 90 + 16
62 + 7 78 + 12 78 + 18 98 + 19
65 + 11 79 + 14 87 + 19 99 + 19
63 + 9 75 + 10 82 + 14 88 + 14
66 + 10 76 + 13 75 + 15 87 + 12
p<0.01 p<0.05 p<0.001
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Table 4.2.3:- Mean systolic blood pressure at each time
point on each treatment.
(mm Hg; n=8; meaniS.D.).
Time
(mins)
Placebo Adrenaline Salbutamol Adren. +
30 119 + 12 116 + 9 115 + 9 116 + 12
60 114 + 8 117 + 13 111 + 9 114 + 12
90 112 + 8 111 + 14 110 + 12 113 + 12
100 111 + 8 111 + 14 108 + 8 113 + 10
110 110 + 10 116 + 11 108 + 11 118 + 12
120 109 + 12 120 + 17 110 + 11 119 + 14
150 108 + 11 122 + 12 106 + 7 120 + 13
165 108 + 9 120 + 16 112 + 7 121 + 16
180 110 + 9 119 + 12 118 + 9 123 + 12
195 113 + 9 117 + 15 122 + 14 131 + 11
210 111 + 8 118 ± 17 123 + 12 121 + 17
240 113 + 7 114 + 10 115 + 16 115 + 10
270 113 + 9 114 + 11 113 + 12 121 + 10
p>0.05 p<0.05 p>0.05
Salb.
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Table 4.2.4:- Mean diastolic blood pressure at each time
point on each treatment.
(mm Hg; n=8;
Time Placebo Adrenaline
(mins)
30 63 + 6 64 + 3
60 62 + 7 59 + 3
90 61 + 3 62 + 3
100 61 + 5 60 + 6
110 59 + 5 .60 + 5
120 62 + 7 60 + 8
150 60 + 8 60 + 6
165 62 + 4 57 + 10
180 61 ± 6 55 + 8
195 63 ± 5 56 + 9
210 62 ± 5 57 + 5
240 60 ± 8 61 + 8
270 62 ± 4 64 + 3
p<0.05
meaniS.D.)
Salbutamol Adren. + Salb.
63 ± 6 63 + 4
59 ± 6 62 ± 4
60 ± 5 59 ± 5
60 ± 4 58 ± 7
60 ± 6 57 + 3
61 ± 6 56 + 4
57 ± 5 58 ± 3
57 ± 5 58 ± 7
58 ± 2 61 ± 5
58 ± 4 56 ± 5
60 ± 4 56 ± 5
+iCMVD 8 62 ± 8
60 ± 4 61 ± 7
p>0.05 p>0.05
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Time
lins)
30
90
120
150
165
180
195
210
240
270
4.2.5:- Mean plasma potassium at each time point on 
each treatment.
(mmol 1“ ;^ n=8: meaniS.D.).
Placebo
3.8 ± 0.3
3.9 ± 0.2
4.1 ± 0.3
4.1 ± 0.2
4.1 ± 0.2
4.1 ± 0.2
4.1 ± 0.2
4.0 ± 0.3
4.0 ± 0.2
4.0 + 0.3
Adrenaline
3.8 + 0.5
4.0 ± 0.3
3.6 ± 0.6
3.5 + 0.6
3.4 ± 0.5
3.4 ± 0.4
3.4 ± 0.4
3.4 ± 0.5
3.5 ± 0.4
4.0 ± 0.4 
p<0.01 J . •
Salbutamol
3.9 ± 0.3
3.8 ± 0.2
4.0 ± 0.2
4.0 ± 0.2
4.0 ± 0.2
3.9 ± 0.4
3.6 ± 0.3
3.4 ± 0.2
3.5 ± 0.3
3.7 ± 0.4
p<0.01
Adren. + Salb.
3.8 ± 0.2
3.9 ± 0.2
3.5 ± 0.3
3.3 ± 0.3
3.3 ± 0.3
3.1 ± 0.4
3.0 ± 0.3
2.9 ± 0.3
3.2 ± 0.2
3.4 ± 0.2
p<0.001
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of adrenaline and salbutamol was 0.94 mmol l"1 and is 
similar to the sum (0.93 mmol l"1) of the individual 
falls observed with adrenaline (0.45 mmol 1“ )^ and 
salbutamol (0.48 mmol 1“ )^ alone.
Insulin levels fell during the control study period (Fig
4.2.2, Table 4.2.6). During the salbutamol alone infusion
there was an insignificant rise in insulin levels, from
16 + 6 i.u. 1”1 to 26 + 18 i.u. 1” .^ Insulin levels were
unchanged during the combined salbutamol and adrenaline
and on the adrenaline alone study periods (Figure 4.2.2).
Insulin levels rose sharply following the cessation of
_ 1
the adrenaline infusion, from 19±6 i.u. 1 x at the end of 
the adrenaline infusion to 39±23 on the adrenaline alone 
day and from 22±5 i.u. 1”  ^ to 56 + 23 i.u. 1“  ^ on the 
adrenaline plus salbutamol day compared to a rise from 
12 + 8 to 14±12 i.u. 1“  ^ on the vehicle control plus 
vehicle control study day.
Glucose concentrations remained unchanged during the 
vehicle control infusion and on salbutamol alone study 
period (Figure 4.2.2, Table 4.2.7). On the other two days 
there was a significant rise in glucose levels during the 
infusion period (adrenaline alone p<0.0 1; adrenaline and 
salbutamol p<0.0 01). There was a dramatic fall in glucose 
levels following the end of the adrenaline infusions 
(Figure 4.2.2, Table 4.2.7).
4.2.4 Discussion.
During the period of the adrenaline infusion plasma
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Table 4.2.6:- Mean plasma insulin at each time point on
each treatment.
_ -i
(i.u. 1 S  n=8, mean ± S.D.)
Time Placebo Adrenaline Salbutamol Adren. +
(mins)
30 33 + 22 42 + 27 33 + 19 38 ± 28
90 20 + 5 24 + 9 27 + 8 26 + 12
120 21 + 8 18 + 6 20 + 10 17 ± 6
150 17 + 6 22 + 9 16 + 6 21 ± 10
165 15 + 5 23 + 8 17 + 6 25 ± 11
180 10 + 4 24 + 12 21 + 7 23 ± 6
195 13 + 5 24 + 10 22 + 13 27 ± 8
210 12 + 8 19 + 6 26 + 18 22 ± 5
240 14 ± 12 39 + 23 18 + 12 56 ± 23
270 20 + 21 19 + 13 21 + 32 58 ± 30
p>0.05 p>0.05 p>0.05
Salb.
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Table 4.2.7:- Mean plasma glucose at each time point on
each treatment.
(mmol l-1, n=8; mean ± S.D.).
Time Placebo Adrenaline Salbutamol Adren. + Salb.
(mins)
30 5.4 +
00•o 5.6 + 1.3 5.6 ± o • 00 5.1 +
00o
90 4.7 + 1.1 4.6 + 0.8 4.2 + 1.0 4.6 + 0.9
120 4.8 + 0.5 5.6 + 0.8 4.3 + 0.5 6.1 + 1.5
150 4.8 + 0.8 7.4 + 1.4 4.5 + 0.5 7.3 + 1.6
165 4.8 + 0.8 8.5 ± 1.6 4.7 + 0.6 7.9 + 1.7
180 4.9 + 0.9 8.7 + 1.9 4.9 + 0.9 8.2 + 1.9
195 4.8 + 0.3 00 • 00 + 1.7 5.5 + 1.0 8.8 + 2.0
210 4.7 + 0.4 8.0 + 1.6 5.5 + 1.2 9.1 + 1.8
240 4.6 + 0.4 7.4 + 1.9 5.4 + 0.9 8.9 + 2.1
270 5.1 + 0.5 5.5 + 1.0 5.5 + 0.7 7.0 + 1.6
p<0.01 p>0.05 p<0.001
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insulin levels did not rise thus excluding insulin 
release as a mechanism of adrenaline induced 
hypokalaemia. Porte and co-workers demonstrated that 
insulin release is inhibited by alpha^-stimulation and 
increased by beta2-stimulation (Porte et al, 1966; Imsura 
et al, 1971). A further study also suggested that the 
inhibitory alpha action is dominant at these levels of 
circulating adrenaline (Williams-Olson et al, 1979). In 
this study plasma glucose rose during the adrenaline 
infusion but insulin failed to rise in response to this 
relative hyperglycaemia until after the adrenaline 
infusion was stopped. During the period of increasing 
insulin levels, following the end of the adrenaline 
infusion, plasma potassium levels actually increased 
providing further evidence that rises in circulating 
insulin are not the mechanism of adrenaline induced 
hypokalaemia.
Salbutamol is a highly selective beta2-receptor agonist 
and has no alpha-agonist properties. Thus during the 
salbutamol infusion insulin levels rose whilst plasma 
potassium levels fell. It has been previously suggested 
that salbutamol induced hypokalaemia, an increasingly 
frequently recognised phenomenon, is the result of 
stimulation of insulin release (Leitch et al, 1976). 
Though these modest changes in plasma insulin cannot be 
definitely excluded as a cause of salbutamol induced 
hypokalaemia, careful analysis of the data reveals that 
the rise ' in plasma insulin was greater following the
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light standard breakfast / a period when plasma potassium 
levels were unaltered, than during the salbutamol 
infusion. Further evidence against insulin being 
implicated is provided by changes in plasma insulin and 
plasma potassium when both adrenaline and salbutamol were 
administered. Plasma insulin levels did not rise yet the 
fall in plasma potassium was increased when the 
salbutamol infusion was added to the adrenaline infusion, 
again suggesting that salbutamol was lowering plasma 
potassium by a mechanism other than increasing plasma 
insulin levels.
The second aim was to examine if adrenaline induced 
hypokalaemia could be the result of beta2 “adrenoceptor 
stimulation by comparing adrenaline and salbutamol. 
Salbutamol is a highly selective beta2 ~receptor agonist 
which has been noted to cause hypokalaemia. Original 
reports of hypokalaemia occurring followed intravenous 
doses (Korda, Lyneham & Jones, 1974; Leitch et al, 1976; 
Neville et al, 1977; Philips et al, 1980; Moravec & 
Hurlebert, 1980; Smith & Thompson, 1977) or self- 
poisoning with salbutamol (O'Brien et al, 1981). Recently 
reports have appeared of hypokalaemia with lower doses of 
salbutamol and other similar selective beta2 -agonists 
administered subcutaneously (Kung, White & Burki, 1984) 
and by inhalation (Smith & Kendall, 1984; Haalboom, 
Deenstra & Struyvenberg, 1985). As salbutamol has a long
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half-life (4-6 hours), salbutamol levels rose throughout 
the infusion period and the maximum effect of this dose 
(120 ng kg-1 min-1), which is equivalent to a dose of 
8.4jig min-1 (33.6nmol min-1) in a 70kg. man,, was not 
observed. Nevertheless, allowing for the differences in 
the infusion regimens used for adrenaline and salbutamol 
the pattern of fall in plasma potassium is very similar, 
though recovery is delayed following salbutamol 
presumably due to its lower rate of clearance.
Finally, combining therapeutic doses of intravenous 
salbutamol and pathophysiological levels of circulating 
adrenaline demonstrated the effects of the combination of 
adrenaline and salbutamol were additive. Clearly neither 
adrenaline nor salbutamol, in the doses given in this 
study, were maximally stimulating the movement of 
potassium from the extracellular compartment. Combining 
the drugs in these doses resulted in profound 
hypokalaemia.
A significant chronotropic action was observed with both 
active agents and this effect was increased by combined 
therapy. Hypokalaemia predisposes to cardiac 
dysrhythmias, however, none were observed in these young 
healthy subjects. As previously discussed in asthmatic or 
bronchitic patients there is conflicting evidence as to 
circulating adrenaline levels (Chapter 2.3). However, the 
use of beta-agonists and other sympathomimetic agents as 
bronchodilators during acute episodes of severe
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bronchospasm, with associated acidosis and hypoxaemia, 
could result in hypokalaemia and increase the risk of 
cardiac dysrhythmias.
In conclusion, this study excludes insulin release as a 
cause of adrenaline induced hypokalaemia and strongly 
suggests, but does not prove, that salbutamol induced 
hypokalaemia is also not the result of insulin release 
and may be due to stimulation of a beta2 ~receptor, most 
probably a membrane-bound beta2 ~linked Na+/K+ ATPase on 
skeletal muscle causing potassium influx into cells.
4.3 Adrenaline induced hypokalaemia: the effect of non- 
selective and selective beta adrenergic antagonists.
4.3.1 Introduction.
If indeed adrenaline induced hypokalaemia is the result 
of stimulation of a membrane bound Na+/K+ ATPase then it 
should be possible to further characterise the beta- 
receptor involved by examining the effects of beta- 
adrenergic antagonists with differing selectivity for 
beta-^ - and beta2 -adrenoceptors. Beta antagonists may, in 
addition, to selectivity, have a number of other 
pharmacological properties including intrinsic 
sympathomimetic activity (ISA), i.e. the drug has a 
partial agonist effect when competitively bound to the 
receptor.
The effects of chronic treatment with three beta- 
antagonists with different pharmacological profiles on
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the hypokalaemia and haemodynamic changes induced by 
adrenaline were studied. The beta-antagonists studied 
were propranolol (non-selective with no ISA); oxprenolol 
(non-selective with modest ISA); and atenolol (P^- 
selective with no ISA).
4.3.2 Methods.
Eight healthy volunteers were studied in a double-blind, 
placebo controlled crossover design. Individual details 
are given in Table 4.3.1. Treatments were randomly 
allocated by a balanced Latin square design. All 
treatments were given in a disguised formulation and had 
an identical appearance.
Volunteers were on no drug therapy and all subjects 
received all the treatments, each for one week, and there 
was a minimum 2 week washout period between treatments. 
Two alternative doses of each treatment were available, 
atenolol lOOmg or 200 mg; propranolol 160mg or 320mg; 
oxprenolol 250mg or 500mg. The dose of the beta- 
antagonist was increased after 48 hours if there was not 
a 20% reduction in exercise induced heart rate compared 
to an identical exercise test on no treatment at the 
start of the study. In all subjects the lower dose was 
used.
Subjects were studied on the seventh day of each 
treatment period having fasted for at least eight hours 
and having abstained from tobacco, alcohol and caffeine
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Table 4.3.1:-Individual volunteer data.
Volunteer No. Sex Age Weight Biochemistry.
(yrs) (kg) (N=normal)
1 Female 25 51 N
2 Female 21 54 N
3 Female 29 73 N
4 Male 36 65 N
5 Male 34 84 N
6 Male 36 76 N
7 Male 31 62 tf-GT 96i.u. I"1
8 Male 23 58 N
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containing beverages for 10 hours. Intravenous cannulae 
were inserted into each antecubital fossa and the 
subjects given a light standard breakfast. The subjects 
were studied supine throughout the study period. 
Following one hour of rest baseline measurements of heart 
rate, blood pressure and plasma potassium were made and a 
5% (+)-glucose (dextrose) infusion with ascorbic acid
(lmg ml” )^ was commenced at an infusion rate of 12 ml 
hour- . After one hour of the vehicle solution the
baseline measurements were repeated. The adrenaline 
infusion was then started and increased stepwise at 10 
minute intervals in the standard infusion protocol as 
detailed in Chapter 3.3. Adrenaline was given for a total 
period of 120 minutes and throughout this period heart 
rate, blood pressure and plasma potassium were measured 
regularly as shown in Fig.4.3.1. Following the 
administration of the adrenaline the vehicle was
continued for a further two hours.
Plasma concentrations of each of the beta-blockers were 
measured by high performance liquid chromatography from a 
5ml. lithium heparin venous sample.
Samples for plasma catecholamines were collected as
outlined in Chapter 3.4 and analysed at a later date by
the radioenzymatic assay method for the samples prior to 
infusion and by the H.P.L.C. method with electrochemical 
detection for the samples taken during the adrenaline 
infusion (see Chapter 3.2).
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Fig. 4.3.1.: OUTLINE OF STUDY DAY
Results are quoted as mean + standard deviation and 
treatment periods were compared with the placebo study 
day by repeated measures analysis of variance and 
significance values are quoted corrected for baseline 
differences (see Chapter 3.5).
4.3.3 Results.
No volunteer reported any adverse effects from either 
the beta-antagonists or the adrenaline infusions. The 
plasma concentrations of the beta-antagonists are shown 
in Table 4.3.2, a wide range being seen with all three 
agents. The baseline plasma adrenaline before the 
adrenaline infusion was significantly different on 
placebo compared with the non-selective beta-adrenoceptor 
antagonists, propranolol and oxprenolol, but not with 
atenolol. Plasma adrenaline increased during the
adrenaline infusion (Table 4.3.3). There were no 
significant differences in adrenaline concentrations 
during the adrenaline infusion between the placebo study 
day and the three active treatment study days, suggesting 
that the beta-antagonists did not influence adrenaline 
clearance.
Haemodynamic Results:
The resting heart rate was significantly reduced 
(p<0.001) by all three active treatments compared with 
placebo. The reduction in resting heart rate following 
oxprenolol, was less than that seen with either
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Table 4.3.2:- Plasma beta-antagonist concentrations on
each treatment.
Volunteer Oxprenolol Propranolol 
No.
(ng ml"1) (ng ml"1)
1 504 122
2 289 46
3 142 8
4 393 35
5 213 37
6 116 6
7 289 103
8 299 132
Mean 281 62
S.D. 128 51
Atenolol
(ng ml"1)
172
103
41
143
88
32
98
159
102
53
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Table 4.3.3:- Mean adrenaline concentrations during the
study period on each treatment.
(nmol l"1, n=8; mean ± S.D.
Time Placebo Propranolol Oxprenolol
(mins)   —
120 0.2 ± 0.1 0.4 ± 0.3 0.5 ± 0.3
210 2.7 ± 1.4 3.4 ± 2.0 3.7±1.5
240 1.5 ± 0.6 2.9 ± 3.0 2.2±1.3
360 0.3 + 0.3 0.4 ± 0.2 0.5 ± 0.3
p>0. 05 „ . _!• •. P>0-05
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Atenolol
0.3 ± 0.2
3.5 ± 0.8
2.6 ± 1.6
0.5 ± 0.6
p>0.05
propranolol or atenolol (Table 4.3.4). During the 
adrenaline infusion maximum heart rates were similar on 
all three active treatments (Table 4.3.4, Figure 4.3.2).
Systolic blood pressure was not significantly different 
on the four study days (Table 4.3.5). Diastolic blood 
pressure fell on the placebo study day during the 
adrenaline infusion (p<0.001). Diastolic pressure was 
unchanged during the adrenaline infusion following 
oxprenolol but rose slightly following propranolol. On 
the atenolol study day there was a significant fall in 
diastolic pressure compared to the other two active 
treatments (p<0.05, Table 4.3.6).
Plasma Potassium Concentrations:
Potassium concentrations fell during the adrenaline
_ -i
infusion from 3.8 + 0.2 to 3.3±0.4 mmol 1 x on placebo 
(p<0.001). No fall in plasma potassium was seen on any of 
the active treatments including the selective beta^- 
antagonist, atenolol. There was a slight rise in 
potassium concentrations after propranolol, and to a 
lesser extent after oxprenolol. All active treatments 
were significantly different from placebo (p<0.01) but 
there was no significant differences between the active 
treatments (Figure 4.3.3, Table 4.3.7).
4.3.4 Discussion.
The persistence of the vasopressor response to 
adrenaline, a beta2-adrenoceptor mediated action, after 
one weeks treatment with atenolol supports the
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Table 4.3.4: ^ Mean heart rate at each time point on
each treatment.
(beats min"1, n=8; mean ± S.D.).
Time Placebo Propranolol
(mins.)
Oxprenolol Atenolol
60 71 + 11 60 + 5 64 + 9 60 +
120 66 + 11 58 ± 8 65 t 8 58 +
130 67 + 8 57 + 7 64 ± 10 57 +
140 73 + 10 57 + 7 61 ± 8 57 +
150 72 + 9 58 ± 5 60 ± 7 58 +
160 74 + 12 57 ± 5 56 ± 6 57 +
175 78 + 13 60 ± 7 62 ± 10 60 +
190 77 + 11 60 ± 6 59 ± 7 60 +
210 77 + 10 61 ± 6 62 ± 8 61 +
225 78 + 13 62 ± 8 62 ± 9 62 +
240 79 + ’16 60 ± 5 59 ± 4 60 +
270 75 + 13 63 ± 7 70 ± 9 63 +
300 74 + 11 63 ± 9 69 ± 9 63 +
360 75 + 14 65 ± 12 69 :± 10 65 +
p<0.001 p<0.001 p<-0 .001
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Table 4,3.5:- Mean systolic blood pressure at each time
point on each treatment.
(mm Hg, n=8; mean ± S.D.).
Tune Placebo Propranolol Oxprenolol Atenolol
(mins.)
60 118 + 10 110 + 8 113 + 10 109 + 7
120 115 + 11 104 + 8 111 + 12 106 + 8
130 115 + 11 105 + 13 110 + 13 104 + 8
140 113 + 10 107 + 13 110 + 15 105 + 8
150 117 + 15 ' 104 + 12 112 + 13 104 + 6
160 121 + 15 107 + 8 114 + 14 107 + 6
175 122 + 12 109 + 12 117 + 12 109 + 5
190 121 + 12 109 + 10 113 + 16 108 ± 8
210 121 + 12 110 + 10 118 + 18 107 + 10
225 121 + 10 113 + 7 117 + 18 109 + 10
240 121 + 12 113 + 9 114 + 16 108 + 8
270 119 + 14 112 + 10 114 + 15 107 + 11
300 121 + 10 109 + 18 109 + 14 107 + 9
360 116 ± 7 110 ' ± 12 109 + 14 108 + 8
p>0.05   p>0.05 p>0.05
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Table 4.3.6:- Mean diastolic blood pressure at each time
point on each treatment.
(mm Hg, n=8; mean ± S.D.).
Time Placebo Propranolol Oxprenolol Atenolol
(mins)
60 65 + 7 59 + 4 62 + 8 58 + 4
120 63 + 5 59 + 8 58 + 6 56 + 4
130 62 + 5 58 + 9 60 + 8 53 + 4
140 60 + 6 59 + 12 59 + 9 54 + 4
150 61 + 7 62 + 9 60 + 9 54 + 6
160 62 + 10 62 + 7 60 + 8 54 + 4
175 60 + 6 62 + 8 61 + 8 54 + 4
190 58 + 7 63 + 9 59 + 10 55 + 4
210 59 + 6 64 + 8 62 + 9 54 + 5
225 60 + 8 64 + 8 61 + 8 55 + 4
240 58 + 6 66 + 7 61 + 10 53 + 3
270 63 + 4 60 + 7 59 + 5 58 + 7
300 65 + 7 52 + 9 55 + 6 53 + 5
360 65 + 6 55 + 6 57 + 7 54 + 5
p > 0 .05 ; P>0.05 p>0.05
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Table 4.3.7:- Mean plasma potassium at each time point on
each treatment.
(mmol I--*-, n=8; mean ± S.D.).
Time Placebo Propranolol Oxprenolol Atenolol
(mins) —
60 3.80 ± 0.21 " 4.20 + 0.31 3.96 + 0.25 3.89 + 0.14
90 3.99 ± 0.24 ' 4.11 + 0.29 3.90 + 0.25 3.88 + 0. 10
120 3.94 ± 0.16 4.01 + 0.29 3.94 + 0.24 3.93 + 0.14
210 3.39 ± 0.41 4.28 + 0.22 4.14 + 0.16 4.01 + 0 . 37
240 3.31 ± 0.41 4.05 + 0.26 4.09 + 0.23 3.99 + 0 . 32
270 3.41 ±0.27 3.84 + 0.26 3.79 + 0.31 3.75 + 0.13
300 3.58 ± 0.23 3.64 + 0.18 3.63 + 0.25 3.70 + 0. 20
360 3.76 ± 0.25 3.64 + 0.26 3.59 + 0.20 3.74 + 0.31
p<0.01 p<0 .01 p<0 .01
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interpretation that the dose of atenolol used in this 
study selectively blocked beta-j_-adrenoceptors. The non- 
selective beta-adrenoceptor antagonists, propranolol and 
oxprenolol, abolished or reversed this response.
However the hypokalaemic response to adrenaline was 
abolished by all three beta-adrenergic antagonists. There 
are a number of possible explanations for the abolition 
of the hypokalaemic response to adrenaline with atenolol. 
Adrenaline induced hypokalaemia may not be mediated 
through a beta-adrenoceptor at all. Though possible it 
would be surprising in view of the published evidence 
that in other mammals adrenaline induced hypokalaemia 
exists and is mediated by a beta2 -adrenoceptor (Clausen & 
Flatman, 1977). An alternative explanation for the 
persistent vasopressor response to adrenaline following 
atenolol would be that adrenaline induced hypokalaemia is 
linked to the beta2 ~adrenoceptor but that different 
beta2 ~adrenoceptor populations in different tissues, in 
this study the vascular beta2-receptors and the skeletal 
muscle membrane beta2-adrenoceptors, may vary in their 
susceptibility to beta-adrenoceptor antagonists. There 
may also be differences in the efficiency of agonist 
coupling to functional responses at different beta2- 
receptors.
In view of the findings of this study which contrasted 
with the other published evidence it was clear that 
further studies were required. The logical first step
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being to repeat the study with a more selective beta^- 
antagonist. Though atenolol is the most highly selective 
k®ta antagonist currently available in the British 
National Formulary there is a more selective beta-^ - 
antagonist currently under development, CGP 17/582B. A 
similar study was therefore carried out using CGP 
17/582B.
4.4 Adrenaline induced hypokalaemia: the effect of a
new, highly cardioselective beta-adrenoceptor 
antagonist, CGP 17/582B.
4.4.1 Introduction.
CGP17/582B is a new beta adrenoceptor antagonist (Fig
4.4.1) which, on experimental studies, appears to combine 
beta-j_-receptor blocking selectivity with partial agonist 
activity. It is claimed to be a highly specific beta^- 
adrenoceptor antagonist and in view of the results of the 
previous study would be ideal for studying the mechanism 
of adrenaline induced hypokalaemia.
The haemodynamic and hypokalaemic effects of adrenaline 
were compared following pretreatment for 7 days with oral 
CGP 17/582B; with similar pretreatment with propranolol 
(non-selective beta blocker with no ISA) and metoprolol 
(selective beta-j_-blocker with no ISA) and an inactive 
placebo control.
4.4.2 Methods.
Eight healthy subjects on no regular drug therapy and
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Fig. 4.4.1.: STRUCTURE OF CGP 17/582B
with normal haematology, biochemistry and
electrocardiograms (4 females, 4 males; age-19-37 years; 
weight 51-67 kgs.) were studied.
This was a placebo controlled, double blind study with 
supplies being dispensed by the Hospital Pharmacy. 
Subjects received all four treatments in a randomised 
Latin square design order with at least two weeks between 
treatments to ensure adequate washout. All drugs were 
matched using a disguising gelatine capsule. The four 
treatments were i) placebo capsule twice daily; ii) 
Propanolol 80 mg twice daily; iii) Metoprolol lOOmg twice 
daily; iv) CGP 17/582B 100 mgs twice daily and each
therapy was administered for one week. Prior to each 
treatment period, and on the second and fifth day of each 
treatment, subjects underwent a standard submaximal 
exercise test, 2 mins of exercise at 100 watts min"1, 
using a bicycle ergometer in order to confirm and compare 
the degree of beta blockade achieved. Subjects attended 
the laboratory on the seventh day of each therapy having 
abstained from caffeine, food, alcohol and tobacco for 10 
hours.
The drug and a standard light breakfast were given 
together and cannulae inserted into each forearm. 
Subjects were studied supine throughout. After one hour a 
5 % (+)-glucose (dextrose) infusion (12 mis hour"1)
containing ascorbic acid (1 mg ml 1) was given, via a 
Braun VI perfusor pump, for one hour followed by an
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infusion of (-)-adrenaline in 5% (+)-glucose which was
increased stepwise in the standard protocol (Chapter 3.3) 
to a rate of 0.06 ug kg"1 min"1 which was continued for 90 
minutes (Fig 4.4.2). Blood pressure, heart rate and 
plasma potassium and catecholamine levels were measured 
at regular intervals (Fig 4.4.2). Following the 
adrenaline infusion the (+)-glucose vehicle infusion was 
continued for a further two hours.
Blood pressure and heart rate were measured by a semi­
automated sphyghmomanometer. An electrocardiogram was 
displayed continously throughout the study period.
Plasma potassium samples and plasma catecholamine 
samples were handled in the standard manner. Plasma 
catecholamines were measured by high performance liquid 
chromatography (Chapter 3.2).
Results are expressed as meanistandard deviation. 
Repeated measures analysis of variance was used for 
comparisions between treatments. Measurements before and 
after a manoeuvre (adrenaline infusion, exercise, etc.) 
were compared using a paired Student's 't' test.
4.4.3 Results
No subjects reported any side effects during the period 
beta-adrenoceptor antagonists were given. During the 
adrenaline infusion two subjects were aware of an 
increase in their heart rate on all treatments but no 
reduction in infusion rate was necessary.
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Effect of beta adrenoceptor antagonists at rest and after 
exercise:-
These results are shown in Table 4.4.1 and there was no 
difference in pretreatment baseline heart rates between 
treatment periods. Following 5 days of placebo there was 
no change in exercise induced tachycardia after 2 mins 
exercise at 100 watts min All active treatments 
significantly reduced exercise induced tachycardia 
(metoprolol - 32% inhibition, p<0.001; CGP 17/582B - 24% 
inhibition, p<0.01 and propranolol - 19% inhibition,
p<0.05) confirming beta adrenoceptor blockade after all 
three active treatments.
Plasma Catecholamine Concentrations:
The plasma adrenaline concentrations prior to the 
adrenaline infusions were not significantly different 
between placebo and any of the active drugs (Table
4.4.2). Following adrenaline administration the 
adrenaline levels were comparable to previous studies. 
There were no significant differences in the adrenaline 
concentrations throughout the infusion period between 
treatments compared to placebo. As the infusion rate was 
the same in all studies this suggests that adrenaline 
clearance was not altered by any of these beta 
antagonists. The baseline plasma noradrenaline levels 
were not different after beta-blockers. However 
noradrenaline levels decreased significantly during the
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Table 4.4.1:- Mean post exercise heart rate on each
treatment.
[beats min mean ± S.D.; n=8, p-values refer to
comparison of heart rate at end of exercise period (2 
mins at lOOvT^ -) prior to therapy and heart rate at the 
end of exercise on day 5 of each treatment by paired 
students 't'-test; N.S.D.=no significant difference.]
Treatment Prior to Therapy Day 5 of therapy
Placebo
CGP 17/582B
Metoprolol
Propranolol
129+17
131 + 9
129±16
115+15
N.S.D.
p<0.01
p < 0 . 001
p<0.05
125+24
99±16
88+8
93 + 22
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adrenaline infusion on the placebo, metoprolol and 
propranolol study days but not following CGP 17/582B, 
(Table 4.4.2).
Effect of adrenaline infusion on blood pressure and heart 
rate:
Changes in heart rate, systolic and diastolic blood 
pressure are shown in Figure 4.4.3. The resting heart 
rate was significantly reduced, compared to the placebo 
study day, by metoprolol (p<0.01) and by propranolol 
(p<0.01) but not by CGP 17/582B (p>0.05). No rise in
heart rate was seen during the adrenaline infusion with 
either metoprolol or propranolol whereas heart rates rose 
with placebo and CGP 17/582B. Correcting for differences 
in baseline measurements on the different study days 
demonstrates significant differences in heart rate 
between metoprolol and propranolol when compared with CGP 
17/582B or placebo following the adrenaline infusion. At 
the end of the study period, these changes in heart rate 
were still evident (Figure 4.4.3, Table 4.4.3).
Baseline systolic blood pressure was significantly 
reduced by metoprolol and propranolol when compared to 
placebo and CGP 17/582B (Table 4.4.4). However when 
corrected for baseline differences there were no 
significant differences in systolic blood pressure 
between treatments during the adrenaline infusion (Figure
4.4.3). The baseline diastolic blood pressure was 
significantly lower on propranolol compared to placebo
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Table 4.4.2:- Plasma adrenaline and noradrenaline levels
on each treatment.
(mean ± S.D.; n=8, p-values refer to comparison between 
120' and 240' by students 't' test).
Time
(mins)
Adrenaline
Concentration
(nmol 1“ )^
120’ 240'
Noradrenaline
Concentration
(nmol I-1)
120' 240'
Treatment
Placebo 0.2 + 0.3 3.7 ± 1.4 2.1 ± 1.0 1.6 ± 0.6
p<0.05
CGP 0.1 ± 0.2 4.0 ± 2.0 1.8 ± 0.7 1.8 ± 0.
N.S.D.
Metoprolol 0.1 ±0.2 3.8 ± 0.5 2.3 ± 0.9 1.7 ± 0.7
p<0.01
Propranolol 0.1 ± 0.1 3.7 ± 2.2 2.5 ± 0.7 1.3 ± 0.4
p<0.01
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Table 4.4.3:- Mean heart rate at each time point on each
treatment.
[ beats min"1; mean ± S.D.; n=8]
CGP 17/582B Metoprolol PropranololTime Placebo
(mins)
60 68 + 10
120 66 + 11
130 64 + 10
140 64 + 9
150 67 + 12
160 68 + 8
175 71 + 7
190 71 + 8
210 77 + 11
225 78 + 10
240 82 + 10
270 80 + 9
300 76 + 7
360 80 + 8
6 6 + 6  54
66 ± 8 54
64 ± 7 51
63 ± 6 52
66 ± 6 51
69 ± 7 54
71 ± 5 52
73 ± 6 52
7 7 + 8  55
76 ± 5 55
77 ± 6 57
7 4 + 7  56
7 2 + 5  59
74 ± 7 57
± 4 58 ± 5
± 4 54 + 4
± 4 56 + 7
± 6 56 + 8
± 4 56 + 10
+ 4 54 + 7
+ 4 53 + 6
+ 3 50 + 3
+ 5 49 + 2
+ 5 52 + 6
± 7 52 + 5
+ 5 57 + 6
+ 6 59 + 6
+ 8 58 + 9
p>0.05 _ P<0-01 P<0.01
\
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Table 4.4.4:- Mean systolic blood pressure at each time
point on each treatment.
[mm Hg; mean ± S.D.; n=8]
Time Placebo CGP 17/582B Metoprolol
(mins)
Propranolol
60 112 + 8 106 + 11 103 + 8 103 + 4
120 108 + 11 107 + 4 95 + 5 100 + 4
130 105 + 8 107 + 8 95 + 6 100 + 4
140 105 + 7 106 ± 3 94 + 5 102 + 3
150 104 + 5 108 + 4 97 + 3 101 + 8
160 108 + 7 111 ± 7 100 + 7 101 + 5
175 108 + 13 114 ± 5 101 + 7 101 + 6
190 114 + 9 114 + 8 101 + 6 104 + 5
210 114 + 10 115 + 7 100 + 5 104 + 8
225 113 + 9 114 + 7 101 + 5 103 + 9
240 112 + 10 114 + 6 100 + 6 106 + 9
270 109 + 7 100 + 15 102 + 5 103 + 7
300 106 + 11 113 + 4 99 + 12 100 + 4
360 112 + 8 115 + 5 101 + 6 101 + 5
p>0.05 p>0.05 p>0.05
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and this difference was maintained throughout the study 
period. After propranolol pre-treatment there was a rise 
in aiastolic pressure during the adrenaline infusion 
compared to placebo (p<0.05). After metoprolol there was 
a modest difference from placebo throughout which was not 
significant when corrected for baseline differences 
(p>0.05). On the CGP 17/582B study day changes in 
diastolic blood pressure during the adrenaline infusion 
did not differ significantly from those seen on the 
placebo study day (Table 4.4.5).
Plasma Potassium:
Changes in plasma potassium are shown in Figure 4.4.4. 
(Table 4.4.6). There was no significant effect on 
baseline plasma potassium with any beta-blocker 
pretreatment. Following placebo pretreatment potassium 
fell significantly during the adrenaline infusion and a 
similar fall was seen with CGP 17/582B. A small but 
insignificant rise in plasma potassium was observed with 
propranolol but plasma potassium fell during the 
adrenaline infusion by an insignificant amount following 
metoprolol. The pattern of plasma potassium response to 
the adrenaline infusion was significantly different from 
placebo following both metoprolol and propranolol 
(p<0.05) but not following CGP 17/582B pretreatment 
(Figure 4.4.4, Table 4.4.6). One hour after the end of 
the adrenaline infusion plasma potassium was not 
significantly different between the four study periods.
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Table 4.4.5:- Mean diastolic blood pressure at each time
point on each treatment.
[mm Hg; mean ± S.D.; n=8]
Time Placebo CGP 17/582B Metoprolol , Propranolol
(mins)
60 63 + 6 58 + 7 55 ± 7 52 ± 6
120 60 + 7 60 + 5 54 ± 6 56 ± 3
130 62 + 5 57 + 2 52 + 5 57 + 5
140 60 + 7 55 + 7 54 ± 4 58 + 4
150 61 + 8 • 57 + 3 55 ± 7 59 ± 5
160 56 + 9 58 + 7 56 ± 5 57 + 5
175 60 + 7 57 + 5 54 ± 4 58 ± 5
190 58 + 3 56 + 3 56 ± 8 60 ± 6
210 56 + 5 56 + 3 54 ± 4 62 ± 7
225 57 + 5 59 + 7 56 ± 5 58 i+ h-
1 o
240 54 + 7 56 + 4 54 ± 3 61 ± 8
270 59 ± 7 54 + 11 54 ± 5 54 ± 5
300 59 ± 6 59 + 8 50 ± 3 52 ± 5
360 59 ± 7 62 + 1 54 ± 8 55 ± 5
p>0.05 p>0.05 p<0.05
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Table 4.4.6:- Mean plasma potassium at each time point on
each treatment.
[mmol l-1; mean ± S.D., n=8].
Time Placebo CGP 17/582B Metoprolol - Propranolol
(mins)
60 4.1 ± 0.3 4.0 ± 0.4 4.1 + 0.2 4 . 2 1 0 . 3
90 4 . 1 1 0 . 2  4 . 1 1 0 . 4  3 . 9 1 0 . 3  4.2 1 0 . 3
120 4 . 1 1 0 . 3  4 . 0 1 0 . 4  4 . 1 1 0 . 3  4 . 3 1 0 . 4
210 3 . 7 1 0 . 4  3 . 7 1 0 . 3  4 . 1 1 0 . 2  4 . 3 1 0 . 2
240 3 . 5 1 0 . 3  3.6 1 0.3 4.0 1 0.3 4.2 1 0.2
270 3 . 5 1 0 . 3  3 . 7 1 0 . 4  3 . 9 1 0 . 3  4 . 1 1 0 . 3
300 3 . 6 1 0 . 3  3 . 7 1 0 . 4  3 . 9 1 0 . 2  4 . 0 1 0 . 3
360 3 . 8 1 0 . 3  3 . 8 1 0 . 3  3 . 9 1 0 . 2  4 . 0 1 0 . 4
p>0.05 p<0.05 p<0.05
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4.4.4 Discussion.
CGP 17/582B is highly selective beta^-adrenoceptor 
antagonist with intrinsic sympathomimetic activity 
(Klepzig & Strauer, 1986). Though its basic structure is 
a phenoxypropranolamine, common to most beta-blockers, it 
has two unusual features. The methoxy-ethoxy group is in 
the para position, leading to cardioselectivity and mild 
intrinsic sympathomimetic activity, and the amino-group 
has a salicylate moiety, which may explain the very high 
receptor affinity of this compound (Fig 4.4.1).
The heart rate response to exercise allowed accurate 
tritration of the dose of each individual beta-blocker to 
achieve adequate beta^-blockade. Using a dose of each 
beta-blocker sufficient to reduce exercise induced heart 
rate by 25% should ensure that, with selective beta- 
blockers such as CGP, excessive beta-blockade does not 
occur. This is important as with all ’selective' beta- 
antagonists the degree of selectivity is relative and 
with increasing doses a degree of beta2 ~adrenoceptor 
blockade occurs (Lertora et al, 1975).
Propranolol, a non-selective beta-blocker, abolished 
completely adrenaline induced hypokalaemia whereas 
metoprolol, which has a degree of selectivity, though not 
as highly selective as CGP, attenuated adrenaline induced 
hypokalaemia. CGP, which is a highly selective beta-j_- 
adrenoceptor antagonist, had no effect on adrenaline 
induced hypokalaemia. The results of the present study
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with propranolol and metoprolol are consistent with the 
hypothesis that the fall in potassium which follows 
adrenaline infusion is mediated by a membrane bound 
Na+/K+ ATPase linked to a beta adrenoceptor of the beta2  
subtype. The haemodynamic and metabolic effects are in 
keeping with non-selective and relatively selective beta-L 
blockade respectively.
The failure of CGP to alter the pressor effects of 
adrenaline provides evidence that the" dose of CGP used in 
this study was selective to the beta^-adrenoceptor and 
that beta2 “adrenoceptors on peripheral blood vessels were 
unaffected. Additional evidence is provided by the 
noradrenaline levels with each drug. Beta agonist 
infusion leads to increases in plasma noradrenaline due 
to stimulation of presynaptic facilitatory beta2  
receptors (Stjarne & Brundin, 1975; Yamaguchi et al , 
1977; Majewski et al, 1980; Vincent et al, 1982). 
Adrenaline which has both beta^- and alpha2 " agonist 
activity did cause plasma noradrenaline to fall in this 
study. This could be due to an imbalance in adrenaline’s 
effects, at the concentrations achieved during the 
infusion, on the facilitatory beta2 “ and inhibitory 
alpha2 ”presynaptic mechanisms (Musgrave, Backmann & 
Gordon, 1984). After betablockade it might be expected 
that unopposed alpha2-inhibitory action of adrenaline 
would lead to a fall in plasma noradrenaline. 
Noradrenaline fell during the adrenaline infusion and
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this was greater with propranolol and metoprolol 
pretreatment than with placebo. There was no effect on 
noradrenaline with CGP 17/582B suggesting that, due to 
its high selectivity, the facilitatory presynaptic beta2- 
adrenoceptor was not blocked.
The results of this study agree with the hypothesis 
that adrenaline induced hypokalaemia is mediated via a 
beta2-adrenoceptor. The partial agonist action of CGP 
17/582B had no effect on either basal plasma potassium 
levels or adrenaline induced hypokalaemia suggesting it 
is of no relevance.
4.5 Summary.
The results of the three studies described in this 
chapter demonstrate that adrenaline and salbutamol 
induced hypokalaemia are not the result of changes in 
circulating insulin levels. Secondly, that salbutamol, a 
selective beta2-agonist, induces hypokalaemia to a 
similar extent as adrenaline suggesting that adrenaline 
induced hypokalaemia is the result of beta2-stimulation.
The results from the first beta-blocker study were more 
difficult to interpret and would appear to conflict with 
this conclusion. The abolition of the hypokalaemic 
response to adrenaline by atenolol would suggest that 
either the hypokalaemic response is not mediated via the 
beta2-adrenoceptor or that this dose of atenolol was too 
high and, though selective for some beta2-adrenoceptor
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populations, e.g. vascular beta2 _adrenoceptors, the dose 
was sufficient to blockade beta2 -adrenoceptors on 
skeletal muscle. This may be the result of differences in 
the efficiency of agonist coupling to functional 
responses at different beta2-receptors. Other workers 
(Vincent et al, 1984) have also reported abolition of 
this response with a similar dose of atenolol whereas 
with a lower dose of atenolol a further group have 
reported attenuation of the hypokalaemic response to 
adrenaline (Struthers et al, 1984).
The results of the third study with the highly 
selective beta^-antagonist, CGP 17/582B, strongly suggest 
that adrenaline induced hypokalaemia is mediated via the 
beta2 “adrenoceptor and not via the beta-^-adrenoceptor. In 
this study the vascular tissue response was similar to 
the hypokalaemic response, unlike the second study using 
atenolol.
In conclusion these studies support the thesis that 
adrenaline induced hypokalaemia is mediated via the 
beta2 -adrenoceptor. The final proof would be to study the 
recently developed agent ICI-118551 which is a highly 
selective beta2 ~adrenoceptor antagonist. Studies with 
this expensive, and scarce drug, have been carried out by 
two groups of workers (Struthers & Reid, 1984; Brown, 
Brown & Murphy, 1983). Both these studies have confirmed 
that ICI-118551 totally abolishes adrenaline induced 
hypokalaemia, confirming that the hypokalaemic response 
to adrenaline is mediated via the beta2 -adrenoceptor.
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CHAPTER 5 
DIURETICS AND HYPOKALAEMIA
5. DIURETICS AND HYPOKALAEMIA.
5.1 Diuretic induced hypokalaemia.
As previously discussed (Chapter 2), hypokalaemia is 
potentially dangerous to patients with both ischaemic 
heart disease and hypertension. Diuretic therapy is a 
well recognised cause of hypokalaemia. Surprisingly the 
exact mechanisms of potassium losses remains uncertain, 
and the significance of low serum levels as an indicator 
of total body depletion is unclear.
As plasma potassium is not protein bound 100% is 
filtered at the glomerulus, 80-90% of the filtered load 
is reabsorbed in the ascending loop of Henle and the 
remainder beyond so that by the distal tubule all the 
filtered potassium has been reabsorbed. The source of 
urinary potassium is secretion along the late distal 
tubule and the collecting duct, resulting in a fractional 
secretion of 5-15% (Giebisch, Malnic & Berliner, 1981). 
As discussed previously (Chapter 1.4) the exact 
mechanisms and control of renal tubular active and 
passive secretion of potassium are not known but evidence 
suggests that they are dependent on intraluminal sodium 
concentration and rate of flow of tubular fluid (Figure 
1.4.1) .
The effect of diuretics on potassium excretion depends 
on the site of action of the diuretic (Figure 5.1.1). As
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a general rule, diuretics that act at sites proximal to 
the potassium secretory sites, i.e. late distal tubule 
and collecting ducts, will increase urinary potassium 
secretion by increasing the delivery of sodium and fluid 
to the potassium secretory sites. The increased luminal 
sodium concentration alters potassium secretion, possibly 
by creating a larger transepithelial gradient. Diuretics 
such as frusemide and the thiazides also enhance 
potassium excretion by increasing aldosterone levels, 
thus increasing intraluminal sodium concentrations. In 
addition they induce a metabolic alkalosis (Knochel, 
1984; Chapter 1.4) which results in an ingress of 
potassium into cells. Indeed it has been argued that 
diuretics do not lead to whole body potassium depletion 
but only alter internal balance and disposition of 
potassium (Kassirer & Schwartz, 1966). There is, however, 
convincing recent evidence that diuretics do increase 
urinary potassium loss and deplete whole body potassium 
stores. After several weeks of diuretic therapy potassium 
excretion does fall into the ’normal’ range. This 
excretion is, however, abnormal when measured as 
fractional excretion of whole body potassium, which has 
itself fallen as a result of the diuretic therapy 
(Schuck, 1982).
Agents which act in the late distal tubule and the 
collecting duct do not cause potassium loss and are often 
referred to as 'potassium-saving' diuretics. Two groups
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of drugs have been developed; sodium-channel blockers 
such as amiloride and triamterene; and the aldosterone 
antagonists such as spironolactone.
'Loop' Diuretics
Diuretics acting in the ascending loop of Henle, e.g. 
frusemide, bumetanide and ethacrynic acid, result in 
large increases in intraluminal sodium concentrations, 
increased tubular fluid flow and hence increased 
secretion of potassium. The incidence of hypokalaemia in 
patients receiving frusemide is unclear from the 
literature but is probably dose-dependent. In a study of 
adverse reactions to frusemide in hospitalized patients 
only a 3.5% incidence of hypokalaemia was reported (Lowe 
et al, 1979), confirming a previous smaller study 
(Greenblatt et al, 1977).
Thiazide diuretics
Thiazide diuretics act on the 'early' distal tubule 
(Figure 5.1.1) and lead to significant potassium losses, 
though there is controversy over both the incidence and 
clinical significance of such losses. Potassium losses 
are related to both the dose (Giebisch et al, 1981) and 
duration of treatment (Whelton & Watson, 1986). The 
mechanism of the potassium loss is still disputed. One 
suggestion is that the effect of thiazides are purely due 
to increased fluid flow in the distal tubule and are not 
influenced by intraluminal sodium changes or any change 
in transepithelial gradient (Constazo & Windhager, 1978).
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Effect of diuretic therapy on tissue potassium levels.
A review of the literature (Dyckner & Wester, 1987a) 
reported that all studies had shown numerically lower 
potassium values after diuretics and in 11 of the 23 
studies quoted this difference was statistically 
significant. A recent study by the same authors 
demonstrated that 48% of diuretic treated patients with 
congestive cardiac failure had decreased skeletal muscle 
potassium (Wester & Dyckner, 1985). These authors have 
also shown that the combination of a thiazide with a 
potassium sparing diuretic increases skeletal muscle 
potassium (Dyckner & Wester, 1984).
Serum and muscle potassium levels have been found to 
correlate, though only weakly in patients with congestive 
cardiac failure. However, the inter-individual 
variability in response makes serum levels a poor 
predictor of muscle potassium levels (Dyckner & Wester, 
1987b).
5.2 The effect of diuretic therapy with bendrofulazide, 
frusemide and spironolactone on plasma potassium 
during adrenaline infusions.
5.2.1 Introduction.
The most popular groups of diuretics, thiazides and loop 
diuretics, are frequently given to patients with 
ischaemic heart disease and hypertension and these 
diuretics can cause hypokalaemia. Such patients with
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hypokalaemia secondary to diuretic therapy could, 
therefore, be at greater risk from adrenaline induced 
hypokalaemia during acute stress.
Spironolactone is an aldosterone antagonist and has not 
been reported to reduce plasma potassium concentrations 
(Ochs et al, 1978).
The effect on adrenaline induced hypokalaemia of 
pretreatment with three diuretics: bendrofluazide, a
thiazide; frusemide, a 'loop' diuretic; and 
spironolactone was studied in healthy normotensive 
subjects using a double blind, placebo controlled, 
crossover design. The dose of each diuretic chosen for 
this study was the standard and most commonly used daily 
dose.
In addition, the effect of increased circulating 
adrenaline levels in the presence and absence of diuretic 
pre-treatment on erythrocyte intracellular potassium 
concentrations was studied. The erthyrocyte was chosen 
because it is simple to obtain samples, though it is not 
known if erythrocytes have membrane bound beta2 ~ 
adrenoceptors.
5.2.2 Methods.
Eight healthy normotensive volunteers (4 males, 4 
females; age range 21-37 years) were studied. All 
subjects had normal routine haematology, biochemistry and 
electrocardiograms and were on no regular drug therapy.
The study was placebo controlled and double blind with
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supplies being dispensed by the hospital pharmacy. 
Subjects received four separate treatments in a 
randomised order using a Latin square design with at 
least two weeks between treatments to ensure adequate 
washout. All drugs were matched using a disguised 
gelatine capsule. The four treatments were i) 
bendrofluazide 5 mgs daily; ii) placebo capsule one 
daily; iii) frusemide 40 mg daily; and iv) spironolactone 
lOOmgs daily. Each therapy was given for two weeks.
On the fourteenth day of each treatment limb subjects 
attended the laboratory having abstained from all food, 
caffeine, alcohol and tobacco for 10 hours.
The drug and a standard light breakfast were given and 
cannulae inserted. Subjects were studied supine 
throughout and after one hour of rest they received a 
period of a control 5% (+)-glucose solution followed by 
stepwise increases in the rate of adrenaline infusion in 
the standard infusion protocol (Chapter 3.3).
Baseline measurements were made during the one hour 
control glucose infusion. Exact details of the timing of 
all measurements are shown in Figure 5.2.1.
Blood pressure and heart rate were measured in duplicate 
by a semi-automated sphygmomanometer. An electro­
cardiogram was displayed continously throughout the study 
period.
Plasma potassium was measured by standard methods on an 
autoanalyser. Venous samples for catecholamine
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concentrations were collected in the standard fashion and 
were analysed by the high performance liquid 
chromatography assay method (Chapter 3.2).
Red cell potassium was measured by direct sampling of 
whole blood into lithium sulphate using a flame 
photometer (Corning Model 430).
Results are expressed as mean + standard deviation. 
Comparisons between treatments were made by repeated 
measures analysis of variance with corrections made for 
baseline differences. Measurements before and after a 
manoeuvre (e.g. adrenaline infusion) were compared using 
a paired Students t-test.
5.2.3 Results.
All subjects completed the study and no subject reported 
any side-effects, although several commented on increased 
urine volume while taking frusemide.
Plasma catecholamines.
Baseline adrenaline and noradrenaline were not 
significantly different on the four treatments. The 
adrenaline levels at the end of the adrenaline infusion 
showed considerable variation between study days in the 
same subject and between subjects but the levels were 
increased at least 20 fold by the infusion. Adrenaline 
levels were not significantly different on the four study 
days (Table 5.2.1) .
Haemodynamic measurements.
There were no differences in the baseline heart rates
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for all four treatments. Following the adrenaline 
infusion at a rate of 0.06y.g kg-1 min-1 for 90 minutes the 
heart rate was similar for all treatments (Table 5.2.2). 
The mean increase with the infusion of adrenaline was 
10±3 beats min-1. No cardiac rhythm disturbances were 
noted. There were no significant differences in either 
systolic or diastolic blood pressure between treatments 
(Table 5.2.3 & 5.2.4).
Plasma potassium
Baseline potassium levels were not significantly 
different on any of the three active therapies compared 
to placebo (Table 5.2.5). The rank order was that 
potassium was lowest on bendrofluazide and unaltered on 
spironolactone and frusemide (placebo - 4.1+0.1;
spironolactone - 4.1±0.3; frusemide - 4.110.5; and
bendrof luazide - 3.8 + 0.5 mmol l-1 ). Plasma potassium
fell during the period of the adrenaline infusion on all 
four treatments (Figure 5.2.2). This fall was larger on 
the frusemide (0.5mmol l-1) and bendrofluazide (0.4mmol 
l-1) study days. As the baseline values were lower on 
bendrofluazide this fall resulted in hypokalaemia with a 
nadir of 3.3 mmol l-1. The fall on the placebo and 
spironolactone study days was the same.
Red cell potassium 
Though baseline red cell potassium was lower on 
spironolactone (101 mmol l-1)and bendrofulazide (101 mmol 
l-1) these were not significantly less than the values on
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Table 5.2.1 Mean plasma catecholamines at each time point
on each study day.
(nmol l-1; n=8, mean ± S.D.)
Adrenaline Concentrations 
PLACEBO SPIRONOLACTONE FRUSEMIDE BENDROFLUAZIDE
Time
(mins)
60 0.1 + 0.05 0.1+0.05 0.1+0.05 0.110.4
120 0.1+0.05 0 .110.1 0.1+0.05 0.1+0.1
240 2.2±1.7 4.1+5.8 4.015.0 2.311.2
360 0.110.1 0.410.5 2.416.0 0.310.7
p>0.05 p>0.05 p>0.05
Noradrenaline Concentrations 
PLACEBO SPIRONOLACTONE FRUSEMIDE BENDROFLUAZIDE
Time
(mins)
60 2.010.9 1.911.0 2 .111.0 2 . 211.1
120 2.010.7
240 2.110.4
360 2.011.0
2.411.3
2.011.2
1.210.5
2.211.2
3.614.0
2.111.5
2.010.6
2.110.9
2.010.7
p>0.05 p>0.05 p>0.05
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Table 5.2.2 Mean heart rate at each time point on each
study day.
(beats min"1; n = 8; mean ± S.D.)
Time Placebo Spironolactone Frusemide Bendrofluaz.
(mins)
60 70 + 6 74 + 9 73 + 10 71 + 9
90 68 + 7 69 + 8 70 + 11 68 + 7
120 69 ± 5 69 + 7 72 + 10 69 + 7
130 71 ± 6 68 ± 7 71 + 10 70 + 10
140 73 ± 4 68 ± 4 73 + 10 68 ± 8
150 73 ± 5 71 ± 6 74 + 9 70 + 9
160 71 ± 5 73 + 10 72 + 10 73 + 10
175 77 ± 9 74 + 9 76 + 10 76 + 10
190 75 ± 6 77 + 8 76 + 10 77 + 10
210 79 ± 9 77 + 10 81 + 11 79 + 9
225 81 ± 10 78 + 13 80 + 12 79 + 9
240 85 ± 1'3 79 + 12 78 + 8 77 + 12
270 81 ± 12 78 ± 14 83 + 15 84 ± 8
300 77 + 6 76 + 10 79 + 8 77 + 10
360 81 + 8 77 ± 11 81 ± 7 81 + 6
p>0.05 p>0.05 p>0.05
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Table 5.2.3 Mean systolic blood pressure at each time
point on each study day.
(mm Hg; n = 8; mean ± S.D.)
Time Placebo Spironolactone
(mins)
60 118 + 9 117 + 8
90 113 + 10 117 + 8
120 114 + 11 113 ± 11
130 112 + 13 117 ± 11
140 111 + 14 114 ± 9
150 115 + 12 118 ± 11
160 114 + 8 120 ± 15
175 118 + 9 118 ± 10
190 118 + 8 123 ± 10
210 120 + 11 124 ± 14
225 123 + 13 124 ± 10
240 122 + 10 121 ± 8
270 120 + 13 122 + 9
300 117 + 13 119 + 10
360 116 + 10 117 + 10
p>0.05
Frusemide Bendrofluaz.
121 + 9 116 + 16
117 + 10 123 + 23
115 ± 11 116 ± 6
119 + 10 116 ± 8
117 + 12 115 ± 7
117 + 8 117 ± 11
118 + 8 117 ± 8
120 + 8 122 ± 9
126 + 10 127 ± 9
128 + 14 127 ± 7
126 + 12 124 ± 8
127 + 13 120 ± 8
122 + 14 120 + 10
120 + 10 119 + 10
116 + 8 120 + 10
> p>0.05 p>0 . 05
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Table 5.2.4 Mean diastolic blood pressure at each time
point on each study day.
(mm Hg; n = 8; mean ± S.D.)
Time Placebo
(mins)
Spironolactone Frusemide Bendrof1
60 61 + 7 61 + 5 63 + 5 62 + 8
90 61 + 5 64 + 3 65 + 5 64 + 8
120 61 + 8 63 + 5 64 + 7 67 + 6
130 60 + 9 63 + 4 65 + 6 64 + 6
140 58 + 8 61 + 8 63 + 6 63 + 5
150 58 + 7 62 + 6 63 + 5 63 + 6
160 58 + 4 61 + 8 62 + 6 62 + 7
175 57 + 8 61 + 5 62 + 7 63 + 6
190 58 + 7 59 + 4 63 ± 4 60 + 5
210 58 + 7 62 + 2 61 ± 7 64 + 2
225 58 + 7 61 + 4 61 ± 6 61 + 7
240 60 + 8 61 + 4 63 ± 8 58 + 6
270 61 + 7 64 + 3 67 ± 4 65 + 6
300 54 + 9 65 + 7 67 ± 3 65 + 5
360 59 + 6 63 + 11 63 ± 6 66 + 7
p>0 . 05 ; p>0.05 p>0.05
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Table 5.2.5 Mean plasma potassium at each time point on
each study day.
(mmol l-1; n = 8; mean ± S.D.)
Time Placebo Spironolactone Frusemide Bendrofluaz
(mins)
60 4.1 ± 0.1 4.1 ± 0.3 4.110.5 3.910.5
90 4.1 1 0.2 4.2 1 0.3 4.1 1 0.4 3.8 1 0.4
120 4.010.2 ’ 4.210.3 4.010.4 3.810.4
210 3.810.4 3.910.3 3.510.3 3.410.3
240 3.710.5 3.810.3 3.510.2 3.410.3
270 3.810.3 3.810.3 3.410.3 3.510.3
300 3.9 1 0.2 3.8 1 0.1 3.6 1 0.2 3.5 1 0.3
360 3.9 1 0.2 3.8 1 0.1 3.6 1 0.3 3.5 1 0.2
p>0.05 :£ , p>0.05 p>0 . 05
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the placebo (104 mmol 1” )^ and frusemide study days 
—  1(105mmol 1 ). Red cell potassium did not alter during
the period of the adrenaline infusion (Table 5.2.6, 
Figure 5.2.3).
5.2.4 Discussion.
The fall in plasma potassium during the adrenaline 
infusion was similar with all three diuretics. However 
the nadir of the plasma potassium was dependent on the 
initial plasma potassium level which was, in turn, 
dependent on the action of each diuretic on potassium 
homeostasis. As baseline plasma potassium was lower on 
bendrofluazide and frusemide, the adrenaline infusions 
caused an apparently greater degree of hypokalemia. 
During the increased sympathoadrenal activity of severe 
acute illness, such as myocardial infarction, 
pretreatment with these diuretics may therefore place 
patients at increased risk of clinically significant 
hypokalaemia. Spironolactone, by not altering baseline 
potassium values, had the same effect as inactive placebo 
treatment.
Many cells have membrane bound Na+/K+ ATPase and in this 
study the effect of adrenaline on intracellular potassium 
concentrations of the erythrocyte was studied. No 
significant effect on intracellular potassium 
concentration was demonstrated. As the vast majority of 
potassium is intracellular and only a small proportion is 
extracellular then only a small intracellular shift is
e
153
mean, n = 8 
a— a PLACEBO 
m— k FRUSEMIDE 
■— ■ BENDROFLUAZIDE 
a— a SPIRONOLACTONE
Q100
LU
60
f-lAdrenalins Infusion
180 240
tima (mins)
120 300 360
Fig. 5.2.3: CHANGES IN RED CELL POTASSIUM ON 
EACH STUDY DAY
7
Table 5.2.6 Mean red cell potassium at each time point on
each study day,
(mmol l”1; n = 8; mean ± S.D.)
Time Placebo Spironolactone Frusemide Bendrofluaz
(mins)
60 106 ± 5  1 0 3 + 6 107 ± 3 103 + 4
90 103 ± 6  101 ± 5 104 + 4 100 ± 5
120 104 ± 4 101 ± 4 105 + 3 101 ± 5
210 103 ± 4 102 + 4 105 ± 3 102 ± 5
240 103 ± 5 100 + 6 105 + 3 102 ± 6
270 102 + 5 100 + 6 104 + 3 101 ± 6
300 102 ± 5 102 + 5 104 + 4 101 ± 5
360 103 ± 5 99 ± 5 104 + 3 101 ± 6
p>0.05 p>0.05 p>0.05
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necessary to cause a significant and detectable fall in 
plasma potassium. In contrast this intracellular shift is 
such a small proportion of the intracellular potassium 
content that it will not alter the concentration. 
However, it is unknown if erythrocytes have membrane 
bound beta2-adrenoceptors and if no such receptors exist 
this would explain these results.
Diuretic therapy is frequently used in patients with 
hypertension and ischaemic heart disease. Fifty percent 
of hypertensive patients treated with thiazide diuretics 
have a resting serum potassium less than 3.5 mmol I”-'- 
(Morgan & Davidson, 1980; MRC Working Party on Mild to 
Moderate Hypertension, 1981). The incidence of
ventricular ectopic beats has been claimed to be
inversely related to the serum potassium level (MRC 
Working Party on Mild to Moderate Hypertension,1983) but 
this claim is controversial (Moser, Black & Stair, 1986; 
Madias, Madias & Gavras, 1984; Caralis & Perez-Stable, 
1986). Hypokalaemia increases the incidence of
ventricular arrhythmias in patients with acute myocardial 
infarction (Dyckner et al, 1975)). Both hypertensive 
patients and those with cardiac failure are at increased 
risk of myocardial infarction and the accompanying rises 
in circulating catecholamine levels. This study4suggests 
that patients receiving chronic thiazide therapy could be 
at increased risk of severe hypokalaemia and, thus, 
cardiac dysrhythmias following infarction. There is some
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evidence from one large trial of thiazide therapy in the 
treatment of mild to moderate hypertension that the 
actively treated group did less well than the placebo 
group with a higher incidence of sudden death (MRFIT, 
1982). It is possible that the hypokalaemic effect of 
thiazide diuretics increased the incidence of cardiac 
dysrhythmias in these patients.
The effect of pretreatment with frusemide is more 
difficult to interpret. Frusemide, did not lower baseline 
potassium levels significantly. However there was a 
greater fall in plasma potassium during the adrenaline 
infusion following frusemide. The clinical significance 
of this finding is unclear.
Spironolactone neither altered baseline potassium levels 
nor did it alter the degree of adrenaline induced 
hypokalaemia. This finding would suggest that 
spironolactone may prove a safer form of diuretic therapy 
in patients with an increased risk of myocardial 
infarction or ischaemia.
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CHAPTER 6 
THEOPHYLLINE AND HYPOKALAEMIA
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6: THEOPHYLLINE AND HYPOKALAEMIA
6.1 Introduction - Interactions between methylxanthines, 
sympathomimetics and the sympathetic system.
Methylxanthines, principally theophylline, are probably 
the most commonly used bronchodilators and are frequently 
used in combination with sympathomimetic drugs such as 
salbutamol. The evidence that this combination has useful 
therapeutic benefit is controversial, studies 
investigating the potential benefit on pulmonary function 
or exercise tolerance in asthma (Hartnett & Marlin, 1976; 
Dyson & Campbell, 1977; Wolfe et al, 1979) and in chronic 
bronchitis (Barclay et al, 1981; Leitch et al, 1981; 
Alexander, Dull & Kasik 1980; Eaton et al, 1980; Evans 
1984; Taylor et al, 1985) have been conflicting though 
the majority have suggested an additive effect. There are 
very few studies of the interaction between methyl­
xanthines and sympathomimetics in other tissues. 
However, it is known that methylxanthines increase 
noradrenaline induced cardiac inotropic responses (Rail 
& West, 1963), aortic muscle contraction (Kalsner, 1971) 
and coronary artery strip contraction (Kalsner, Frew & 
Smith, 1975). Patients receiving both a methylxanthine 
and a sympathomimetic have an increased incidence of 
side-effects (Weinberger & Bronsky, 1975). 
Nevertheless,it has become common practice, with the
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advent of modern slow-release theophyllines, to use 
combinations of theophylline and sympathomimetics, such 
as the beta2“selective agonists, salbutamol. The safety 
of this combination has been questioned recently. Asthma 
deaths have risen in recent years, as discussed 
previously, and this rise has paralleled the increasing 
use of this combination. The Federal Food and Drug 
Administration sponsored a number of studies in animals 
of the safety of the combination and these studies 
reported a lower threshold for ventricular fibrillation 
in animals treated with the combination (F.D.A. 1981;
Nicklas et al, 1982; Joseph et al,1981). The combination 
was associated with the development of myocardial 
necrotic lesions (Green, Guideri & Lehr, 1980).
There are, therefore, a number of potential 
interactions between theophyllines and sympathetic 
agonists in patients with asthma or bronchitis.
As discussed below (6.2), the mechanism of action of the 
methylxanthines remains unknown. One postulated mechanism 
is increases in circulating catecholamine concentrations. 
This theory has never been investigated in subjects 
receiving chronic therapy with these drugs. To study this 
question was the aim of the first study described in this 
chapter.
The studies outlined in this chapter were designed to 
answer the following questions;
1) Does chronic theophylline therapy increase circulating
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adrenaline, or noradrenaline concentrations, or alter 
adrenaline clearance? 2) Do steady state therapeutic 
plasma theophylline concentrations increase the 
hypokalaemic or haemodynamic response to adrenaline?
3) Do steady state therapeutic plasma theophylline 
concentrations increase salbutamol induced hypokalaemia 
and, if adrenaline concentrations are also raised in
severe attacks of bronchospasm, is there a further fall 
in plasma potassium?
6.2 The pharmacology and clinical uses of the
methylxanthines.
6.2.1 Pharmacology of the methylxanthines.
The methylxanthines are a group of closely related 
plant alkaloids, theophylline, theobromine and caffeine, 
which have been used in medicinal preparations for 
hundreds of years (Rail, 1985). Early pharmacological 
studies confirmed that these compounds are central 
nervous system stimulants. They are derivatives of 
xanthine, dioxypurine, with a variety of methyl
substitutions at three sites on the ring, hence 
methylxanthines (Figure 6.2.1). The use of the methyl-
xanthines as stimulant beverages and medicinal potions 
led to the observation that they had a number of other 
actions in addition to C.N.S. stimulation, they act on 
the kidney to promote a diuresis, stimulate cardiac 
muscle and relax smooth muscle, particularly bronchial
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smooth muscle (Rail, 1985).
Coffee was first recommended for the treatment of 
asthma in 1859 (Salter, 1859). In 1888 the active agent 
was extracted from tea leaves, named theophylline, 
derived from the Greek 'divine leaf' (Kossel, 1888) and 
was soon identified as 1,3-dimethylxanthine (Fischer & 
Ach, 1895). Thereafter the other methylxanthines were 
identified, extracted and more recently synthetised. It 
is as bronchodilators that methylxanthines, and 
specifically theophyllines, are used today and world 
wide theophylline is probably the most commonly 
prescribed bronchodilator.
The pharmacology of the methylxanthines is complex. 
Theophylline has a very low solubility which has led to 
the production of a number of complexes, such as 
aminophylline (theophylline and ethylenediamine) in an 
attempt to improve solubility for parenteral 
administration.
Theophylline principally undergoes hepatic metabolism 
(90%) by microsomal oxidative enzymes and demethylation 
to 3, methylxanthine, 1,3 dimethyluric acid and 1,
methyluric acid. There is a wide inter-individual 
variation in the clearance rate of theophylline making 
prediction of individual's dose requirements difficult. 
Many factors alter theophylline clearance, e.g. hepatic 
enzyme inducing drugs and hepatic congestion secondary to 
cor pulmonale (Ogilvie, 1978; McElnay, Smith & Helling,
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1982). Thus monitoring of plasma theophylline levels is 
required to ensure adequate therapy.
The therapeutic plasma range of theophylline is 10-20 
y.g ml  ^ (Mitenko & Ogilvie, 1973), though controversy 
continues as to the threshold level for theophylline's 
actions which probably lies between 5-8 ug ml-1 (Piafsky 
& Ogilvie, 1975). Theophylline has a low therapeutic 
index and serious toxicity can occur with plasma levels 
as low as 35 ug ml“ ,^ though rare below 50 \ig ml” .^ In 
addition theophylline, even in therapeutic doses, may 
produce side-effects, with headache and upper 
gastrointestinal symptoms being the most common.
The plasma half life of theophylline is short, 3-4 
hours, and this requires frequent drug administration, 
4-6 hourly, to maintain adequate plasma levels. This 
problem has been surmounted by the development, in 
recent years, of effective slow release preparations 
requiring 8 or 12 hourly administration. These slow 
release preparations, combined with the development of 
relatively cheap therapeutic plasma monitoring, have led 
to increased use of theophyllines in the U.K. , 
particularly in the treatment of nocturnal symptoms in 
asthma. Thus, though theophylline is a relatively 
difficult drug to use, it is widely prescribed.
6.2.2 Mechanism of action of methylxanthines.
Despite its popularity and long history theophylline's
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mechanism of action remains unknown. A number of possible 
mechanisms of action have been proposed but evidence for 
the importance of each mechanism at therapeutic tissue 
levels is conflicting.
Theophylline is a phosphodiesterase inhibitor. 
Phosphodiesterase catalyses the breakdown of adenosine 
cyclic 3 ' , 5 ' monophosphate (cyclic AMP), which is the 
second messenger mediating many hormonal effects 
including the bronchodilator effect of [3-agonists, to 
adenosine 5'-monophosphate (AMP). Thus, a 
phosphodiesterase inhibitor will increase cellular 
concentrations of cAMP and will produce bronchial smooth 
muscle relaxation. In vitro synergism between the two 
agents has been shown to affect cyclic AMP
concentrations (Kaliner et al, 1971) and for many years
this was thought to be the principal mechanism by which 
theophyllines bronchodilate (Anonymous, 1970). There are 
a number of pieces of evidence that suggest that
phosphodiesterase inhibition is not the mechanism of 
action. Firstly, there are many other phosphodiesterase 
inhibitors described, e.g. dipyridamole, yet none of 
them are effective bronchodilators (Fredholm, Brodin & 
Strandberg, 1979). Secondly, at the tissue levels 
thought to occur at therapeutic plasma levels, in vivo 
experiments have reported that theophylline only has a 
minor inhibitory effect on phosphodiesterase, 
approximately 10% (Poison et al, 1978a; Poison et al
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1978b). Finally, if theophylline's principal action is 
phosphodiesterase inhibition then concentrations of cAMP 
should increase in both cells and plasma in vivo. Two 
studies have reported an increase in plasma cAMP levels 
following an intravenous bolus of aminophylline 
(Campbell et al 1977; Mackay, Baldwin & Tattersfield,
1983). However, other studies have been negative 
(Lohmann, Miech & Butcher, 1977; Parrott et al, 1976; 
Trembath & Shaw 1978).
The second proposed mechanism of action is alteration 
of intra-cellular calcium kinetics or the sensitivity of 
the sarcoplasmic reticulum to calcium. Methylxanthines 
augment the twitch response of isolated skeletal muscle 
(Bianchi, 1975) and current evidence is that this is due 
to increased permeability of the sarcoplasmic reticulum 
to calcium. The sarcoplasmic reticulum is involved in the 
termination of the contractile process by active uptake 
and sequestration of calcium (Bianchi, 1975). The 
threshold for these effects on intracellular organelles 
is reported to be considerably greater than maximal 
therapeutic concentrations and would not, therefore, 
explain the observed pharmacological actions of 
methylxanthines (Rail, 1985).
Currently, two mechanisms are favoured as possible 
explanations of the observed actions of methylxanthines, 
a direct effect on the sympathetic system or adenosine
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antagonism, and. a third possiblity is emerging, an 
indirect effect on the sympathetic system.
Many of the observed actions of theophyllines would be 
consistent with increased sympathetic stimulation. A 
number of studies have clearly demonstrated that, 
following aminophylline, circulating catecholamines or 
urinary catecholamines increase (Atuk et al, 1967; Snider 
& Waldek, 1974; Robertson et al, 1978; Higbee, Kumar & 
Galant, 1982; Vestal et al, 1983) and that, in vitro, 
theophylline causes degranulation of adrenal medullary 
catecholamine storage granules (Aunis et al, 1975). No 
studies have examined the chronic effect of theophyllines 
on catecholamine levels. The cellular mechanism by which 
theophyllines could increase catecholamine release remain 
unknown.
Adenosine, the endogenously produced purine nucleoside 
which is formed from cAMP has been known for many years 
to have potent effects in the circulation (Rail, 1982), 
though the mechanism of its effects was unclear. In 1965 
in a detailed report it was observed (De Gubareff & 
Sleator, 1965) that the circulatory effects of adenosine 
could be antagonized by caffeine. Yet only recently has 
it been appreciated that there are in fact adenosine 
receptors on a wide variety of cell surfaces which either 
inhibit (Rj_ A^) or stimulate (R^ ^2^ a-denyl cyclase
leading to increased cellular cyclic AMP (Wolff, Londos & 
Cooper, 1981). The adenosine receptors are distinct from 
the purinergic receptors described in the gut and the
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circulation. Theophyllines are capable of adenosine 
antagonism in vitro and in vivo. In vitro caffeine and 
theophylline were found to be competitive anatagonists of 
adenosine in a wide variety of tissues (Rail, 1982). In 
vivo theophylline has been shown to antagonise the 
bronchoconstriction induced by adenosine (Cushley, 
Tattersfield & Holgate 1983, Mann & Holgate 1985). 
Adenosine levels rise during antigen induced 
bronchoconstriction. If theophylline were to inhibit Ax- 
receptors and thus decrease the inhibition of adenyl 
cyclase then intracellular cAMP levels would rise. At 
therapeutic levels theophylline is a competitive 
adenosine antagonist. However, enprofylline (3-propyl- 
xanthine) is a potent bronchodilator (Lunell, Anderson & 
Persson, 1984) yet has been shown to have no action at 
the A^-receptor (Persson, 1983), though there is 
controversy over whether it may have effects on A 2 - 
receptors in some tissues (Fredholm & Persson, 1982). 
Clearly if enprofylline has no A^-activity then the 
implication is that theophyllines do not bronchodilate by 
blocking adenosine receptors.
Finally, yet another mechanism has been suggested as a 
result of recent work. Originally it was thought that 
methylxanthines had no effect on purinergic receptors 
(Rail, 1982). Recently it has been shown that purines 
such as adenosine and ATP may exert a co-transmitter role
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at sympathetic effector sites via purinergic receptors on 
cell membranes. It has been demonstrated that in
sympathetic nerves supplying blood vessels ATP and 
adenosine inhibit pre-junctional P-^-purinoceptors 
decreasing noradrenaline release and this effect is 
blocked by methylxanthines (Burnstock, 1985). Thus 
suggesting a possible path by which theophyllines could 
stimulate the sympathetic system.
In summary the mechanism of action of the theophyllines 
remains uncertain, though currently adenosine antagonism 
is the favoured mechanism, despite some opposing 
evidence.
6.3 The effect of chronic theophylline therapy on
circulating catecholamines and adrenaline clearance.
6.3.1 Introduction:
Theophyllines may act by increasing catecholamine
release, principally adrenaline, from the adrenal medulla 
(6.2.2). Increased catecholamine release could, in turn, 
to maintain homeostasis, result in an increase in 
adrenaline clearance.
This placebo controlled, crossover study examined the 
effects of chronic therapeutic theophylline therapy on 
circulating adrenaline and noradrenaline levels and, by 
infusing adrenaline, on adrenaline clearance. This 
design also allowed examination of the effects of 
chronic therapeutic theophylline therapy on adrenaline
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induced hypokalaemia. The results of this subsidiary 
study are presented in the succeeding section (6.4).
6.3.2 Methods
Eight healthy subjects, 5 females and 3 males, aged 18
to 33 years were studied. They had normal
electrocardiograms, serum biochemistry and haematology.
They were on no drug therapy.
Each subject was studied at the same time of day on two
occasions on the fifth day of treatment with either a
slow release theophylline preparation (Neulin SA, 10-15 
_ 1
mg kg -1- m  divided doses, Riker Laboratories,
Loughborough, U.K.) or an identical placebo in a single 
blind randomised’ fashion. Study days were at least 10 
days apart (Figure 6.3.1).
On the study day subjects abstained from caffeine
containing beverages for eight hours and following a 
light standard breakfast which contained no caffeine, 
intravenous cannulae were inserted into the antecubital 
veins of both arms. Blood was then taken for a trough 
theophylline level and that morning’s dose was 
administered by mouth. The subjects were supine
throughout the study.
After one hour's rest an infusion of 5% ( + )-glucose
(12ml hr” )^ was given for one hour. Subjects then
received increasing stepwise infusions for 10 minutes 
each, of 0.01, 0.02, 0.04 and 0.06 \ig kg^min-1 (-)-
adrenaline (Antigen Ltd.) infused by Braun Perfusor
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VI pump by the standard protocol (3.3). If no symptoms 
or adverse haemodynamic effects occurred then 0.06 \ig 
kg "-^min”1 (-)-adrenaline was continued for a further 90 
minutes. On discontinuation of the adrenaline infusion, 
(+)-glucose was continued for a further two hours.
Blood pressure, heart rate, E.C.G., catecholamines and 
serum potassium were measured at intervals throughout the 
study (Fig 6.3.1). Blood for plasma theophylline level 
was taken at the start of the study and during the period 
of the adrenaline infusion (Fig 6.3.1).
Plasma adrenaline and noradrenaline samples were 
collected in the standard manner (Chap 3.4) and assayed 
by radioimmunoassay (Chap. 3.3). Theophylline plasma 
concentration was measured by high pressure liquid 
chromatography (Gere & Benje, 1977).
The plasma clearance of adrenaline was calculated from
the difference between steady state adrenaline plasma
levels during infusions of 0.06y.g kg-1 min-1 adrenaline
and basal adrenaline during the 5% (+)-glucose infusion
using the formula (Clutter et al, 1980) : —
Clearance = Infusion Rate
Steady state adrenaline - basal adrenaline
Results are expressed as mean+standard deviation. 
Placebo treatment was compared with theophylline by 
Student's t-test.
6.3.3 Results
Theophylline concentrations.
The mean plasma concentration of theophylline measured
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before dosing on the fifth day (trough concentration) was
—  I14.3+6.3 |ig ml A. Individual values are given In Table
6.3.1. The therapeutic range Is 10-20 ug ml-1. Very 
small amounts of theophylline, <1.0 ug ml"1, were 
detected after placebo in 3 subjects despite the 10 day 
washout period. It is probable that the assay was 
detecting dietary xanthines such as caffeine or 
theobromine.
Adrenaline and noradrenaline concentrations and 
adrenaline clearance.
Basal plasma adrenaline concentration, prior to the 
adrenaline Infusion, was 0.37±G.43 nmol I"1 on 
theophylline and 0.4910.96 niaol I"1 on placebo (p>0.05) . 
Plasma adrenaline concentration at steady-state during 
the (-)-adrenaline Infusions was 4.14+0.16 nmol I-1 on 
placebo, compared to 3.1112.86 nmol I-1 on theophylline 
(p> 0.05, Table 6.3.2). individual1s adrenaline clearance 
varied widely but there was no significant difference 
between study days (10.018.5 1 kg-1 hr-1 on theophylline;
5.514.4 1 kg“l hr-1 on placebo. Table 6.3.2). Basal 
plasma noradrenaline concentrations were not 
significantly different between the two study days 
(Table 6.3.2).
6.3.4 Discussion.
Therapeutic plasma concentrations of theophylline were 
achieved after 5 days of oral dosing. There was no
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Table 6.3.1:- Plasma theophylline concentrations on
the placebo and theophylline study days.
(n=8)
Volunteer Theophylline concentration (ug ml-1)
No.
Placebo Day Theophylline Day
1 0 10.3
2 0.1 9.8
3 0 8.0
4 0 5.8
5 0 18.3
6 0.7 25.0
7 0.2 16.2
8 0.6 17•5
Mean 0.2 14.3
S.D. 0.1 6.3
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Table 6.3.2:- Plasma adrenaline, noradrenaline and
adrenaline clearance on each study day. 
(n=8; volunteer (8) plasma adrenaline undetectable (u.d.)).
Subject Adrenaline Noradrenaline Adrenaline
No. Concentration Concentration Clearance
(nmol 1"^) (nmol i-1) (1 kg-1 hr-1)
Placebo Theoph. Placebo Theoph. Placebo Theoph
1 0.13 0.10 2.5 1.9 6.3 12.3
2 0.96 0.30 3.5 2.0 5.2 27.8
3 0.17 0.15 1.0 2.1 4.7 7.0
4 0.22 0.20 1.0 2.1 14.9 9.2
5 0.19 0.16 1.0 2.3 2.3 7.3
6 2.8 0.30 2.1 6.5 2.8 2.2
7 0.4 0.30 4.2 1.4 2.8 4.4
8 u.d. u.d. 2.1 3.2 - —
Mean 0.63 0.17 2.2 2.7 5.5; 10.
S.D. 0.97 0.09 1.2 1.6 4.4 8.5
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significant difference in circulating adrenaline levels 
during supine rest between theophylline and placebo. 
Similarly, noradrenaline levels were unaltered by 
theophylline. These findings are in conflict with 
previous studies of the effects of acute doses of 
methylxanthines on catecholamine levels.
In 1967 Atuk and colleagues infused 485mg of 
theophylline into volunteers and reported significant 
rises in urinary catecholamines concentrations (Atuk et 
al, 1967). Robertson and co-workers administered oral 
caffeine, 250mg, in normal subjects and demonstrated a 
rise in circulating adrenaline (207%) and noradrenaline 
(75%) (Robertson et al, 1978). Similarly, a small single 
oral dose of theophylline (5mg kg--*-) was shown to 
increase circulating adrenaline levels 3 hours after 
ingestion, and this was accompanied by an insignificant 
rise in noradrenaline (Higbee et al, 1982). More 
recently Vestal found that a short infusion of 
adrenaline resulted in a rise in both plasma adrenaline 
and noradrenaline (Vestal et al, 1983).
The effect of methylxanthines on isolated bovine adrenal 
glands is to stimulate release of catecholamines, 
principally adrenaline, from the adrenal medulla, 
independently of the nervous system (Poisner, 1973). This 
study also suggested that there may be two independent 
mechanisms involved, one calcium independent and one 
calcium dependent. Relatively high concentrations of
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xanthines have been shown to be required to trigger such 
release (Snider & Waldeck, 1974). Finally, intravenous 
theophylline increases plasma dopamine beta-hydroxylase 
activity suggesting that theophylline triggers 
degranulation of catecholamine storage granules (Aunis et 
al, 1975).
All these studies consistently showed increases in 
catecholamines but all used single doses or very short 
infusions of theophylline and are, therefore, not 
directly comparable to this study of the effects of 
chronic theophylline therapy. An alternative explanation 
for the conflicting results between chronic and acute 
therapy could be .that adrenaline clearance increases in 
response to increased catecholamine release to maintain 
homeostasis. No significant increase in adrenaline 
clearance was demonstrated in this study. These results 
suggest that catecholamine release is not stimulated by 
chronic theophylline therapy and, thus, increased 
circulating catecholamine concentrations cannot explain 
the chronic actions of theophylline.
6.4 The effect of theophylline and circulating
adrenaline on plasma potassium
6.4.1 Introduction
Hypokalaemia has not been reported with therapeutic 
plasma theophylline levels, though plasma potassium 
levels do fall on acute dosing (Zangvoort et al., 1986). 
Hypokalaemia is common following self-poisoning with
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large doses of theophylline (Buckley et al, 1983). In a 
placebo controlled trial of norn\al subjects the effect of 
steady-state therapeutic theophylline concentrations on 
adrenaline induced hypokalaemia was examined.
6.4.2 Methods
The subjects studied and the protocol followed was as 
outlined in the previous study (6.3.2).
Each subject was studied at the same time of day on two 
occasions on the fifth day of treatment with either a 
slow release theophylline preparation (Neulin SA, 10-15 
mg kg--*- in divided doses, Riker Laboratories, 
Loughborough, U.K.) or identical placebo in a single 
blind randomised fashion. Study days were at least 10 
days apart (Fig 6.3.1).
Blood pressure, heart rate, E.C.G., catecholamines and 
serum potassium were measured at intervals throughout the 
study (Fig 6.3.1) and by the methods outlined in the 
preceding sections (3.4 and 6.3.2).
Results are expressed as mean+standard deviation. 
Placebo treatment day is compared with theophylline 
treatment by analysis of variance, as applied to 
repeated measures.
6.4.3 Results 
Side-effects
Seven of the eight volunteers complained of side— 
effects on active therapy, theophylline, compared to
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only one on placebo. Six had nausea, the seventh had 
insomnia and 2 volunteers complained of headache and 
tremor, in addition, to nausea and insomnia.
Theophylline concentrations.
The plasma concentration of theophylline measured before 
dosing on the fifth day (trough) was 14.3+6.3 \ig ml"1 
within the therapeutic range. Very small amounts of 
theophylline (<1.0 ug ml"1) were detected after placebo 
in 3 subjects (Table 6.3.1).
Adrenaline and noradrenaline concentrations.
As discussed above there was no significant differences 
in baseline adrenaline and noradrenaline concentrations 
or in adrenaline concentrations at steady-state during 
the adrenaline infusions (see Table 6.3.2).
Plasma potassium concentrations.
Mean plasma potassium concentrations are given in Table
6.4.1. Though baseline plasma potassium was 3.88±0.32
1 —  1mmol 1 on theophylline compared to 4.08±0.16 mmol 1
on placebo prior to the (-)-adrenaline infusion, this was
not significantly different. Plasma potassium levels at
the end of ’ the (-)-adrenaline infusion, were
significantly lower on theophylline (3.03+0.48 mmol 1 1)
compared to the placebo (3.41+0.20 mmol 1 1; p<0.02, [Fig
6.4.1], with plasma potassium consistently lower on
theophylline. There was wide individual variation in the
fall in plasma potassium with adrenaline, 0.25-1.4 mmol
l"1 (Fig 6.4.2). During the theophylline study day plasma
potassium levels as low as 2.35 mmol 1 1 were noted
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during the adrenaline infusion.
Haemodynamic measurements.
Mean heart rates at each time are given in Table 6.3.2. 
Baseline heart rate, prior to the (-)-adrenaline 
infusion, on theophylline (78.5+14.9 beats min-1) was 
higher compared to placebo (68.9+9.0) but this difference 
was not statistically significant. Heart rate, throughout 
the study period, was significantly higher (p<0.05) on 
theophylline compared to placebo when corrected for 
baseline differences (Fig 6.4.3).
Mean systolic and diastolic blood pressure results are 
given in Table 6.4.3. Baseline systolic blood pressure 
was unchanged on theophylline (117113 mmHg) compared to 
placebo (113+7) (p>0.05). Systolic blood pressure was,
however, significantly higher during the whole study 
period on the theophylline compared to placebo (p<0.05). 
Diastolic blood pressure was not significantly different 
between study days.
All subjects remained in stable sinus rhythm throughout 
the infusions.
6.4.4 Discussion
Plasma concentrations of theophylline within the 
therapeutic range were achieved following 5 days of oral 
dosing. There was significant potentiation of the 
haemodynamic and hypokalaemic effects of adrenaline by 
theophylline. There has been one previous report of
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Table 6.4.1:- Mean plasma potassium concentrations
at each time point on each study day. 
(n=8; mean + S.D.)
Plasma Potassium (mmol l- )^
Time
(mins)
60
120
210
240
300
360
Placebo 
4.08 ± 0.16 
4.06 ± 0.10 
3.42 ± 0.22 
3.41 ± 0.20 
3.62 ± 0.18 
3.78 ± 0.22
Theophylline 
3.88 ± 0.32 
3.90 ± 0.28 
3.00 ± 0.50
3.03 ± 0.48 
3.33 ± 0.32 
3.40 ± 0.38
p<0.02
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Table 6.4.2:- Mean heart rate at each time point on
each study day.
(n=8; meaniS.D.).
Heart Rate (beats min”^).
Time Placebo Study Day Theophylline Study Day
(mins)
60 69 + 9 79 ± 15
120 68 + 9 79 ± 18
130 70 + 9 81 ± 18
140 74 + 11 93 ± 22
150 78 + 13 95 ± 23
160 81 + 12 96 ± 23
175 84 + 9 102 ± 21
190 85 + 9 101 + 24
210 89 + 9 105 + 20
225 89 + 10 104 + 20
240 92 + 9 104 + 21
270 84 + 10 98 + 17
300 84 + 12 95 + 15
330 88 + 11 106 + 13
88 + 7 96 + 22
p<0.05
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Table 6.4.3:- Mean systolic and diastolic blood
pressure at each time point on each study day.
(n=8; mean 1 S.D.)
Systolic B.P. (iranHg) Diastolic B.P.
Time Placebo Theophylline Placebo Theophylline
(mins)
60 113±13 116+13 70+10 64 + 8
120 112±10 116+12 69 + 9 65 + 12
130 111+13 118+10 66 + 10 61 + 11
140 114±11 116+16 61 + 11 60 + 11
150 115±14 123+16 62 + 11 61 + 11
160 121+14 125+14 63 + 12 61 + 9
175 121115 127+16 62 + 11 60 + 10
190 122+13 131+12 64111 60 + 10
210 124+13 128±12 62 + 12 61 + 9
225 119115 129±12 61 + 12 53 + 9
240 122+18 128+13 61 + 10 61 + 11
270 114+14 120±10 67 + 11 58 + 9
300 114113 123112 68 + 10 58 + 10
330 112113 120119 65 + 10 58 + 10
360 114+11 125+12 71115 57 + 8
p<0 .05 p>0.05
(mmHg)
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theophylline potentiating the actions of another beta- 
adrenoceptor agonist, terbutaline, resulting in increased 
hypokalaemia (Smith & Kendall, 1986). It was well 
recognised when combinations of sympathomimetics, such as 
ephedrine and theophylline, were widely used that there 
was an increased incidence of side-effects with such 
combination therapy though there is a paucity of 
published data in vivo (Weinberger & Bronsky, 1975). This 
study shows that therapeutic doses of theophylline and 
pathophysiological levels of adrenaline interact 
resulting in increased tachycardia and hypokalaemia.
There are still a number of oral combination tablets 
containing theophylline and ephedrine available in the 
U.K. (British National Formulary, 1989) and some 
authorities, particularly in North America, still 
recommend the parenteral administration of adrenaline and 
aminophylline in the therapy of severe asthma (Zagelbaum 
& Pare, 1982).
The results of this study suggest that there is the 
potential for interaction between theophylline and either 
endogenous adrenaline or exogenously administered 
sympathomimetics resulting in increased hypokalaemia, 
tachycardia and possibly cardiac dysrhythmias in severe 
attacks of asthma.
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_^!_§— — effect of theophylline and therapeutic doses of 
salbutamol on plasma potassium
6.5.1 Introduction
The previous study, 6.4, demonstrated that theophylline 
increases adrenaline induced hypokalaemia. A previous 
study (Chap 4.1) suggested that the mechanism of the 
hypokalaemic effect of the beta2-agonist, salbutamol, was 
by stimulation of a membrane bound beta2-adrenoceptor 
possibly linked to Na+/K+ATPase.
Combination therapy with salbutamol, or similar 
selective beta2-agonists, and theophylline is common in 
acute attacks of bronchospasm. This study aimed to 
examine the changes.in plasma potassium and haemodynamics 
when therapeutic doses of theophylline were added to 
conventional intravenous doses of salbutamol.
As previously discussed (Chap 2.3) circulating 
adrenaline concentrations may be raised in lifelong 
attacks of bronchospasm and a secondary aim was to study 
the effect on the hypokalaemia and haemodynamic changes 
induced by salbutamol in combination with theophylline of 
raising circulating adrenaline concentrations into the 
pathophysiological range.
6.5.2 Methods
Fourteen healthy volunteers (7 males, 7 females; age 
range 19-29 years) who had normal haematology, 
biochemistry and electro-cardiographs were studied in a 
single-blind, randomised, placebo controlled, balanced
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Latin square crossover design arranged so that the active 
agents adrenaline, salbutamol and theophylline with 
appropriate placebos, could be compared in the 
combinations of interest in the course of three study 
days. The combinations studied were:-
(1) Intravenous salbutamol + placebo theophylline + 
vehicle control adrenaline;
(2) Intravenous salbutamol + theophylline + vehicle 
control adrenaline;
(3) Intravenous salbutamol + theophylline + (-)- 
adrenaline;
A diagram of the study design is given in Figure 6.5.1.
In the run-in phase each individual subject's
theophylline dose requirement of a slow release
theophylline preparation (Uniphyllin Tablets, Napp
Laboratories) taken twice daily ( 5-7.5 mg kg"-*- day"-*- for
- 1 - 12 days then 10-15 mg kg ± day -1- for 5 days) was 
determined. If tolerated then a trough theophylline level 
was measured by H.P.L.C. (Gere & Benje, 1977) and the 
required daily dose to achieve a therapeutic plasma level 
throughout was calculated using a microcomputer based 
optimisation programme (OPT, Nodecrest Ltd.). This dose 
was used for the remainder of the study.
Subjects attended the laboratory on the seventh and 
ninth day of active theophylline treatment period and. on 
only the seventh day of their placebo phase, having 
fasted for 10 hours and abstained from caffeine, alcohol 
and smoking for 12 hours. By careful conduct of the
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procedure it was possible to do this without breaking the 
blind. A light standard breakfast was given along with 
the morning dose of the drug. Intravenous cannulae were 
inserted into each forearm. Subjects were studied supine 
throughout the study period. The procedure on each 
separate study day was identical except for the infusions 
administered. Following a control 5% (+)-glucose
infusion, an (-)-adrenaline infusion or an identical 
control adrenaline vehicle solution was commenced and 
after one hour salbutamol was added.
Salbutamol 4 ug kg--*- (16 nmol kg--*-) was administered as 
an intravenous loading dose over 5 minutes followed by a 
maintenance infusion 8jig kg--*- hour--*- (32 nmol kg--*- hour--*-) 
continued for 55 minutes.
The (-)-adrenaline infusion was modified from previous 
studies and adrenaline was commenced at a rate of 0.015 ]±g 
kg--*- min-1 for 10 minutes and, if tolerated, the 
infusion rate was doubled at 10 minute intervals to 0.06 
y.g kg-1 min-1, if there were no side effects, and this 
dose continued for a further 100 minutes. Both the (-)- 
adrenaline infusion and the control adrenaline vehicle 
infusion contained ascorbic acid (1 mg ml 1) to prevent 
oxidation of the adrenaline.
At the end of the second hour of active infusions the 
salbutamol and (-)—adrenaline infusions were both stopped 
and a 5% (+)-glucose infusion was continued for a further
two hours.
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Throughout the study period heart rate and blood 
pressure were measured frequently and blood taken for 
plasma potassium and catecholamine assay (Chap 3.3 & 3.4; 
Fig 6.5.1). Catecholamine concentrations were measured by 
high performance liquid chromatography (Chapter 3.2).
Before the start of the study and at 180 minutes trough 
and peak theophylline concentrations were measured by a 
competitive binding assay based on fluorescence 
polarization (T.D.X. system, Abbot Laboratories Ltd.). 
Blood was taken at 150 and 180 minutes to measure plasma 
salbutamol concentrations by high performance liquid 
chromatography in the Clinical Research Unit of Glaxo 
Laboratories.
Results are presented as mean + standard deviation. 
Repeated measures analysis of variance v . - t s  used to 
compare individual variables on separate study days.
6.5.3 Results.
Tolerance
One volunteer withdrew during the initial treatment 
period because of nausea, her plasma theophyline level 
was 14.6 y.g ml"1. Two volunteers withdrew during the main 
study. One subject was unable to tolerate the salbutamol 
infusions on two occasions due to salbutamol induced 
vomiting. One subject was withdrawn as a result of 
developing premature supraventricular beats at a rate of 
6-8 beats min-1 during the combination of (-)-adrenaline 
and salbutamol infusions during active theophylline 
therapy. These extrasystoles persisted for 4 hours after
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stopping the infusions. Data from the remaining 11 
subjects is presented.
All subjects noted palpitations during the salbutamol 
loading dose. No dysrhythmias were seen but heart rate 
increased. The salbutamol infusion caused tremor of the 
hands in two subjects. No other adverse effects occurred. 
Serum Theophylline Levels
Theophylline levels are shown in Table 6.5.1 The mean 
theophylline concentration on active therapy at time 0' 
(trough) was 11.9ug ml”1 (range- 6.3-17.9ug ml-1) and 
13. 5jig ml-1 (range- 8.3-23.5 ]ig ml"1) at time 180' 
(peak). On placebo therapy theophylline was not 
detected.
Plasma Salbutamol Concentrations
Plasma salbutamol levels were between 5.0-12.0ng ml"1 
(Table 6.5.1). With this infusion regimen some subjects 
demonstrated a small fall in salbutamol concentrations 
between the first and second measurement and others 
modest rises. Neither theophylline, nor the adrenaline 
infusion significantly altered salbutamol levels (Table
6.5.1).
Plasma Adrenaline Concentrations
Baseline plasma adrenaline levels were similar on all 
study days (Table 6.5.1) and did not alter with the 
control infusions of the adrenaline vehicle. On the 
active adrenaline infusion plasma adrenaline 
concentration increased from 1.55+3.34 to 4.28+4.23 nmol
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Table 6.5,1:_____Plasma catecholamine and salbut amo 1
concentrations.
(n=ll; mean ± S.D.; T = theophylline; A = Adrenaline 
infusion period)
[catecholamine levels before (30') and during the 
adrenaline infusion period (180') and salbutamol 
concentrations during (150')and at the end of the 
salbutamol infusion (180') on each study day.]
Adrenaline Cone. Noradrenaline Cone. Salbutamol Cone.
(nmol 1” )^ (nmol 1” )^ (ng ml” )^
Time
30' 180' 30' 180' 150' 180'
Plac. T + Plac. A
1.44±2.96 1.48+3.37 1.97+0.91 3.15±0.97 6.74±0.90 7.74+1.14 
Active T + Plac. A
0.77±1.05 0.78+1.28 3.75+1.97 4.70±2.25 7.34+0.64 7.71+1.70 
Active T + Active A
1.55±3.34 4.28+4.23 3.47± 1.84 4.45±1.85 7.12±1.01 7.58±1.10
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1 1 at the end of the (-)-adrenaline infusion, falling to 
0.88+1.01 nmol 1 1 by the end of the study period.
Plasma Potassium Concentrations
Baseline plasma potassium concentrations were similar on 
each study day. Salbutamol infusion (8 ]±g kg"1 hr-1), 
without the active (-)-adrenaline infusion or 
theophylline, caused a fall in plasma potassium from 4.0+ 
0.3mmol I-1 to 3.0+0.3 mmol l"1 (Fig 6.5.2, Table 6.5.2). 
Salbutamol induced hypokalaemia was significantly greater 
following chronic pretreatment with theophylline, plasma 
potassium falling from 3.9 + 0.3 mmol I-1 to 2.6±0.3 mmol
_ I
1 (p<0.05). The combination of (-)-adrenaline and
theophylline, in addition to salbutamol, did not cause 
any further fall of potassium, the nadir being similar, 
2.6±0.3 mmol l"1. By the end of the study plasma 
potassium levels were similar on each of the study days. 
Plasma potassium concentrations had still not, however, 
returned to baseline levels two hours after the active 
infusions (Fig 6.5.2, Table 6.5.2).
Haemodynamic Measurements
There was no difference in baseline heart rate at 60' on 
any study day (Table 6.5.3). Heart rate increased during 
the salbutamol infusion on all three study days and this 
rise was significantly greater on the two study days when 
active theophylline was given compared to the placebo 
theophylline study day (p<0.05). Adding the (-)-
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Table 6.5.2; Mean plasma potassium concentrations
at each time point on each study day.
(n=ll; mean ± S.D.).
PLASMA POTASSIUM (mmol l-1)
Time
(mins)
Placebo
+
Placebo
Theophylline
+
Placebo
Theophylline
+
Adrenaline
30 4.1 ± 0.4 3.7 + 0.3 3.8 + 0.4
60 3.9 + 0.2 3.7 + 0.3 3.6 + 0.3
120 4.0 + 0.3 3.9 + 0.3 3.1 + 0.4
135 3.3 ± 0.3 3.1 + 0.4 2.7 + 0.4
150 3.1 ± 0.2 2.7 ± 0.4 2.6 + 0.3
180 3.0 ± 0.3 2.6 + 0.3 2.6 + 0.3
210 3.0 + 0.3 2.7 + 0.3 2.7 + 0.3
240 3.1 + 0.3 2.8 + 0.3 2.9 + 0.3
270 3.3 + 0.2 3.0 + 0.3 3.0 + 0.4
300 3.4 + 0.3 3.2 + 0.3 3.1 + 0.3
p<0.05 p<0.05
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adrenaline infusion to the combination of theophylline 
and salbutamol caused only a further small rise in heart 
rate (Fig 6.5.3). Heart rate fell after the end of the 
active infusions but remained elevated at the end of the 
study period on all treatments, compared to baseline 
values (Fig 6.5.3).
Salbutamol consistently lowered diastolic blood pressure 
and increased systolic blood pressure on all three study 
days but there was no significant difference between the 
three study days (Table 6.5.4, 6.5.5 & Fig 6.5.3).
6.5.4 Discussion
The results demonstrate that theophylline increases the 
potassium lowering effect of salbutamol but (-)- 
adrenaline makes no further difference. The theophylline 
concentrations were well within the established 
therapeutic range and achieved by an oral slow release 
formulation employed in conventional doses. The dose of 
salbutamol used was in the lower half of the recommended 
intravenous dosage schedule for the treatment of asthma 
(A.B.P.I., 1988).
The addition of the adrenaline infusion, leading to high 
concentrations of adrenaline, did not alter the absolute 
extent of hypokalaemia seen with the salbutamol and 
theophylline combination, suggesting the beta2 -receptor 
linked Na+/K+ ATPase pump was already maximally 
stimulated. Alternatively, rapid changes in beta2- 
receptor affinity or number may have occurred, even in
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Table 6.5.3: Mean heart rate at each time point on
each study day.
(n=ll; mean ± S.D.).
MEAN HEART RATE (beats min”^).
Time
(mins
Placebo
+
Placebo
Theophylline
+
Placebo
Theophy1line 
+
Adrenaline
30 74 + 8 77 ± 14 75 + 5
60 72 + 7
+i00r- 12 76 + 6
75 70 + 7 77 + 13 75 + 8
90 70 + 8 79 + 13 83 + 10
105 71 + 9
+i00 11 86 ± 11
120 72 + 8
+1o00 14 94 ± 13
125 111 + 18 121 ± 22 122 ± 19
130 99 + 15 110 + 19 119 ± 20
135 99 + 15 108 ± 19 114 ± 14
140 101 + 13 109 ± 19 113 ± 12
145 103 + 14 110 + 20 113 ± 11
150 101 + 15 112 + 17 113 ± 13
160 101 + 12 115 + 17 114 ± 12
170 103 + 15 115 ± 18 113 ± 13
180 101 + 15 115 + 16 113 ± 13
210 97 + 14 110 ± 17 106 ± 12
240 88 + 13 104 ± 16 102
± 10
270 90 + 8 101 ± 15 99
± 11
300 87 + 9 99 + 15 97
± 8
p<0.05 p<0.05
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Table 6.5.4: Mean systolic blood pressure at each
time point on each study day.
(meaniS.D., n=ll).
MEAN SYSTOLIC BLOOD PRESSURE (mmHg)
Time
(mins)
Placebo
+
Placebo
Theophyl1ine 
+
Placebo
Theophylline 
+
Adrenaline
30 120 + 11 123 ± 8 126 + 8
60 122 + 13 121 ± 8 125 + 7
75 119 + 10 121 ± 6 125 + 9
90 120 + 11 122 ± 9 125 + 6
105 118 + 10 122 ± 7 127 + 8
120 119 + 11 120 ± 7 132 + 13
125 132 + 14 128 ± 18 136 + 15
130 138 + 13 136 ± 8 141 + 13
135 135 + 11 135 ± 13 141 + 11
140 134 + 12 130 + 12 133 + 10
145 134 + 9 130 + 13 132 + 12
150 134 + 8 130 ± 10 133 + 9
160 133 + 10 129 ± 10 130 + 11
170 130 + 7 127 ± 11 127 + 8
180 128 + 7 123 ± 9 126 + 7
210 125 + 10 126 + 12 126
+ 8
240 121. + 8 125 ± 11 128
+ 6
270 121 + 8 126 + 9 125
+ 8
300 119 + 9 125 ± 6 124
± 7
V o 05 p>0.05
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Table 6.5.5: Diastolic blood pressure at each time
point on each study day.
(meaniS.D., n=ll).
DIASTOLIC BLOOD PRESSURE (mm Hg)
Time Placebo 
(mins) +
Placebo
Theophylline
+
Placebo
Theophylline
+
Adrenaline
30 69 ± 7 69 ± 4 67 ± 5
60 68 + 5 68 + 5 67 + 5
75 65 + 5 66 ± 6 66 + 5
90 65 ± 6 70 ± 7 63 ± 5
105 67 ± 5 69 ± 6 64 ± 5
120 67 ± 6 ' 68 + 9 66 ± 6
125 60 ± 8 61 ± 13 63 ± 8
130 66 + 7 62 ± 7 64 ± 9
135 61 ± 5 61 ± 8 64 ± 10
140 61 ± 6 59 ± 7 61 ± 10
145 61 ± 6 58 + 9 61 ± 11
150 60 ± 5 59 ± 8 60 ± 9
160 61 ± 9 61 ± 9 60 ± 7
170 60 ± 8 58 ± 6 60 ± 10
180 62 ± 9 59 + 6 55 ± 9
210 62 ± 6 61 ± 11 60 ± 9
240 60 ± 5 63 + 9 63 ± 8
270 61 ± 4 62 ± 5 63 ± 6
300 64 + 4 62 ± 8 61 ± 5
p>0.05 p>0.05
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the short time of these experiments, with agonist 
induced receptor down regulation limiting the extent of 
the response. These explanations are clearly not 
mutually exclusive. Recent studies with radioligand 
binding to guinea pig skeletal muscle membranes suggest 
that agonists do indeed cause down regulation of beta- 
receptors (Elfellah & Reid, 1987) and that such changes 
may occur relatively rapidly (Snaveley, Zeiler & Insel, 
1985).
Theophylline potentiated adrenaline-induced hypokalaemia 
by an unknown mechanism but failed to increase adrenaline 
induced vasodilation in a previous study (Chap 6.4). 
Similarly, in this study, during the salbutamol 
infusion, no enhanced vasodilator effect, the result of 
stimulation of beta2 ~adrenoceptors on peripheral 
vascular smooth muscle, of either theophylline or 
adrenaline was seen. The fall in diastolic blood 
pressure during the salbutamol infusion was similar on 
the placebo and active theophylline study days. Other 
cardiovascular homeostatic responses may have been 
recruited to maintain blood pressure.
A previous unconfirmed report has suggested theophylline 
has a beta-agonist action (Mackay et al, 1983). The 
enhancement of the chronotropic effects of salbutamol, a 
beta^-adrenoceptor action, by theophylline seen in this 
study suggests that the action of theophylline is not 
specific to beta2 ~adrenoceptors. As theophylline and not
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adrenaline increased salbutamol effects it appears that 
the former is either exerting its action independently of 
the beta adrenoceptors or by activating second or 
subsequent messengers in the cell membrane or 
intracellularly.
Acknowledgement I would like to acknowledge the able 
assistance of Dr. C. Reid in the supervision of some of 
these studies in my absence.
6.6 Summary
In summary, the results of the studies presented in 
this chapter demonstrate a metabolic and haemodynamic 
interaction between theophylline and adrenaline, by an 
unknown mechanism which does not involve increased 
adrenomedullary release of catecholamines.
Steady state therapeutic theophylline levels increase 
adrenaline induced hypokalaemia and tachycardia, at 
pathophysiological concentrations of adrenaline. The 
clinical importance of this finding requires further 
study, especially as most asthmatics probably do not have 
high circulating levels of adrenaline during attacks. 
However, in very severe attacks of asthma adrenaline 
levels may be raised and such patients could be at 
increased risk of cardiac dysrhythmias.
Of greater clinical importance is the demonstration that 
theophylline and salbutamol, a widely used combination, 
can interact both metabolically and haemodynamically.
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However, it is important to emphasise that these 
interactions were seen with intravenous infusions of 
salbutamol which achieve much higher plasma and tissue 
levels than are seen after inhalation therapy, the 
commonest route of administration. Oral preparations of 
salbutamol are available which achieve plasma levels 
intermediate between inhaled and intravenous. New slow 
release preparations are now available which are already 
resulting in a rapid increase in the use of oral 
salbutamol therapy and thus higher plasma salbutamol 
levels.
The clinical importance of this interaction is likely to 
be limited with inhaled therapy but may be more relevant 
if oral (32"a9°nist therapy is used. It is in life- 
threatening attacks of bronchospasm, accompanied by 
hypoxia and acidosis, which lead to an increased risk of 
cardiac dysrhythmias, when large doses of theophyllines 
and beta2-agonists would be given parenterally then the 
interaction demonstrated in these studies could 
precipitate dysrhythmias.
It is noteworthy that theophylline and salbutamol 
maximally stimulated the Na+/K+ ATPase, or led to down 
regulation, such that further stimulation by 
pathophysiological levels of adrenaline had no effect. If 
the mechanism was down regulation in such a short period, 
one hour, then it suggests powerful homeostatic 
mechanisms exist to attenuate acute adrenergic induced
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falls in plasma potassium. Such tachyphylaxis may further 
limit the risks that the interactions demonstrated in 
these studies pose to patients.
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CHAPTER 7 
CATECHOLAMINES AND MAGNESIUM.
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7: CATECHOLAMINES AND MAGNESIUM.
7.1 Background
Magnesium, the second most abundant intracellular
cation, is present in the plasma, but in relatively 
small amounts. As discussed in Chapter 1 the control of 
magnesium ion movements across cell membranes is poorly 
understood.
Reviewing the literature, it is clear that
hypomagnesaemia has been reported to occur in a number 
of situations in which circulating adrenaline is known 
to be raised. These situations include myocardial 
infarction (Dyckner, 1980), cardiac surgery (Holden et 
al, 1972; Schiemann et al, 1969) and insulin induced 
hypoglycaemia (Lindsay, 1976). Hypomagnesaemia has also 
been reported following the selective beta2 ~agonist, 
salbutamol (Philips et al, 1980). Hypomagnesaemia
increases the risks of cardiac dysrhythmias, both in 
isolation and when combined with hypokalaemia (Chapter 
2 ) .
The studies described in this chapter had the aim of
examining the following questions:
1) Does increasing circulating adrenaline cause
hypomagne s aemi a ?
2 ) is a beta2-adrenoceptor involved in adrenaline
induced hypomagnesaemia?
3) Finally, as diuretics may causehypomagnesaemia,
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is there any interaction between diuretic induced 
hypomagnesaemia and adrenaline induced hypomagnesaemia?
7.2 Adrenergic control of plasma magnesium.
7.2.1 Introduction
As discussed above, the published literature suggests 
that catecholamines could have a role in the movement of 
magnesium across cell membranes. In this study the 
effects of increased adrenaline levels on plasma 
magnesium was examined in volunteer subjects.
It has been suggested that insulin may be involved in 
the internal regulation of magnesium (Lindsay, 1976) and, 
as adrenaline alters insulin release, changes in plasma 
insulin and glucose levels were also studied.
7.2.2 Methods
Eight healthy subjects, four males and four females, 
receiving no drugs, aged 22-37 years participated.
The protocol followed was identical to that described in 
Chapter 4.2, except that subjects only received three 
treatments and were studied on three separate occasions 
one week apart. In a single-blind study subjects received 
each of three treatments, placebo salbutamol and placebo 
adrenaline; placebo salbutamol and active adrenaline; or 
active salbutamol and placebo adrenaline, given in a 
random order by a balanced Latin square design. Subjects 
fasted overnight then received a light standard breakfast
200
3 0 minutes before commencing the study period and,
thereafter, fasted throughout the study period. After 30
minutes supine rest an infusion of 5% (+)—glucose (12mls 
— 1h ) was administered for one hour. Subjects then 
received either an active solution of (-)-adrenaline or 
an identical vehicle control solution. If after 10 
minutes of infusion of (-) adrenaline at a rate of 
0.03y,g kg  ^ min  ^ there were no symptoms or adverse 
effects then the rate was increased to 0.06ug kg"-1- min"-1- 
and this rate was continued for 110 minutes, a total of 
120 minutes of (-)-adrenaline.
During the last 60 minutes of the (-)-adrenaline infusion
period either an active salbutamol infusion or an
identical vehicle control infusion was commenced at a
dose of 40ng kg”-1- min"-1- and increased by increments at 15
—  1 - 1minute intervals to a dose of 120ng kg m m  x which was 
then continued for 30 minutes, a total of 60 minutes of 
salbutamol infusion. Thereafter a 5% (+)-glucose control 
solution was continued for a further 1 hour (Figure 
7.2.1).
Plasma potassium was measured by standard flame 
photometric methods. (Magnesium concentrations were 
measured by atomic absorption spectro-photometry using a 
Perkin Elmer AA Spectrophotometer. Glucose levels were 
measured using Trinders Glucose oxidase method on a 
Technicon RA 1000 analyser. Insulin samples were measured 
by an identical method to that described in section 4.2.
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Plasma salbutamol levels were measured by high 
performance liquid chromatography system with 
electrochemical detection, courtesy of Glaxo 
Laboratories.
Samples for plasma adrenaline levels were measured by 
radio-enzymatic assay (Chap 3.2). Results are expressed 
as mean and standard deviation. Placebo treatment is 
compared to active treatments, salbutamol and adrenaline, 
by analysis of variance, as applied to repeated 
measures, and corrected for variations in baseline
measurements prior to analysis.
7.2.3 Results
Plasma adrenaline concentrations were <0.1 nmol 1“  ^
prior to and at the end of the placebo infusions on the 
placebo adrenaline + placebo salbutamol study day and 
0.12 and <0.1 nmol I--'- before and at the end of the 
infusion period on the placebo adrenaline + salbutamol 
study day. On the active adrenaline + placebo salbutamol 
study day adrenaline concentrations rose from <0.1 to 
2.33 nmol I-1 by the end of the adrenaline infusion
(Table 7.2.1).
Baseline magnesium levels were not significantly
different on the three study days (Table 7.2.2). There 
was a significant fall in magnesium at the end of the 
active adrenaline + placebo salbutamol infusion 
(0.67±0.07 mmol l"1; p<0.02) compared to the placebo
salbutamol + placebo adrenaline study day. The fall in
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Table 7.2.1: Mean plasma adrenaline and salbutamol
concentrations on each study day.
(n=8; mean ± S.D.)
[ A=adrenaline; S=salbutamol; U.D.=undetectable]
Time
Treatment 
Vehicle A 
+
Vehicle S
Salbutamol
Concentration
(ng ml--*-)
180' 210’
U.D.
Adrenaline
Concentration
(nmol l-1)
30' 210'
U.D. <0.1 <0.1
Adrenaline
+
Vehicle S
U.D. U.D. 0.16±0.16 2.33±1.62
Vehicle A 
+ 2.6+0.8 
Salbutamol
4.6+0.8 0.12±0.03 < 0.1
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Table 7.2.2: Mean plasma magnesium at each time
point on each study day.
(mmol 1” ;^ n=8; mean ± S.D.).
Time Placebo Adrenaline Salbutamol
(mins) - - -
30 0.73 + 0.04 0.69 + 0.06 0.74 + 0.05
90 0.74 + 0.04 0.70 + 0.06 0.76 + 0.05
120 0.75 + 0.04 0.71 + 0.06 0.76 + 0.04
150 0.75 + 0.04 0.71 + 0.04 0.75 + 0.04
165 0.75 + 0.04 0.68 + 0.05 0.73 + 0.05
180 0.75 + 0.04 0.67 + 0.04 0.73 + 0.04
195 0.75 + 0.04 ' 0.67 + 0.06 0.72 + 0.05
210 0.75 + 0.03 0.67 + 0.07 0.70 + 0.06
240 0.75 + 0.03 0.66 + 0.06 0.69 + 0.07
270 0.74 + 0.04 0.66 + 0.07 0.68 + 0.06
p<0.02 p<0.05
204
magnesium during the active salbutamol + placebo
adrenaline study day was slower and continued after the 
end of the infusion to 0.68±0.06 mmol l"1 (p<0.05,
Figure 7.2.2).
Plasma potassium concentrations fell on the active 
adrenaline + placebo salbutamol (p<0.005) and on the 
active salbutamol + placebo adrenaline (p<0.01). On the 
placebo adrena_ine + placebo salbutamol study day
potassium levels rose (Figure 7.2.2, Table 7.2.3).
Insulin concentrations fell during the run-in period on 
all study days. During the placebo salbutamol + placebo 
adrenaline infusion and during the active adrenaline + 
placebo salbutamol infusion insulin levels fell but they 
then rose sharply after the adrenaline infusion. During 
the period of the active salbutamol + placebo adrenaline 
infusion insulin levels did not alter. There were no 
significant differences between the three study days 
(Figure 7.2.3, Table 7.2.4). Glucose levels were
unchanged during the placebo salbutamol + placebo
adrenaline infusion and the active salbutamol + placebo 
adrenaline infusion but rose significantly during the 
active adrenaline + placebo salbutamol infusion 
(p<0.005 , Figure 7.2.3, Table 7.2.5).
7.2.4 Discussion
As discussed previously (Chapter 3.2) the infusion of 
adrenaline at this dose (0.06ug kg 1 min )^ leads to
205
n = 8, MEAN + S.D. o PLACEBO 
*  p <  0-05 
*  •  p <  0-02 a SALBUTAMOL
O ADRENALINE
O—
 1 SALBUTAMOL
OR PLACEBO INF.
( - )  ADRENALINE OR PLACEBO INFUSION
210150 2709030
TIME (MINUTES)
Fig. 7 2.2.: CHANGES IN PLASMA MAGNESIUM ON EACH STUDY DAY
PL
AS
MA
 
GL
UC
OS
E 
(n
m
ol
 
l“
M 
PL
AS
MA
 
IN
SU
LIN
 
(l
.u
.l"
1) 60-
40-
20-
0-
100-1
8 0- 
60- 
40-
n r  8, MEAN! S.D. 
*  •  *  p <  0 005 
O -  PLACEBO 
•  -  ADRENALINE 
A -  SALBUTAMOL
—J SALBUTAMOL 
OR PLACEBO INF.
( - )  ADRENALINE OR PLACEBO INFUSION
90 210 240 27030 150
TIME (MINUTES)
Fig. 7.2.3: CHANGES IN PLASMA INSULIN AND GLUCOSE ON EACH STUDY DAY
 7»2«3 Mean plasma. potassium at each time
point on each study day.
(mmol l"1; n=8; mean ± S.D.).
Time Placebo - Adrenaline Salbutamol
(mins)
30 3.8 + 0.3 3.8 + 0.5 3.9 + 0.3
90 3.9 + 0.2 4.0 + 0.3 3.8 + 0.2
120 4.1 + 0.3 3.6 + 0.6 4.0 + 0.2
150 4.1 + 0.2 3.5 + 0.6 4.0 + 0.2
165 4.1 + 0.2 3.4 + 0.5 4.0 + 0.2
180 4.1 + 0.2 3.4 + 0.4 3.9 + 0.4
195 4.1 + 0.2 3.4 + 0.4 3.6 + 0.3
210 4.0 + 0.3 3.4 + 0.5 3.4 + 0.2
240 4.0 + 0.2 3.5 + 0.4 3.5 + 0.3
270 4.0 + 0.3 4.0 + 0.4 3.7 + 0.4
p<0.005 p<0.01
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Table 7.2.4: Mean plasma insulin at each time point
on each study day.
(i.u. 1” ;^ n=8; mean ± S.D.)
Time Placebo 
(mins)
- - I Adrenaline Salbutamol
30 33 + 22 42 + 27 33 + 19
90 20 + 5 24 + 9 27 + 8
120 21 + 8 18 + 6 20 ± 10
150 17 + 6 22 + 9 16 + 6
165 15 + 5 23 + 8 17 + 6
180 10 + 4 24 + 12 21 + 7
195 13 + 5 24 + 10 22 + 13
210 12 + 8 19 + 6 26 + 18
240 14 + 12 39 + 23 18 + 12
270 20 + 21 19 + 13 21 + 32
p>0.05 P>0.05
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Table 7.2.5; Mean plasma glucose at each time point
on each study day.
(mmol l”1; n=8; mean ± S.D.).
Time Placebo Adrenaline Salbutamol
(mins)
30 5.4 + 0.8 5.6 + 1.3 5.6 + 0.8
90 4.7 + 1.1 4.6 + 0.8 4.2 + 1.0
120 4.8 + 0.5 5.6 + 0.8 4.3 + 0.5
150 4.8 + 0.8 7.4 + 1.4 4.5 + 0.5
165 4.8 + 0.8 8.5 + 1.6 4.7 + 0.6
180 4.9 + 0.9 8.7 + 1.9 4.9 + 0.9
195 4.8 + 0.3 8.8 + 1.7 5.5 + 1.0
210 4.7 + 0.4 8.0 + 1.6 5.5 ± 1.2
240 4.6 + 0.4 7.4 + 1.9 5.4 + 0.9
270 5.1 + 0.5 5.5 + 1.0 5.5 + 0.7
p<0.005 p>0.05
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levels similar to those observed, in acute myocardial 
infarction. This study shows that such adrenaline levels 
result in a small, though significant, fall in plasma 
magnesium levels. Falls in magnesium did not parallel 
the falls in potassium; they were slower in onset and 
did not recover during the hour long observation period 
following adrenaline. Magnesium ions are small, highly 
polarised, have a large hydrated size in solution and 
will therefore pass with difficulty through water filled 
channels. These physical characteristics will make a 
highly specific, high affinity magnesium binding site 
unlikely. However there is evidence that there are 
moderate affinity binding sites which do select 
magnesium ions (Flatman, 1984). This difference in the 
likely affinity of binding sites for magnesium compared 
to the highly specific binding sites for potassium may 
explain the different time courses in the change in each 
ion's concentration in response to the infusions.
Plasma potassium levels rose after the end of the active 
infusions and magnesium levels did not rise. Adrenaline 
inhibits insulin release and glucose levels rose during 
the adrenaline infusion resulting in rebound 
hyperinsulinaemia after the adrenaline infusion (Figure 
7.2.3). Lindsay has reported that insulin-induced 
hypoglycaemia is associated with falls in magnesium 
levels and postulated an insulin stimulated magnesium 
transport system (Lindsay, 1976). As insulin also
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stimulates potassium transport into cells and potassium 
levels rose during this period of relative 
hyperinsulinaemia, but when insulin levels still did not 
exceed baseline levels, it is unlikely that this 
mechanism would explain these findings. An alternative 
explanation for these findings would be increased renal 
excretion, and this cannot be excluded as urinary 
magnesium concentrations were not examined. In support 
of this hypothesis is a recent report demonstrating that 
urinary magnesium levels increase during terbutaline 
infusion, a beta2 -agonist (Bos, Postma & Doormaal, 
1988) .
A therapeutic dose of salbutamol caused a significant 
fall in magnesium levels, though the time course of this 
fall was slower and more prolonged than with adrenaline. 
The salbutamol infusion regimen used in this study would 
have failed to achieve steady-state salbutamol levels. 
Salbutamol clearance is low and this may explain the 
continued fall in plasma magnesium levels following the 
salbutamol infusion.
These results suggest that magnesium may flux between 
extracellular and intracellular compartments under the 
influence of beta-adrenergic receptors, possibly of the 
be ta 2 subtype. Two studies in animals indirectly support 
this hypothesis. Devane and his colleagues demonstrated 
that major surgery in dogs resulted in hypokalaemia and 
hypomagnesaemia with an increase in erythrocyte and
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lymphocyte concentrations of both cations during the 
period of adrenomedullary stress (Devane , Donnelly & 
Ryan, 1980). Rayssiguer reported adrenaline-induced 
hypomagnesaemia in sheep which was abolished by beta- 
adrenoreceptor blockade with propranolol
(Rayssiguer,1979). This worker also suggested another 
possible mechanism by which adrenaline could lower plasma 
magnesium levels. Adrenaline stimulates lipolysis and, 
hence, increases free fatty acids which, in turn, bind 
magnesium thils lowering plasma magnesium. One group of 
workers have shown in acute alcohol withdrawal, another 
situation with increased circulating adrenaline levels, 
that plasma magnesium falls as free fatty acid levels 
rise. (Flink et al., 1979; Flink, Brick & Shane, 1981).
Hypomagnesaemia has commanded less attention than 
hypokalaemia, possibly because deficiency of both 
cations often co-exists and hypokalaemia is a much more 
common cause of cardiac dysrhythmias. However, 
hypomagnesaemia is associated with an increased 
incidence of cardiac dysrhythmias even in the absence of 
a low potassium (Chadda et al, 1973; Flink, 1980). The 
clinical significance of such a small fall in plasma 
magnesium, as seen in this study, is uncertain and 
further studies in man are required to determine the 
mechanism of adrenaline-induced hypomagnesaemia and its 
clinical relevance.
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7.3 The effect of diuretic pre-treatment on adrenaline 
induced hypomagnesaemia.
7.3.1 Introduction
As previously discussed diuretic therapy is widely used 
in patients with ischaemic heart disease. Therapy with 
loop diuretics and thiazides may result in 
hypomagnesaemia and, potentially, cause cardiac 
dysrhythmias.
Diuretic associated hypomagnesaemia
Renal handling of magnesium is very different from 
potassium (Fig 1.4.1). As some plasma magnesium is 
protein bound only approximately 80% is filtered at the 
glomerulus and only 25% reabsorbed in the proximal 
tubule. The principal site of reabsorption is the loop of 
Henle (50-60%), probably controlled by two factors. A 
sodium chloride/potassium co-transporting system and, 
secondly, backflux of sodium and potassium creating a 
trans-epithelial gradient favouring magnesium 
reabsorption. At the distal tubule a small amount (5%) 
of further reabsorption occurs. Thus, urinary magnesium 
is between 3-5% of the filtered load. Controversy exists 
as to the possible existence of mechanisms for active 
secretion of magnesium. Such a system is almost 
certainly not operative under normal circumstances, but 
may operate in certain pathologies (Sachtjan, Meyer & 
Massry 1979; Brunette, Vigneault & Carriere, 1974).
The effect of diuretics on magnesium differ from there
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effects on potassium (Fig 5.1.1). Diuretics, such as 
carbonic anh.yd.rase inhibitors, which act on the proximal 
tubule, may cause significant potassium losses but do 
not affect magnesium excretion. Presumably any blockade 
of magnesium reabsorption in the proximal tubule is 
compensated for by increased reabsorption in the loop of 
Henle. Diuretics which act on the loop of Henle, e.g. 
frusemide, have profound effects on magnesium 
reabsorption and result in major increases in urinary 
magnesium. Thiazides, which act in the early distal 
tubule, a site of only minor magnesium reabsorption, 
would not be expected to have significant effects on 
magnesium excretion and, indeed, short term animal 
studies have shown this to be the case (Ryan, 1986). 
However, a number of clinical studies of chronic 
thiazide therapy have demonstrated significant magnesium 
losses and either hypomagnesaemia (Dyckner & Wester, 
1979) or muscle magnesium deficiency (Wester & Dyckner 
1985). Further studies found that hypomagnesaemia 
following thiazides was dependent on dose (Hollifield & 
Slaton, 1981, Hollifield 1986) and duration (Dyckner & 
Wester 1979). In contrast, studies over 3 to 10 years in 
hypertensives have failed to demonstrate significant 
intracellular magnesium depletion (Ryan 1986). It has 
been suggested that the effects of thiazides are 
indirect, secondary to delayed thiazide induced 
alterations in the renin-angiotensin-aldosterone system
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and/or due to alterations in calcium metabolism which 
may interfere with magnesium reabsorption (Ryan 1986).
The two groups of agents which act in the late distal 
tubule and collecting ducts act differently. Current 
evidence suggests that triamterene and amiloride conserve 
magnesium. The situation is less clear with 
spironolactone, acute studies in animals show little 
effect (Devane & Ryan, 1983) whilst long term studies in 
man have demonstrated increased skeletal muscle magnesium 
when spironolactone is added to chronic conventional 
diuretic therapy (Dyckner & Wester, 1986).
The effect of pretreatment with each of these diuretics, 
frusemide, bendrofluazide and spironolactone on plasma 
potassium and magnesium changes during an adrenaline 
infusion was studied in healthy subjects.
7.3.2 Methods 
Subjects
Eight healthy normotensive volunteers (4 males, 4 
females; age range 21-37 years) were studied. All 
subjects had normal routine haematology, biochemistry and 
electrocardiograms and were on no regular drug therapy.
Treatment Protocol
This was a placebo controlled, double blind study with 
supplies being dispensed by the hospital pharmacy. 
Subjects received four separate treatments in a 
randomised order using a Latin square design with at
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least two weeks between treatments to ensure adequate
washout. All drugs were matched using a disguised
gelatine capsule. The four treatments were:
i) bendrofluazide 5 mgs daily;
ii) placebo capsule one daily;
iii) frusemide 40 mg daily;
iv) spironolactone lOOmgs daily;
and each therapy was administered for two weeks.
On the fourteenth day of each treatment limb subjects
attended the laboratory having abstained from all food,
caffeine, alcohol and tobacco for 10 hours. The drug
and a standard light breakfast were given and cannulae
inserted into each forearm. Subjects were studied supine
throughout and, after one hour of supine rest a 5% (+)-
_ -1
glucose solution, containing ascorbic acid (1 mg ml x) 
to prevent oxidisation of the adrenaline, was commenced, 
via a Braun VI perfusor pump, at a rate of 12 ml hr"1. 
Baseline measurements were made during the one hour 
control (+)-glucose infusion. (-)-adrenaline infusion 
(Antigen Ltd.) was commenced at a rate of O.Oljig kg 
min"1 and, if after ten minutes there were no adverse 
effects, then the infusion rate was increased stepwise 
at 10 minute intervals to 0.06p.g kg"1 min"1 in the 
standard protocol, as described in Chapter 3. This dose 
was continued for 90 minutes. Following the adrenaline 
infusion the control (+)-glucose infusion was continued 
for a further two hours (Fig 7.3.1).
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Plasma magnesium was measured by spectrophotometry using 
a Perkins-Elmer atomic absorption spectrophotometer 
(Perkins-Elmer Ltd.).
Red cell magnesium was measured by dilution of the red 
cells into lanthanum nitrate and then measuring the 
magnesium level by spectrophotometry.
Samples for plasma catecholamines were collected in the 
standard fashion and analysed by high performance liquid 
chromatography (Chap 3.3).
Results are expressed as mean and standard deviation. 
Repeated measures analysis of variance was used for 
comparisions between treatments. Measurements before and 
after a manoeuvre (e.g. adrenaline infusion) were 
compared using a paired Students t test.
7.3.3 Results
All subjects completed the study and none reported any 
adverse effects.
Plasma catecholamines.
Baseline adrenaline, steady-state adrenaline during the 
infusion periods and noradrenaline were not significantly 
different on the four treatments. Adrenaline levels at 
the end of the adrenaline infusion showed considerable 
variation between study days in the same subject, and 
between subjects, but the levels were increased at least 
20 fold by the infusion (Table 7.3.1).
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Table 7.3.1: Mean plasma adrenaline and
noradrenaline at each time on each study day.
(n=8; mean S.D.; ADR=adrenaline; NADR=noradrenaline). 
Adrenaline Concentration (nmol 1“ )^
Time PLACEBO SPIRONOLACTONE FRUSEMIDE BENDROFLUAZ.
(mins)
60 0.1 + 0.05 0.1 + 0.05 0.1 + 0.05 0.1 + 0.4
120 0.1+0.05 0.1±0.1 0.1+0.05 0.1+0.05
240 2.2+1.7 4.1±5.8 4.0±5.0 2.3+1.2
360 0.1+0.1 0.410.5 2.416.0 0.310.7
p>0.05 p>0.05 p>0.05
Noradrenaline Concentration (nmol 1”^)-
Time PLACEBO SPIRONOLACTONE FRUSEMIDE BENDROFLUAZ
(mins)
60 2.010.9 1.911.0 2.111.0 2.211.1
120 2.010.7 2.411.3 2.211.2 2.010.6
240 2.110.4 2.011.2 3.614.0 2.110.9
360 2.011.0 1.210.5 2.111.5 2.010.7
p>0.05 p>0.05 P>0.05
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Plasma and red cell magnesium
Baseline plasma magnesium levels were not altered by 
any of the three active therapies compared to the placebo 
study day ( placebo - 0.76 mmol 1"^; spironolactone - 
0.75 mmol l"1; frusemide - 0.78 mmol l"1 and
bendrofulazide - 0.79 mmol l"1 ). During the adrenaline 
infusion plasma magnesium fell by 0.3-0.6 mmol l-1 
(Figure 7.3.2, Table 7.3.2). The effect of adrenaline on 
plasma magnesium was prolonged beyond the period of the 
infusion and the lowest magnesium values were seen 
between 30 and 60 minutes after the adrenaline infusion. 
The plasma magnesium changes induced by the adrenaline 
were identical with the placebo study day on all the 
active treatments (Fig 7.3.2).
Baseline red cell magnesium levels were higher on 
spironolactone and frusemide (2.1 mmol 1“ )^ compared to
_ i
placebo and bendrof luazide (1.9 and 2.0 mmol 1 
respectively). Red cell magnesium did not alter during 
the adrenaline infusion on any study day (Fig 7.3.3, 
Table 7.3.3).
7.3.4 Discussion.
Pathophysiological adrenaline levels again caused 
plasma magnesium to fall as in the previous study (7.2).
In this study no pretreatment, with any of the 
diuretics, altered baseline plasma magnesium. This 
contrasts with previous published work demonstrating
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Table 7.3.2: Mean plasma magnesium at each time
point on each study day.
(n=8; mean ± S.D.; mmol 1“ )^
Time Placebo Spironolactone Frusemide Bendrofluaz
(mins)
60 0.77±0.03 0.72+0.05 0.78+0.04 0.78+0.05
90 0.77±0.03 0.74+0.05 0.79±0.05 0.80±0.05
120 0.76+0.03 0.75±0.04 0.78+0.04 0.79+0.06
210 0.74+0.02 0.73+0.03 0.74±0.03 0.77±0.05
240 0.73±0.02 0.71+0.04 0.72±0.03 0.75±0.05
270 0.72±0.03 0.70±0.05 0.71±0.02 0.74+0.05
300 0.73+0.01 0.70±0.04 0.7210.03 0.74+0.05
360 0.74+0.01 0.7210.05 0.74+0.02 0.74+0.05
p>0.05 p>0.05 p>0.05
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Table 7.3.3: Mean red cell magnesium concentrations
at each time point on each study day.
(n=8; mean ± S.D.; mmol l- )^
Time Placebo Spironolactone Frusemide Bendrofluaz
(mins)
60 1.9+0.3 2.1+0.2 2.1±0.2 2.0+0.3
90 1.9±0.3 2.1+0.2 2.1+0.3 2.0+0.2
120 1.910.2 2.110.2 2.110.3 2.010.3
210 2.010.2 2.210.4 2.210.3 2.010.2
240 1.910.2 2.210.3 2.110.3 2.010.2
270 1.910.2 2.210.5 2.210.3 1.910.3
300 1.910.3 2.310.6 2.110.4 2.010.2
360 1.910.2 2.210.2 2.110.4 2.010.2
p>0.05 p>0.05 P>0.05
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that both chronic thiazide and frusemide therapy may 
cau.se hypomagnesaemia (Dyckner & Wester , 1981) . Possible 
explanations for this finding include the use of an 
inadequate dose, though this would seem unlikely from 
the published evidence (Wester & Dyckner, 1981), or too 
short a period of therapy, two weeks, to significantly 
alter plasma magnesium concentrations. Finally, not 
everyone develops diuretic associated hypomagnesaemia 
and, possibly, too few subjects were studied to detect a 
significant magnesium losing effect.
Adrenaline induced hypomagnesaemia did not increase
following pretreatment with any of the diuretics
suggesting that these diuretics would not increase the
risk of severe hypomagnesaemia during periods of 
adrenomedullary stress, such as myocardial infarction.
However, in view of the failure of this study to
demonstrate diuretic induced hypomagnesaemia, a commonly
reported phenomenon, such an interpretation cannot be
regarded as conclusive.
In an attempt to confirm that adrenaline induced 
hypomagnesaemia was the result of intracellular shift of 
magnesium, rather than increased renal excretion, red 
cell magnesium was measured in this study. However no 
significant change in red cell magnesium concentrations 
were observed. This could be because a much larger 
proportion of magnesium in humans is intracellular and 
only a small proportion is extracellular. Only a small
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intracellular shift of magnesium would be necessary to 
cause significant, and detectable, falls in extracellular 
concentrations. In contrast, this intracellular shift is 
such a small proportion of the intracellular magnesium 
concentration that it will be difficult to detect. It 
cannot, therefore, be concluded that the failure to 
detect any change in intracellular cation concentrations 
excludes intracellular shift as the mechanism of 
adrenaline induced hypomagesaemia.
This study suggests that patients receiving chronic 
thiazide or frusemide therapy would not be at. increased 
risk of severe hypomagnesaemia and, thus, cardiac 
dysrhythmias during acute stress, such as myocardial 
infarction.
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CHAPTER 8; GENERAL DISCUSSION AND CONCLUSIONS
8: GENERAL DISCUSSION AND CONCLUSIONS.
8,1 The adrenegic system and potassium homeostasis.
As demonstrated in Chapter 3, it is possible to design 
an effective infusion regimen to achieve circulating 
pathophysiological concentrations of adrenaline which 
can be safely administered to volunteer subjects.
Using this infusion regimen the studies presented in 
this thesis show that circulating adrenaline 
concentrations, 10-25 times basal level, similar to those 
seen in the stress of acute severe illness, such as 
myocardial infarction, have both metabolic and 
cardiovascular effects.
On average heart rate increased by 10-15 beats per 
minute and the changes in blood pressure were modest, a 
fall of approximately 5 mm Hg in diastolic and a rise of 
less than 10 mmHg in systolic blood pressure. This 
contrasts with the cardiovascular changes reported in 
situations of acute psychological stress (Anfilogoff et 
al, 1987) where, despite more modest rises in adrenaline, 
4-5 times basal level, there are dramatic increases in 
heart rate (60-80 beats per minute). In situations of 
psychological stress noradrenaline increases 4 fold 
suggesting large increases in adrenergic tone from the 
central nervous system and, in addition, vagal tone will 
also alter. These factors may explain the disrepancy 
between the findings in these two situations. During
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severe physical exercise the increases in circulating 
adrenaline are even more modest (approximately 2-3 fold, 
Struthers et al, 1988).
In all studies presented in this thesis the rise in in 
circulating adrenaline results in a rapid and significant 
fa.ll in plasma potassium. No such fall was seen during 
the placebo infusions.
8.2 Mechanism of adrenaline induced hypokalaemia.
In Chapter 4 adrenaline induced hypokalaemia was shown 
to be independent of changes in plasma insulin. The 
mechanism of adrenaline induced hypokalaemia is likely to 
be a direct effect of adrenaline on potassium transport 
mechanisms across cell membranes, principally active 
transport of potassium by the Na+/K+ pump linked to its 
enzyme, Na+/K+ ATPase.
However, there is some conflicting evidence which has 
led to alternate hypotheses. Activity of Na+/K+ ATPase 
can be measured directly and such studies have suggested 
that the enzyme, as opposed to the pump, only responds 
to high concentrations of (3-agonist (Coffey, Hadden & 
Hadden, 1975; Wu & Phillis, 1980). Also adrenaline 
stimulates Na+/K+ pump activity in intact leucocytes but 
Na+/K+ ATPase activity does not increase (Baron, Green & 
Kahn, 1985). This study may be at fault as pump activity 
is measured on intact cells, whilst Na /K ATPase 
activity reguires homogenization of the cell which may 
alter the link between beta2-receptors and Na /K
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ATPase. Similarly, another group has also reported that 
stimulation of Na+/K+ ATPase isolated from sacrolemmal 
membranes was not linked to receptors (Cheng, Rogus & 
Zierler, 1977). Yet, paradoxically, the same group
demonstrated that in intact skeletal muscle the 
stimulation of the pump by catecholamines is specific 
and mediated by beta-adrenoceptors (Rogus, Cheng & 
Zierler, 1977). Pump activity is not stimulated by beta- 
agonists in all tissues, rat salivary gland (Batri et 
al, 1973) fails to respond. It is possible that in other 
tissues the Na+/K+ ATPase is not linked to (3-receptors.
An alternative hypothesis is that the catechol moiety, 
rather than the intact hormone, increases Na+/K+ ATPase 
activity, possibly by chelating an inhibitory metal ion 
(Lee & Phillis, 1977; Schaefer, Komlos & Serge, 1979; 
Krogt & Belfroid 1980). However, these studies were all 
carried out on cortical tissue and Na+/K+ ATPase is 
known to differ in different tissues. Clearly for this 
theory to be valid a-agonists would also have to 
stimulate the Na+/K"*" pump. This has been studied, but 
the evidence is conflicting, with some groups showing 
stimulation of the pump ( Brown & Caulfield 1979; Smith 
1984; Coffey et al, 1975) and others inhibition 
(Martinez, Quissell & Giles, 1976; Smith & Jones, 1985; 
Riozzi et al, 1984). Further evidence against this 
theory is the absence of any fall in plasma potassium 
during infusion of a-adrenergic agonists in intact
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animals (D’Silva 1934) or in humans.
The studies in Chapter 4 suggest that adrenaline induced 
hypokalaemia is mediated through the sympathetic nervous 
system, most likely via a beta2 ~adrenoceptor. The highly 
selective beta2 “agonist, salbutamol, results in a similar 
fall in plasma potassium, both in degree and in time 
course, as adrenaline. Adrenaline induced hypokalaemia is 
blocked by beta-adrenoceptor antagonists. This blockade 
of adrenaline induced hypokalaemia is progressively less 
as increasingly selective beta^-antagonists are used. The 
effect of ICI118551, a highly selective beta2 ~ 
adrenoceptor antagonist, has also been studied, though 
not in the studies described in this thesis, and shown to 
completely abolish adrenaline induced hypokalaemia (Brown 
et al, 1983 ) .
The mechanism by which stimulation of the beta2 “ 
adrenoceptor increases Na+/K+ ATPase activity is 
uncertain. The most likely route is via the 'second 
messenger', cAMP, phosphorylating protein kinase which 
increases Na+/K+ ATPase activity. The combination of 
dibutyrl cyclic AMP plus theophylline mimics all the 
effects of adrenaline on ion transport (Clausen & 
Flatman, 1977, Rogus et al, 1977).
Do all tissues respond similarly to adrenaline? As such 
a large percentage of the body's potassium pool is in the 
skeletal muscle cells (Ginsberg & Wilde, 1954), this is 
clearly the predominant tissue and its response will
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determine the change in plasma potassium. Other tissues 
which have been reported to respond similary include 
frog stomach smooth muscle cells (Scheid et al, 1979) 
and human leucocytes (Baron et al, 1985). As stated 
previously, rat salivary gland cells fail to respond 
(Batri et al, 1973). Possibly of crucial importance, in 
determining the risks of dysrhythmias during adrenaline 
induced hypokalaemia, is a report that adrenaline causes 
an efflux of potassium from cardiac muscle cells 
(Struthers et al, 1987), in contrast to its action on 
skeletal muscle. Rapid potassium intracellular shifts 
result in hyperpolarization of the cell membrane in 
skeletal muscle but adrenaline could, in cardiac muscle, 
result in hypopolarization or maintenance of a stable 
membrane potential, if the fall in intracellular and 
extracellular potassium concentrations are in a balanced 
ratio.
8.3 Is there an adrenergic potassium sensor?
Thus, there is considerable evidence that the adrenergic 
system has a role in the control of potassium 
homeostasis. What is less clear is, under which 
circumstances adrenergic control of potassium is 
physiologically important? From the data presented in 
these studies, and other studies referred to in the 
course of discussion, the adrenergic system will 
influence plasma potassium during the stress of heavy
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muscular exercise and. during severe adrenomedullary 
stress, such as myocardial infarction. In these 
situations the primary stimulus to catecholamine release 
is, clearly, not plasma potassium levels but is from the 
central nervous system.
Does the adrenergic system have any role in control of 
plasma potassium levels in healthy non-exercising humans? 
The rise in plasma potassium after chronic beta-blockade 
with propranolol (Pedersen, Pedersen & Pedersen, 1979) 
suggests that physiological levels of adrenaline and 
noradrenaline do have a role in potassium homeostasis. In 
support of this hypothesis, the disposal of exogenous 
potassium loads is impaired following beta-blockade and 
this impairment is unrelated to changes in circulating 
aldosterone or insulin levels (DeFronzo, 1987). Further 
the hyperkalaemia of chronically adrenalectomized 
animals is reversed by the physiological replacement of 
fasting plasma adrenaline levels (Bia et al, 1982). 
Finally, insulinopenia superimposed on adrenalectomy 
causes a marked deterioration in potassium tolerance 
(DeFronzo et al, 1980), suggesting that in 
circumstances, such as diabetes, adrenergic control 
plays a more central role due to the absence of another
potassium controlling hormone.
If an adrenergic control system does exist ■ for 
potassium homeostasis, then what is the sensor by which 
adrenal release of catecholamines is influenced by
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plasma potassium to form a feedback loop? It has been 
reported that potassium can stimulate tyrosine 
hydroxylase, the first enzyme in catecholamine 
synthesis, in adrenal culture cells (Silberstein et al, 
1972). However, when KC1 was infused in humans to raise 
circulating plasma potassium levels by 0.5-1.0 mmol l"1 
no rise in circulating catecholamine levels could be 
demonstrated (DeFronzo, Bia & Birkhead, 1981). Further 
studies of this interesting question are required.
8.4 Implications for beta-adrenoceptor blocker therapy.
Beta-adrenoceptor antagonists are widely used in the 
treatment of hypertension and angina pectoris. The great 
majority of patients are taking beta-adrenoceptor 
antagonists which are either unselective or, at best, 
only partially selective for the beta-j_-adrenoceptor. 
These drugs will, therefore, interfere with adrenaline 
induced hypokalaemia. Is this likely to have any 
potential benefits or risks for these patients?
Possible benefits of beta-adrenoceptor antagonists 
would include protection of the patient from hypokalaemia 
during the acute stress, of myocardial infarction, when 
their threshold for dysrhythmias is low. In one placebo 
controlled study all patients admitted with an acute 
myocardial infarction were given either intravenous 
timolol or placebo and their plasma potassium monitored 
over the subsequent 24 hours (Nordrehaug et al, 1985). 
The patients who received the beta-adrenoceptor
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antagonist did have significantly higher plasma 
potassium levels. There have been numerous studies of 
the use of chronic beta-adrenoceptor blockade after
myocardial infarction which have demonstrated improved 
survival (Practolol Multicenter International Study, 
1975; Timolol Norwegian Multicenter Study group, 1981). 
The protective mechanism of beta-blockade remains 
unknown. It may be hypothesised that, by protecting
patients from hypokalaemia, induced by rises in
circulating adrenaline during further ischaemic events 
these patients are at less risk of cardiac dysrhythmias.
Postulated risks of beta-adrenoceptor blockade include 
the risk of hyperkalaemia during exercise. Small, but
significant, rises in plasma potassium occur during 
chronic beta-adrenoceptor blockade (Pedersen et al,
1979) and are due to an extracellular shift, and not net
retention of potassium (Pedersen et al, 1979). One 
probable homeostatic advantage of adrenaline induced 
intracellular flux of potassium would be to restore 
plasma potassium towards normal during strenous muscular 
exercise, as potassium leakage increases from exercising 
muscle, thus replenishing muscle potassium stores. 
During constant muscular exercise, such as cycling,
plasma potassium levels increase by approximately
0.5mmol l"1 (DeFronzo, 1987). However, during beta- 
adrenoceptor blockade much greater rises (2-2.5 fold) in
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plasma potassium occur (Carlsson et al, 1978; 
Castellino, Simonson & DeFronzo, 1986). There is, 
however, no proof that this increase in plasma potassium 
associated with exercise, when taking beta-adrenoceptor 
antagonists, is harmful. A recent report (Struthers et 
al, 1988) suggests that potassium fluxes during exercise 
are also under other influences. During the intense 
short bursts of muscular activity of a game of squash 
these authors showed very rapid transient falls in 
plasma potassium, unrelated to changes in circulating 
adrenaline and unaffected by beta2 _adrenoceptor blockade 
by ICI118551. Insulin levels fall during such exercise 
and, thus, the mechanism of the hypokalaemia is unclear. 
Possibly, vasodilatation and increased muscle blood 
flow, whether directly or indirectly, stimulate uptake 
of potassium by exercising muscle.
Currently, there is overwhelming clinical evidence 
that beta-adrenoceptor blockade offers patients with 
ischaemic heart disease significant benefits, whilst the 
risks remain speculative and unproven. The theoretical 
advantage of selective beta-^-blockade, as it would not 
interfering with adrenaline induced hypokalaemia, is not 
supported by current evidence, as both selective and 
non-selective beta-adrenoceptor antagonists have been 
shown to benefit patients.
8.5 Implications for diuretic therapy..
The results of the study of the effect of diuretics
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(Chapter 5) demonstrated no interaction between any of 
the diuretics studied and adrenaline. Nonetheless, it did 
show that there was a potential increase in the risks 
associated with adrenaline induced hypokalaemia with 
potassium losing diuretics, simply because baseline 
plasma potassium levels are lower. Thus, the lower the 
baseline plasma potassium, then the more profound the 
hypokalaemia induced by adrenaline during stress and the 
greater the risk of dysrhythmias. Assessment of the risk 
of therapy with frusemide or thiazide diuretics is 
impossible because of the uncertainty that exists in 
guaging the severity of the chronic hypokalaemia and 
total body potassium induced by these diuretics and, in 
turn, the effects of such changes in potassium 
homeostasis on membrane polarization in cardiac muscle. 
If chronic diuretic therapy, despite resulting 
hypokalaemia, causes no change in cardiac membrane 
polarization due to balanced intracellular potassium 
losses then adrenaline induced hypokalaemia will not 
lead to increased risk in patients receiving such 
therapy. As a result, the risks of diuretic induced 
hypokalaemia remains a matter of continuing controversy 
(Moser et al, 1986; Madias et al, 1984; Caralis & Perez- 
Stable, 1986) and further studies are required.
8.6 Implications for bronchodilator therapy.
Theophylline has been reported ’in vitro' to increase
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adrenaline induced Na efflux, K^ " influx and membrane 
hyperpolarization suggesting an effect on Na+/K+ATPase 
activity (Clausen & Flatman 1977; Rogus et al 1977). In 
the first study described in Chapter 6 a similar effect 
was shown 'in vivo' in normal humans. This was not the 
result of theophylline increasing circulating levels of 
adrenaline. The mechanism of this interaction is probably 
at a cellular level and remains unclear.
The clinical implications are, that therapeutic levels of 
theophylline could increase adrenaline induced 
hypokalaemia in acute severe stress. It is impossible to 
quantify the size of such a risk to patients with chronic 
respiratory disease but it is likely it would be 
relatively small.
Theophylline, the most widely used bronchodilator, and 
the beta2 -adrenoceptor agonist bronchodilator,
salbutamol (Chapter 6.5) do interact leading to a 
potential increase in the fall in plasma potassium. In 
Chapter 6.4 chronic theophylline therapy was shown to 
increase adrenaline induced hypokalaemia. In Chapter 6.5 
the effect of acute intravenous dosing with salbutamol 
was studied. This contrasts with many clinical 
situations, where patients are likely to have been 
receiving chronic therapy with beta2 -agonists. Thus, it 
is possible that down-regulation of the receptors- may 
have occurred in some patients with chronic therapy. 
The extent of down-regulation is probably dependent on 
both the' route and the doses that the patients were
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receiving. "In vivo" desensitization has been 
demonstrated in animals (Avner & Noland, 1978), though 
controversy persists in this area as there is no 
convincing evidence that down-regulation occurs with 
standard doses of beta2 ~agonists inhaled from metered 
dose inhalers (Jenne et al, 1982). However,
increasingly widespread use of nebulisers is resulting 
in patients being exposed to higher doses and increased 
systemic absorption of drug which has been deposited in 
the oropharynx and then swallowed. Whether clinically 
significant down-regulation of the bronchodilator action 
or of the hypokalaemic action of beta2 ~agonists occurs 
with these higher doses is not known, though there is 
one preliminary report suggesting significant down 
regulation occurs in asthmatics (Lipworth et al, 1989). 
The very recent introduction of effective slow release 
preparations of salbutamol will also result in more 
patients achieving chronic steady state salbutamol 
tissue concentrations, unlike the transient blood levels 
that occur with metered dose inhalers. Tachyphlaxis may 
become more relevant in clinical situations more 
frequently.
The clinical implications of the interaction between 
theophylline and salbutamol are, therefore, difficult to 
assess. It may well be that patients with severe asthma 
or bronchitis, who have been exposed to large doses of
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beta2~agonists, but who are also likely to be the 
patients at highest risk of significant hypoxaemia and 
acidosis, will be at lower risk of theophylline 
potentiation of salbutamol induced hypokalaemia because 
of a degree of down-regulation. Patients with less
severe disease, and hence not regularly take high doses 
of these bronchodilators, who suffer an acute severe 
attack of bronchoconstriction and who are then given
large doses of beta2 -agonists, along with therapeutic 
doses of theophylline may be at greater risk of 
significant hypokalaemia resulting from the interaction 
between these bronchodilators. Nevertheless, it must be 
stated that the combination of oral slow release
theophyllines and inhaled or oral beta2 ~agonists is 
widely used, both acutely and chronically, often in 
patients with co-existent heart disease, and there is 
little evidence to suggest these patients are being
placed at risk by this therapy. If there is a risk it is 
probably greatly outweighed by the benefits such therapy 
offers patients.
8.7 Adrenergic control of plasma magnesium.
As discussed previously little is known of the internal 
regulation of magnesium disposal. The results in Chapter 
7 show that adrenaline, in pathophysiological doses, leads 
to small falls in plasma magnesium levels. The mechanism 
is unclear but the time course is different from the time
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course of adrenaline induced hypokalaemia. It may well be 
an indirect effect of adrenaline rather than a primary 
control mechanism, possibly as suggested by Rayssiguer 
due to increased magnesium binding by free fatty acids 
secondary to adrenergic stimulation of adipocytes 
(Rayssigeur, 1979). Further study will be required to 
attempt to define the mechanisms and clinical importance 
of adrenaline induced hypomagnesaemia.
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APPENDIX FOUR
INDIVIDUAL SUBJECT DATA FROM STUDY PRESENTED IN SECTION 4.2
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SUBJECT NO* 1
TREATMENT: PLACEBO.
Time Serum K+ Systolic Diastolic Heart Rate
—  i B.P. B.P.(mins) (mmol 1  -1-) (mm Hg) (mm Hg) (beats min
60 3.8 116 62 74
90 4.0 - _
120 3.9 113 58 80
130 - 109 64 79
140 - 113 61 80
150 - 1 1 2 61 80
160 - 119 69 8 6
175 - 1 2 1 60 89
190 - 125 65 90
210 3.5 119 58 84
225 - 1 2 1 59 81
240 3.5 117 59 82
270 3.4 1 1 2 63 87
300 3.8 117 71 8 6
360 4.0 1 1 2 72 83
SUBJECT NO. 1
TREATMENT: PROPRANOLOL
Time
(mins)
60
90
120
130
140
150
160
175
190
210
225
240
270
300
360
Serum K+ Systolic Diastolic Heart Rate
B.P. B.P.
(mmol l"1) (mm Hg) (mm Hg) (beats min"
3.8 99 55 63
4.0 - - —
4.0 97 62 67
_ 1 1 2 65 60
_ 117 73 58
1 2 0 73 55
— 114 6 8 53
113 73 56
109 73 58
4.0 113 60 74
117 6 6 56
3.9 109 70 65
3.4 109 61 67
3.3 103 56 85
3.5 107 53 72
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SUBJECT NO. 1
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
_ 1 B.P. B.P.
(mins) (mmol 1  -*-) (mm Hg) (mm Hg) (beats min
60 4.2 1 1 1 62 6 8
90 3.9 - _
120 3.9 96 56 67
130 - 103 60 65
140 - 1 0 2 58 6 8
150 - 103 62 63
160 - 103 6 6 57
175 - 113 65 6 8
190 - 1 1 0 67 63
210 4.2 1 1 2 6 8 62
225 - 1 0 2 59 65
240 4.1 1 1 1 65 60
270 3.9 104 59 71
300 3.6 98 52 64
360 3.7 1 0 1 55 69
SUBJECT NO. 1
TREATMENT: ATENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
B.P. B.P. -l
(mins) (mmol l-1) (mm Hg) (mm Hg) (beats min"-1)
60 4.0 1 0 1 57 60
90 4.0 - - —
120 4.0 98 56 56
130 - 96 53 58
140 - 1 0 0 56 57
150 - 1 0 2 56 57
160 — 105 57 54
175 _ 107 56 55
190 — 106 60 63
210 4.4 106 58 63
225 — 96 52 62
240 4.1 103 56 60
270 3.7 1 1 0 59 6 6
300 3.5 1 0 2 53 64
360 4.0 106 58 69
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SUBJECT NO.2
TREATMENT: PLACEBO
Time Serum K+
(mins) (mmol 1 “ -^)
60
90
120
130
140
150
160
175
190
210
225
240
270
300
360
3.5
3.7
3.9
2.7
2.8
3.2
3.3
3.4
Systolic Diastolic Heart Rate
B.P. B.P.
(mm Hg) (mm Hg) (beats min"l)
108 62 82
103 59 69
109 59 71
1 1 1 52 90
109 54 77
107 51 91
116 52 104
107 52 92
107 52 94
108 51 1 0 2
1 1 0 54 114
107 63 99
117 71 92
1 1 0 72 89
SUBJECT NO. 2
TREATMENT: PROPRANOLOL
Time Serum K+ Systolic Diastolic Heart
«i B.P. B.P.
(mins) (mmol 1  ) (mm Hg) (mm Hg) (beats
60 4.1 1 0 0 52 59
90 3.9 - - -
120 3.9 106 53 62
130 - 104 55 54
140 - 105 56 53
150 - 105 61 51
160 - 105 65 48
175 - 1 1 2 65 48
190 - 1 1 2 64 48
210 4.1 109 64 53
225 - 1 1 0 67 52
240 4.1 116 62 56
270 3.8 105 49 73
300 3.6 1 0 0 53 73
360 3.4 99 54 69
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SUBJECT NO. 2
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
_ 1 B.P. B.P.
(mins) (mmol 1  ■*■) (mm Hg) (mm Hg) (beats min
60 3.8 106 55 73
90 3.7 - —
120 3.8 1 0 1 55 65
130 - 107 61 6 6
140 - 104 63 64
150 - 1 1 2 61 56
160 - 117 63 53
175 - 116 6 8 65
190 - 113 58 64
210 3.9 119 59 60
225 - 1 2 1 62 69
240 3.8 109 61 64
270 3.3 106 58 71
300 3.4 107 55 81
360 3.6 1 1 1 55 77
SUBJECT NO. 2 
TREATMENT: ATENOLOL
Time Serum K+ Systolic Diastol
B.P. B.P.
(mins) (mmol l- )^ (mm Hg) (mm Hg)
60 3.9 1 1 0 54
90 3.8 - -
120 3.8 1 0 2 54
130 - 109 44
140 - 98 52
150 - 106 48
160 - 103 48
175 - 106 48
190 - 107 51
210 3.7 1 0 1 49
225 - 107 53
240 3.7 1 0 2 50
270 3.5 109 56
300 3.6 105 54
360 3.6 1 0 2 57
Heart Rate 
_ 1
(beats min A) 
66
65
66 
63 
66 
65
71
72 
75 
75 
69
73 
78
71 .
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SUBJECT NO. 3
TREATMENT: PLACEBO
Time Serum K+ Systolic Diastolic
- 1 B.P. B.P.(mins) (mmol 1  L) (mm Hg) (mm Hg)
60 4.1 116 69
90 4.0 -
120 4.1 113 64
130 - 1 1 1 63
140 - 1 1 1 61
150 - 1 1 1 59
160 - 1 2 1 59
175 - 119 59
190 - 117 59
210 3.0 124 61
225 - 131 69
240 3.0 127 67
270 3.2 115 80
300 3.5 1 1 0 55
360 4.1 1 1 1 61
Heart Rate
beats min~^)
78
72
67
74
79 
83 
79 
79 
81 
93 
81
75
76 
79
SUBJECT NO. 3
TREATMENT: PROPRANOLOL
Time Serum K+
«i
Systolic
B.P.
Diastolic
B.P.
Heart
(mins) (mmol I""1) (mm Hg) (mm Hg) (beats
60 4.0 1 1 1 59 67
90 3.9 - - -
120 3.9 99 5 80
130 - 81 43 62
140 - 90 37 58
150 - 92 56 60
160 - 104 60 54
175 - 105 58 60
190 - 1 0 2 59 54
210 4.3 106 65 59
225 — 1 0 1 56 58
240 3.9 108 62 6 6
270 3.8 104 58 73
300 3.8 82 53 63
360 3.7 98 56 71
- 1
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SUBJECT NO. 3
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
— 1 B.P. B.P.(mins) (mmol 1  x) (mm Hg) (mm Hg) (beats min
60 4.1 106 65 69
90 4.1 -
1 20 4.0 81 55 78
1 30 - 89 45 72
1 4 0 - 91 41 65
1 5 0 - 93 44 6 6
1 6 0 - 95 44 58
1 75 - 1 0 0 46 57
1 9 0 - 1 0 2 50 58
2 10 4.2 117 63 69
2 25 - 1 1 1 61 69
2 40 4.2 105 60 59
2 70 4.3 1 0 0 51 83
3 00 4.0 92 45 81
3 60 3.8 96 46 82
SUBJECT NO. 3
TREATMENT: ATENOLOL
Time Serum K+
_ i
(mins) (mmol 1  )
60 3.6
90 3.8
1 2 0 3.9
1 3 0 -
1 4 0 -
1 5 0 -
1 6 0 -
1 7 5 -
1 9 0 -
2 1 0 3.9
2 25 -
2 40 3.8
2 7 0 3.7
3 00 3.9
3 60 3.6
Systolic
B.P.
(mm Hg)
107
99
96
94 
99
104
108 
102
99
100
103
84
95 
99
Diastolic
B.P.
(mm Hg)
57
52
54 
47 
49 
69 
57
56
57 
61
55 
42 
46 
46
Heart Rate
(beats min”1)
66
64
63
68
63
63
64 
63 
62 
70
63 
62
64 
72
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SUBJECT NO* 4
TREATMENT: PLACEBO
Time Serum K+ Systolic Diastolic Heart Rate
B.P. B.P.
(mins) (mmoll-1 ) (mm Hg) (mm Hg) (beats min
60 4.0 109 61 60
90 4.2 -
120 3.9 105 61 50
130 - 107 59 57
140 - 103 55 60
150 - 1 0 2 54 55
160 - 116 52 55
175 - 1 1 1 57 65
190 - 1 1 0 53 6 6
210 3.4 1 1 2 54 65
225 - 109 54 67
240 3.3 108 52 6 8
270 3.5 104 59 63
300 3.8 1 1 1 58 6 8
360 3.9 105 56 54
SUBJECT NO. 4
TREATMENT: PROPRANOLOL
Time Serum K+ Systolic Diastolic Heart Rate
B.P. B.P.
(mins) (mmol l”1 ) (mm Hg) (mm Hg) (beats min”
60 4.1 105 60 47
90 4.0 - - —
120 4.1 99 56 45
130 - 99 57 45
140 — 103 58 47
150 — 93 61 48
160 _ 103 58 47
175 _ 107 60 45
190 _ 108 65 44
210 4.3 108 69 50
225 _ 117 79 50
240 4.3 114 79 48r- h
270 4.2 114 70 51C "7
300 4.2 115 58 57c  o
360 3.5 1 0 0 51
52
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SUBJECT NO. 4
TREATMENT: OXPRENOLOL
Time Serum K+
(mins) (mmol-1)
Systolic
B.P.
(mm Hg)
Diastolic
B.P.
(mm Hg)
60 4.1 109 6 6
90 3.9 -
120 4.1 109 54
130 - 105 58
140 - 98 59
150 - 104 61
160 - 108 63
175 - 113 63
190 - 1 1 2 65
210 4.2 1 1 1 63
225 - 108 56
240 4.2 99 55
270 3.9 108 55
300 3.6 1 0 2 56
360 3.5 1 0 2 63
SUBJECT NO. 4
TREATMENT: ATENOLOL
Time Serum K+ Systolic Diastolic
B.P. B.P.
(mins) (mmol l”1 ) (mm Hg) (mm Hg)
60 3.9 99 55
90 3.8 - —
120 3.9 1 0 1 57
130 - 91 53
140 - 103 53
150 - 97 52
160 - 1 0 2 53
175 - 107 53
190 - 104 51
210 4.4 105 50
225 - 108 56
240 4.5 99 50
270 3.8 99 59
300 3.4 97 51
360 3.4 98 50
Heart Rate
(beats min”-*-)
50
55
51 
48
50
45
46 
44 
46 
46
51 
57 
61 
60
Heart Rate
(beats min" 1
52
43
43
46
52
50
51
50 
59 
54
53
51 
49 
49
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SUBJECT NO* 5
TREATMENT: PLACEBO
Time Serum K+ Systolic Diastolic
(mins) (mmol 1 “1 )
B.P.
(mm Hg)
B.P.
(mm Hg)
60 3.9 138 80
90 4.0 —
120 3.8 126 71
130 - 129 67
140 - 1 2 0 70
150 - 139 75
160 - 127 65
175 - 135 72
190 - 133 71
210 3.3 128 71
225 - 133 75
240 2 . 8 141 6 8
270 3.2 129 71
300 3.3 132 73
360 3.5 123 69
Heart Rate
(beats min- )^
78
67
69
69 
80
70 
70
73
76
74
77
75 
77 
77
SUBJECT NO. 5
TREATMENT: PROPRANLOL
Time Serum K+ Systolic
B.P.
Diastolic
B.P.
Heart Rate
(mins) (mmol l"1) (mm Hg) (mm Hg) (beats min
60 4.0 1 2 1 65 72
90 3.8 - - -
120 3.8 109 63 62
130 -  • 1 1 2 59 58
140 - 115 69 57
150 - 1 1 2 69 54
160 - 1 2 2 71 61
175 _ 128 71 64
190 — 125 76 65
210 4.3 134 77 74
225 — 124 64 59
240 4.2 124 6 6 61
270 3.7 1 2 1 61 71
300 3.8 119 58 69
360 4.1 123 62 74
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SUBJECT NO. 5
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
- 1 B.P. B.P.(mins) (mmol 1 x) (mm Hg) (mm Hg) (beats min
60 3.7 1 2 0 77 7490 3.8 -
120 3.8 129 67 76
130 - 124 70 82
140 - 128 63 72
150 - 128 6 6 69
160 - 137 67 6 6
175 - 136 72 70
190 - 139 71 65
210 4.0 143 71 70
225 - 145 69 72
240 4.0 142 80 60
270 3.9 130 65 80
300 3.9 127 64 75
360 3.9 127 64 81
SUBJECT NO.
TREATMENT: ATENOLOL
Time Serum K+ Systolic
B.P.
Diastolic
B.P.
(mins) (mmol I-1) (mm Hg) (mm Hg)
60 3.8 138 80
90 3.8 - -
120 3.8 126 71
130 - 129 67
140 - 1 2 0 70
150 - 139 75
160 - 127 65
175 - 135 72
190 - 133 71
210 3.4 128 71
225 - 133 75
240 3.5 141 6 8
270 3.7 129 71
300 3.7 132 73
360 3.7 123 69
Heart Rate
(beats min”1) 
78
67
69 
80
70 
70
73
76
74
74
77
75 
77 
77
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SUBJECT NO. 6
TREATMENT: PLACEBO
Time Serum K+ Systolic
-i B.P.
(mins) (mmol l-1) (mm Hg)
60 3.6 125
90 4.3 _
120 4.2 135
130 - 135
140 - 133
150 - 143
160 - 155
175 - 145
190 - 143
210 3.8 146
225 - 132
240 3.7 134
270 3.5 146
300 3.7 138
360 3.9 125
Diastolic Heart Rate
B.P.
(mm Hg) (beats min” )^
63 56
71 60
70 59
67 64
6 6  6 8
81 6 8
65 70
60 6 6
59 71
60 69
55 6 6
65 67
61 65
59 65
SUBJECT NO. 6
TREATMENT: PROPRANOLOL
Time Serum K+ Systolic Diastolic
B.P. B.P.
(mins) (mmol l-1) (mm Hg) (mm Hg)
60 4.3 118 59
90 4.5 - -
120 4.5 1 2 1 76
130 - 128 73
140 - 125 70
150 - 118 71
160 - 1 1 2 6 6
175 - 116 64
190 - 116 6 6
210 4.6 103 6 8
225 - 118 62
240 - 125 71
270 4.1 132 67
300 3.8 143 42
360 4.0 131 63
Heart Rate
—  1beats min x)
53
55
51
55
50
53 
55
50
54
54
51
55 
57 
62
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SUBJECT NO. 6
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
— 1 B.P. B.P.(mins) (mmol 1  x) (mm Hg) (ram Hg) (beats min- 1
60 4.3 135 65 5590 4.4 -
120 4.4 130 69 55130 - 131 73 53140 — 134 74 51150 — 133 73 52
160 - 133 6 8 52
175 - 133 64 55
190 - 132 69 52
210 4.2 141 6 8 57
225 - 139 76 57
240 3.8 136 6 6 61
270 3.4 144 6 6 64
300 3.3 132 63 61
360 3.4 131 65 59
SUBJECT NO. 6
TREATMENT: ATENOLOL
Time Serum K+
•i
Systolic
B.P.
(mins) (mmol l”1) (ram Hg)
60 4.0 1 2 1
90 4.0 -
120 4.2 117
130 - 109
140 - 1 2 1
150 - 103
160 - 116
175 - 116
190 - 119
210 3.8 1 2 1
225 - 1 2 1
240 3.8 118
270 3.8 1 1 2
300 3.8 1 2 1
360 3.9 117
Diastolic Heart Rate
B.P.
(ram Hg) (beats min-1)
57 54
61 55
57 58
55 56
49 58
56 56
53 55
54 57
54 56
52 56
52 56
63 57
52 56
54 57
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SUBJECT NO. 7 
TREATMENT: PLACEBO
Time Serum K+
-|
Systolic
B.P.
(mins) (mmol 1 -J-) (mm Hg)
60 3.6 1 1 0
90 3.6 -
120 3.7 106
130 - 104
140 - 104
150 - 106
160 - 1 1 0
175 - 114
190 - 114
210 3.4 1 1 0
225 - 113
240 3.5 1 1 1
270 3.3 113
300 3.4 116
360 3.6 1 2 1
SUBJECT NO. 7
TREATMENT: PROPRANOLOL
Time Serum K+ Systolic
B.P.
(mins) (mmol l"1 ) (mm Hg)
60 4.6 106
90 4.2 -
120 4.3 104
130 - 104
140 - 8 8
150 - 8 8
160 - 95
175 - 87
190 - 91
210 H 1 0 1
225 - 109
240 H 108
270 4.0 104
300 3.6 104
360 3.3 113
Diastolic
B.P.
(mm Hg)
60
61
56
55
56
57 
55
54 
53
55 
51 
60 
66 
66
Diastolic
B.P.
(mm Hg)
Heart Rate
(beats min-1)
57
53
58
64 
63 
63 
68 
68 
63
65
66 
61 
62 
62
Heart Rate
(beats min" 1
58 57
56 54
56 52
46 51
45 48
51 47
49 51
46 47
52 47
59 46
56 51
65 57
58 55
58 53
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SUBJECT NO. 7
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic Heart Rate
(mins) (mmol I"1) (mm*Hg) (mm Hg) (beats min' 1
60 3.6 103 5 4
90 3.6
120 3.6 105 5 5
130 - 105 5 5
57
62
140 — 106 55 5 Q
150 - 113 56 62
160 - 107 57 61
175 - 108 57 76
190 - 89 42 64
210 4.0 89 43 62
225 - 93 48 61
240 4.1 99 47 62
270 3.9 107 56 64
300 3.8 112 56 62
360 3.4 106 57 62
SUBJECT NO. 7
TREATMENT: ATENOLOL
Time Serum K+ Systolic Diastolic
B.P. B.P.
(mins) (mmol 1 “ )^ (mm Hg) (mm Hg)
60 4.0 113 64
90 4.0 - -
120 4.0- 107 55
130 - 106 55
140 - 107 54
150 - 1 1 0 56
160 - 108 50
175 - 105 52
190 - 96 55
210 4.3 109 48
225 - 109 51
240 4.2 1 1 0 52
270 3.9 115 63
300 4.0 114 56
360 4.3 109 57
Heart Rate 
_1
(beats min x) 
56
53
51 
49
54 
53 
56
56
57
52
55 
57 
60
53
291
SUBJECT NO* 8
TREATMENT: PLACEBO
Time Serum K+ Systolic
(mins) (mmol 1 ”1 )
B.P.
(mm Hg)
B.P.
(mm Hg)
60 3.9 119 6 6
90 4.1 -
120 4.0 116 61
130 - 115 61
140 - 1 1 1 59
150 - 114 60
160 - 116 61
175 - 118 59
190 - 116 50
210 4.0 1 2 2 61
225 - 118 56
240 3.9 117 57
270 4.0 1 2 2 63
300 3.8 123 63
360 1 2 0 61
SUBJECT NO. 8
Heart Rate
(beats min 
82
77 
75 
81 
75 
79 
82 
84
78 
75 
74 
74 
63 
93
- 1
TREATMENT: PROPRANOLOL
Time Serum K+ Systolic
B.P.
Diastolic
B.P.
(mins) (mmol l"1) (mm Hg) (mm Hg)
60 4.7 117 61
90 4.6 - -
120 3.6 1 0 0 58
130 - 1 0 2 55
140 - 1 1 0 60
150 - 106 59
160 - 103 58
175 - 106 59
190 - 108 58
210 4.6 105 53
225 - 109 61
240 3.8 98 63
270 3.7 109 52
300 3.7 104 57
360 3.5 1 1 0 43
Heart Rate
_ i
beats min i)
59
58
53
52
52
53
57
53
54 
54
58
58
59 
63
292
SUBJECT NO* 8
TREATMENT: OXPRENOLOL
Time Serum K+ Systolic Diastolic HeartB. P. B.P.
(mins) (mmol 1  ■*■) (mm Hg) (mm Hg) (beats :
60 3.9 113 54 6 8
90 3.8 - U O
120 3.9 Ill 53 65
130 - 115 57
w
65
140 - 113 60 63
150 - 113 53 59
160 - 114 52 58
175 - 118 54 57
190 - 109 53 63
210 4.4 109 57 70
225 - 114 60 57
240 4.5 113 53 54
270 3.8 1 1 2 58 67
300 3.4 1 0 2 49 70
360 3.4 95 47 62
SUBJECT NO. 8
TREATMENT: ATENOLOL
Time Serum K+ Systolic Diastolic
>i B.P. B.P.
(mins) (mmol 1  ) (mm Hg) (mm Hg)
60 3.9 1 1 1 57
90 3.8 - -
120 3.8 108 54
130 - 108 51
140 - 108 50
150 - 99 54
160 - 1 0 0 50
175 - 103 52
190 - 108 48
210 4.4 92 52
225 — 108 53
240 4.5 107 51
270 3.8 104 56
300 3.4 103 50
360 3.4 115 47
Heart Rate
_ 1
(beats min x
63
62
58
58
59
60
65 
57 
57 
63 
60 
63
66 
69
293
a s go w
